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Stress is a risk factor for the development of psychiatric disorders (e.g. depression, 
anxiety) and drug addiction. Stress induces the release of endogenous neuropeptide, 
dynorphin, which primarily activates kappa opioid receptor (KOPr) and produces 
aversive and depressive-like behaviours in rodents. Stress-induced depressive-like 
behaviours and stressed-induced potentiation of drug self-administration are 
inhibited, at least in part, by blocking KOPrs, showing that KOPr plays an important 
role in mediating stress responses and motivational behaviours, and acts as a 
potential therapeutic target for the treatment of affective disorders. However, 
accumulating studies have reported that stress-induced behavioural effects or stress-
induced KOPrs activation are sex dependent. In this study, the effects of acute forced 
swim stress (FSS) and activation of KOPr by the selective agonist, U50,488 (20mg/kg, 
i.p.) on neuronal activation in different brain regions (prefrontal cortex (PFCx), 
nucleus accumbens (NAc), hippocampus and amygdala) were investigated in both 
male and female mice. 
Adult (9-13 weeks old) male and female C57BL/6 cFos-GFP transgenic mice were used, 
where the cFos acts as a neuronal activity marker and drives the production of green 
fluorescent protein (GFP) upon neuron activation. FSS and U50,488-induced 
neuronal activity (cFos or cFos-driven GFP expression) was detected by 
immunohistochemistry. Our data showed that there is an overlap in brain regions 
that are activated by U50,488 and FSS in male mice, with significant increases in cFos 
and cFos-driven GFP expression seen in the PFCx, NAc and basolateral amygdala 
following both types of stimuli. Only U50,488, not FSS, induced significant cFos 
expression in the hippocampal CA1 region and central amygdala in male mice. 
Different patterns were observed in female mice; in the PFCx, neither U50,488 nor 
FSS induced significant cFos expression. In the NAc, only FSS, not U50,488, increased 
cFos expression. Other regions in females, including hippocampal CA1, central 
amygdala and basolateral amygdala, showed similar cFos expression patterns that 
were seen in male mice. Generally, KOPr activation-induced cFos or GFP expression 
was significantly blocked by pretreatment KOPr antagonist, norBNI (10mg/kg, i.p.), 
whereas FSS-induced effects were not affected by norBNI. Overall, this study 
 xiii
provided a better understanding of stress mechanisms, especially in PFCx and NAc, 
highlighting that PFCx and NAc are the regions that showed different effects 
following KOPr activation and in vivo stressor between male and female mice, which 
may underlie sex differences in stress-induced behaviours. 
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Hypothesis and aims 
 
There is a strong association between sex and stress-induced behavioural responses, 
and the sex differences in stress-induced kappa opioid receptor activation. It is 
hypothesised that in vivo stress or pharmacological activation of KOPr, induces 
neuronal activity at the molecular level is sex dependent. 
To test this hypothesis, the following aims are addressed in this project: 
1. To determine the brain regions activated by stress in cFos-GFP mice and 
optimise the techniques that can be used in determining neuronal activity. 
2. To determine any differences between a physical stressor and 
pharmacological KOPr activation in male cFos-GFP mice. 
3. To investigate any sex differences in the effects of stress and KOPr activation 
on neuronal activation pattern between male and female cFos-GFP mice, and 
investigate if pre-treatment of KOPr antagonist, norBNI would block stress-
induced effects in both sexes. 
4. To identify the types of stress-activated neurons by using GAD-GFP transgenic 
mice and measure the levels of stress-induced steroid hormone e.g. 
corticosterone in response to both forced swim stress and a single KOPr 
agonist treatment. 
 
In this study, I have quantified immunofluorescent labelling for cFos-GFP mice on 
different brain regions, including prefrontal cortex, hippocampus, amygdala and 
nucleus accumbens following stress, or KOPr activation. These are key regions 
involved in neural circuitry mediating the response to stress and KOPr activation. 
These studies will provide us with greater insight into the roles of these brain 
regions in both stress, and the behavioural effects KOPr activation, and whether 




1.1.1 A risk factor for psychiatric disease 
Stress is a well-known risk factor for the development of psychiatric disorders, drug 
addiction and triggers drug relapse. Acute or chronic stressors have been known to 
be involved in the pathogenesis of psychiatric diseases, such as depression and 
anxiety disorders, which are also strongly associated with drug dependence. 
Statistics show that there were 19.7% of people in the UK affected by anxiety 
disorder and mental illness, and more than 2 million people affected by substance 
abuse in the UK in 2014/15 (Evans et al., 2016, NHS Digital, 2017). Depression is one 
of the most serious and prevalent mental disorders that affects approximately 21% 
of the total population in developed countries (Wong et al., 2001). 
 
Stress plays an important role in regulating brain structure and function through a 
number of mediators, including brain-derived neurotrophic factor (BDNF), excitatory 
amino acid neurotransmitters, endocannabinoids and glucocorticoids, resulting in 
neuronal restructuring by altering synapse density for stress adaptation (McEwen et 
al., 2015). For example, it was shown that repeated stress could cause reorganisation 
of dendrites in the hippocampus and prefrontal cortex, leading to impaired cognitive 
behaviours (Radley et al., 2004). Prolonged stress causes neuronal loss in the medial 
amygdala and expansion of dendrites in the basolateral amygdala, which are 
believed to be important changes implicated in depression and anxiety-like 
behaviours (Bennur et al., 2007). Overall, it is becoming clear that stress has a 




1.1.2 Stress and the HPA axis 
The hypothalamic-pituitary-adrenal (HPA) axis is activated during a physical or 
emotional stressor and plays a crucial role in regulating and adapting the stress 
responses (Figure 1.1). The HPA axis induces the release of corticotrophin releasing 
hormone (CRH) from the hypothalamic paraventricular nucleus (PVN), which 
stimulates the anterior pituitary and causes the release of adrenocorticotropic 
hormone (ACTH). The released ACTH enters into the systemic circulation and 
promotes the synthesis and release of glucocorticoids from the cortex of the adrenal 
glands. The main glucocorticoid in humans is cortisol, while corticosterone is the 
main glucocorticoid in rodents e.g. mice, rats (Herman et al., 2016). The released 
glucocorticoids secreted into the systemic circulation act on mineralocorticoid 
receptors (MRs) with a high affinity to regulate basal glucocorticoids levels and bind 
to glucocorticoid receptors (GRs) with a lower affinity. GRs are widely expressed 
throughout the brain, including cortex, hypothalamus, hippocampus and amygdala, 
while MRs are heavily distributed in hippocampus and hypothalamus (Keller et al., 
2017). Importantly, activation of GRs also inhibits the release of CRH and ACTH, 
resulting in reduced further release of cortisol and inhibition of stress responses. This 
negative feedback mechanism is an important mechanism for stress adaptation and 
allostatic processes in the body, illustrated in figure 1.1. (Herman et al., 2016, Keller 
et al., 2017). 
 
Although activation of the HPA axis plays a crucial role in adapting stress responses, 
the exposure of prolonged and repeated stress could lead to excessive release of 
glucocorticoids into the systemic circulation. The dysregulation of MRs or GRs and 
hyperactivity of the HPA axis has been implicated in the development of depression 
and could be pathological in other psychiatric disorders, such as anxiety and cognitive 
dysfunction (Herman et al., 2016). Previous studies have shown that the levels of 
cortisol in the plasma are elevated in 40-60% of patients with depression, suggesting 
that there is a strong association between overactivation of the HPA axis, elevated 









Figure 1.1 Overview of the hypothalamic-pituitary-adrenal (HPA) axis. “+” 
indicates positive feedback, “-” indicates negative feedback. Stressors 
induce the release of CRH from PVN, which are transported to the 
anterior pituitary and cause ACTH release into the systemic circulation. 
The release of ACTH stimulates the production and secretion of 
glucocorticoids (cortisol in man, corticosterone in rodent e.g. rats or 
mice) at the adrenal cortex, which in turns cause a negative feedback 
mechanism on PVN and anterior pituitary gland, resulting in reduction of 
further cortisol release. 
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1.1.3 Brain regions involved in stress 
The brain is the primary and central organ mediating stress responses and regulating 
physiological responses to both social and physical stressors. Three of the primary 
brain regions involved in mediating behavioural responses to stressors are the 
prefrontal cortex (PFCx), hippocampus and amygdala (Figure 1.2). These regions are 
responsible for generating various stress-related responses, and stressors have been 
shown to directly alter gene transcription or active epigenetic modifications in these 
brain regions (McEwen et al., 2010). For example, in the hippocampus and PFCx, 
chronic stressors have been shown to cause shrinkage of dendrites, which could lead 
to impaired memory and cognitive behaviours (Radley et al., 2004). Whereas 
prolonged stress causes dendritic expansion in the basolateral amygdala and spine 
reduction in the medial amygdala, which are thought to be implicated in depression 




Figure 1.2 Schematic diagram of the location and function of brain regions 
that are important in mediating stress responses. 
 
Diagram from McEwen et al., 2015  
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In addition, stress-induced glucocorticoids activate MRs and GRs, which are widely 
expressed throughout the brain, particularly in the CA1 region of hippocampus. 
Interestingly, Lowy and colleagues used in vivo microdialysis to show that 
extracellular glutamate levels in the hippocampus were significantly elevated by 
restraint stress, and this effect was inhibited by adrenalectomy or in MR knockout 
mice, indicating that glutamate levels are dependent on adrenal steroids and 
activation of MRs and GRs produce non-genomic effects (Lowy et al., 1993, Karst et 
al., 2005). This process might explain neuronal loss and dendritic remodelling in the 
hippocampus following chronic stress (McEwen et al., 1999). Similarly, stress-
induced excessive release of glutamate and NMDA activation is responsible for 
dendritic reorganisation in the medial prefrontal neurons (Martin et al., 2011). Other 
studies also showed that central infusion of corticotropin-releasing factor (CRF) into 
basolateral amygdala (BLA) induces anxiety-like behaviours, suggesting that the 
amygdala is one of the key brain regions that mediates stress-induced responses 
(Jochman et al., 2005). 
 
Overall, stress-induced release of hypothalamic CRF and glucocorticoids from the 
adrenal glands affect prefrontal, hippocampal dendritic remodelling, and regulate 
synaptic plasticity and neuronal activity in the amygdala and CA1 region of 
hippocampus during stress responses (Chen et al., 2006, McEwen et al., 2015). 
 
1.1.4 Stress in anxiety and depression 
According to the psychiatric dictionary, depression is defined as ‘a mental condition 
characterised by feelings of severe despondency and dejection’, while anxiety is 
defined as ‘a nervous disorder marked by excessive uneasiness and apprehension, 
typically with compulsive behaviour or panic attacks’. Stress is known to be a major 
risk factor for clinical depression (Grant et al., 2013). Although the precise 
mechanisms for how stress can result in anxiety and depression (Russell et al., 2018), 
prolonged stress induces structural remodelling of dendrites and synaptic 
connections in the hippocampus, PFC and amygdala, which are implicated in 
cognitive impairment and affective disorders, such as depression and anxiety 
(McEwen et al., 2016). Early studies revealed that chronic stress induced dendritic 
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shrinkage in and loss of spines in CA3 region and dentate gyrus of the hippocampus 
in rats (McEwen 1999), which was further supported by other evidence, 
demonstrating that chronic stress-induced neuronal reorganisation and dendritic 
shrinkage were not only found in dentate gyrus and CA3 region, but also in the 
hippocampal CA1 region in rats (Sousa et al., 2000, Brunson et al., 2005). Studies 
reported that the volume of hippocampus was significantly reduced in patients with 
depression (Bremner et al., 2000, Shah et al., 1998). 
 
In addition to altering dendritic morphology in the hippocampus, stress also has been 
shown to affect memory functions and synaptic plasticity. Rats that were exposed to 
chronic stress showed spatial learning and memory deficits in the water maze task 
(Sousa et al., 2000). Similar to the findings in rats, humans who are diagnosed with 
depression and hypercortisolaemia showed impaired hippocampus-dependent 
memory (Starkman et al., 1992). Further evidence showed that stress induced 
impairment of long-term potentiation (LTP) in both mice and rats in the CA1 region 
and dentate gyrus of the hippocampus (Shors et al., 1994, Garcia et al., 1997). It has 
also been shown that stress not only impaired LTP, but also induced long-term 
depression (LTD) in the hippocampal CA1 region in rats (Xu et al., 1997). Such stress-
induced synaptic plasticity facilitates the development of depression and anxiety. 
 
In addition to affecting the hippocampus, chronic immobilisation stress (CIS) induced 
dendritic expansion in the basolateral amygdala (BLA) in rats, and repeated restraint 
stress caused spine density reduction in the medial amygdala in mice (Vyas et al., 
2002, Bennur et al., 2007), as well as causing neuronal remodelling and dendritic 
reduction in the medial prefrontal cortex (mPFC) in rats (Radley et al., 2004). These 
findings suggest that chronic stress could affect the structural modelling of 
hippocampus, amygdala and mPFC regions in the brain, resulting in a higher chance 
of development of mood disorders such as anxiety and depression. Importantly, 
stress-induced HPA activity can be regulated by mPFC (Brake et al., 2000) and 
dysregulation of HPA axis is strongly associated with mood-related disorders, such as 
depression and anxiety, patients with these disorders are characterised with high 
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levels of CRH and cortisol, blunted ACTH function in response to CRH and reduced 
hippocampal volume (Varghese et al., 2001). 
 
1.1.5 Role of stress in addiction 
Addiction is considered to be a chronic, relapsing disorder characterized by 
compulsive drug-seeking and drug-taking, despite serious negative consequences 
(Nestler 1992; Cami and Farre, 2003). Behavioural studies e.g. self-administration or 
conditioned place preference (CPP) experimental paradigms have been used to study 
the reinforcing and rewarding properties following administration of drugs of abuse, 
which showed that the key mechanisms underlying the rewarding pathways of 
addictive drugs are related to the mesocorticolimbic dopamine pathway (Nestler 
1992). The major components of this pathway are a projection of dopaminergic 
neurons from the ventral tegmental area (VTA) to the nucleus accumbens (NAc) in 
the ventral striatum and to the PFCx (Nestler 1992, Adinoff 2004) (Figure 1.3), as early 
animal studies in rats revealed that local administration of opiates into VTA or NAc 
developed CPP, also, lesions of the VTA-NAc pathway blocked cocaine self-
administration and blocked intravenous opiate-induced CPP development (Pettit et 
al., 1984, Wise et al., 1987, Koob et al., 1988). These studies established that the 
mesolimbic dopamine system plays a crucial role in drug-induced reward effect. In 
addition to VTA and NAc regions, microinjection of cocaine into the mPFC in rats 
induced reinforcing properties in a dose-dependent manner, which implies that 
reinforcement process of cocaine is also mediated, at least in part, by the mPFC 
(Goeders et al., 1983). Although dopaminergic input to the nucleus accumbens is 
thought to be responsible for the initial rewarding properties of drugs of abuse (Di 
Chiara et al., 1988), the development and expression of addiction-related behaviours 
also involves other brain regions, such as the hippocampus and amygdala (Barr et al., 
2014). Other evidence also showed that lesions of the amygdala and nucleus 
accumbens impaired cocaine self-administration, and humans with cocaine addiction 
showed impaired recognition memory, suggesting that both hippocampus and 
amygdala are also implicated in drug reward mechanisms (Bolla et al., 2003, 















There is increasing evidence that stress also plays a key role in motivation to seek 
and take drugs of abuse, with stress now seen as a key risk factor for drug addiction 
development (Sinha, 2008). For example, animal studies revealed that stressful 
experiences could modulate extracellular dopamine release, indicating the strong 
correlation between stress and mesolimbic dopamine transmission, which could 
promote drug self-administration and enhances vulnerability to drug addiction 
(Sinha, 2008). In addition, rats with acute footshock stress-induced high levels of CRF 
and corticosterone are much more likely to self-administer cocaine (Erb et al., 1996). 
Although the exact mechanism that underlies how stress overlaps with mesolimbic 
pathway is not fully understood, recent studies suggest that stress-induced CRF in 
the NAc and elevated glucocorticoids facilitates signalling in the mesolimbic 
dopaminergic pathway (Koob et al., 2018). 
Figure 1.3 Illustration of the rewarding mesolimbic dopamine pathway in the 
brain. Dopaminergic neurons (DA, showed in blue circuit) in the ventral 
tegmental area (VTA) project to nucleus accumbens (NAc), hippocampus, 
amygdala and prefrontal cortex. GABAergic neurons (GABA, shown in red circuit) 
originate in the NAc and project directly to VTA and amygdala. NAc receives 
strong glutamatergic transmission (GLU, shown in green) from prefrontal cortex 
(PFCx), hippocampus and amygdala. 5-HTergic neurons (5-HT1B, shown in 
yellow) are populated in NAc and ventral pallidum. 
 
Diagram from Alim et al., 2012 
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The brain regions implicated in mediating stress-related and addiction-related 
behaviours are somewhat overlapping i.e. mesocorticolimbic dopaminergic systems. 
As described earlier, NAc is a key region in mesolimbic dopaminergic pathway, 
involved in motivation and rewarding properties. Electrophysiological studies in mice 
showed that glutamatergic transmission was enhanced in the NAc after two-day cold 
water forced swim stress (Campioni et al., 2009). More importantly, acute restraint 
stress significantly induced immediate early genes cFos and FosB in the NAc in rats 
(Perrotti et al., 2004). Altogether, these stress-induced effects in the NAc might 
contribute to stress-induced reinstatement of drug intake and also emphasise the 
strong correlation between mechanisms that underlying stress and drug addiction-
related behaviours. 
 
Therefore, the brain regions PFCx, hippocampus, NAc and amygdala are key regions 
that are involved in both stress responses and drug dependence development. The 
relationship between stress and the opioid receptor system, as well as their common 





1.1.6 Animal models of stress 
Animal models are extremely useful and beneficial for understanding 
pathophysiology that underlies the mechanisms of psychiatric diseases and 
development of potential therapeutic treatment. Animal models of psychiatric 
diseases, such as depression and schizophrenia have been developed using a wide 
range of methods, including pharmacological approaches, genetic modification, 
environmental manipulations and electrical stimulation (Nestler and Hyman, 2010). 
Forced swim, restraint and tail suspension are widely used as short-term acute 
physical stressors (Nestler and Hyman, 2010). A major limitation of these stressors is 
that it only applies short-term stress on normal animals, which is different to 
depression in humans. However, these physical stressors can also be applied 
chronically to enable the study of chronic stress and the effects on the brain. A 
further model used for chronic stress is ‘chronic unpredictable stress’ where animals 
are exposed to physical stressors (such as restraint) in combination with 
environmental stressors such as cold temperature, changes in lighting conditions, 
water and food restriction. Repeated physical stressors and chronic unpredictable 
stress paradigms have been shown to produce a depression-like phenotype that 
could be blocked by antidepressant administration (Jaggi et al., 2011, Willner, 2016). 
 
Therefore, there are numerous different ways to induce stress in rodents. As 
mentioned above, chronic stress is a complex process, which involves adaptive 
process in the HPA activation and remodelling of the brain region structures (Campos 
et al., 2013). Since acute and chronic stress induces different physiological effects in 
rodents, it is impossible to directly compare the acute and chronic-induced 
physiological or behavioural effects. As previous studies in C57BL/6 mice 
demonstrated that two hours restraint stress or forced swim stress (15 minutes) 
significantly induced high levels of corticosterone levels (Wittmann et al., 2009, 
Sadler and Bailey, 2016). In this project, we used acute restraint and forced swim 
stress to evaluate the impact of stress on neuronal activity in the brain. 
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1.2 Kappa opioid receptor 
1.2.1 What is the kappa opioid receptor?  
 KOPrs are part of the opioid receptor family of G-protein coupled receptors (GPCRs), 
which consist of the  (mu) opioid receptor (MOPr),  (delta) opioid receptor (DOPr) 
and  (kappa) opioid receptor (KOPr). The KOPr is primarily activated by endogenous 
neuropeptide dynorphin (DYN), which is released from large dense vesicles at 
synaptic and extra-synaptic sites in response to stress, i.e. stress induces the release 
of DYN levels (Shirayama et al., 2004). The DYN-activated KOPrs couple to inhibitory 
Gi alpha subunit proteins (Gi), which inhibits adenylyl cyclase, hence decreases 
neuronal activity by inhibiting voltage-gated Ca2+ channels and activating voltage 
gated K+ channels, resulting in reduced release of neurotransmitters and synaptic 
transmission (Bruchas et al., 2010). Electrophysiological and neurochemical studies 
have shown that activation of KOPr in the VTA decreases the release of dopamine 
and dopaminergic transmission in the NAc (Shippenberg et al., 2007). It also produces 
anxiety-like and pro-depressive behaviours, such as increased immobility in the 
forced swim test, also produces negative affective states, such as dysphoria, sedation 
and anxiety (Carlezon et al., 2006). The KOPr and endogenous ligand DYN are highly 
expressed in the NAc, PFCx and VTA regions (Shippenberg et al., 2007). The 
mechanism of stress-induced DYN release is not fully understood, but high level of 
DYN was detected in the hippocampus, amygdala and PVN in hypothalamus of 










U69,593 Naloxone (non-selective) 
Dynorphin B: Tyr-Gly-Gly-Phe-Leu-
Arg-Arg-Gln-Phe-Lys-Val-Val-Thr 
Bremazocine Buprenorphine (non-selective) 
Table 1.1 Summary of ligands that activate on KOPr. Two different forms of 
dynorphin (A and B), which are derived from precursor protein prodynorphin 
with different amino acid sequences. Naloxone also acts on  opioid receptor 
and  opioid receptor. Buprenorphine acts as a partial agonist on  opioid 
receptor and antagonist on ,   opioid receptor. 
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1.2.2 Distribution of KOPrs 
Identification of KOPrs in the key brain regions that are implicated in depression, 
anxiety and addiction would further facilitate the further potential therapeutics 
development. Increasing evidence have shown that KOPrs are widely expressed 
throughout the brain, and the central and peripheral nervous systems. 
 
For example, autoradiographic studies in male Sprague-Dawley rats have shown that 
KOPrs are particularly expressed in limbic brain areas, including the NAc, 
hippocampus, frontal cortex, VTA, basolateral amygdala and hypothalamus at 
relatively high levels (Fan et al., 2002). This localisation of KOPrs in NAc and 
hippocampus was also supported by DYN immunocytochemistry studies in adult 
male Sprague-Dawley rats, demonstrating that acute stress increased DYN 
immunoreactivity in the NAc, CA1, CA3 regions and dentate gyrus of the 
hippocampus (Shirayama et al., 2004). Early studies of northern blot analysis in male 
Sprague-Dawley rats showed that KOPr mRNA was expressed in the hypothalamus, 
cortex, hippocampus, amygdala and NAc (George et al., 1994). Quantitative in vitro 
autoradiography in the guinea pig brain also revealed that high levels of KOPr 
expression were observed in cortex, substantial nigra and NAc, while hypothalamus, 
hippocampus and amygdala express moderate levels of KOPr (Wang et al., 2001). 
More importantly, quantitative autoradiography of KOPr binding in wildtype mice 
revealed high levels of KOPrs are expressed in the NAc, claustrum and hypothalamus, 
moderate levels of KOPrs expression are found in the PFCx and amygdala, relative 
low levels of binding were observed in the hippocampus (Kitchen et al., 1997, Clarke 
et al., 2001). 
 
Altogether, these results demonstrated the regional distribution of KOPrs expression 
in the brain, highlighting the emotional and motivational role of KOPrs in psychiatric 
disorders and drug addiction, as well as modulate the circuits between different brain 





Figure 1.4 The distribution of KOPrs and KOPr system in major circuits 
implicated in stress and addiction responses. Regions involved in mediating 
aversive and dysphoric are labelled with red circles, regions labelled with red 
and white circles are implicated in depressive-like behaviours and reinforcing 
properties. PFC, prefrontal cortex, OFC, orbital frontal cortex, NAc, nucleus 
accumbens, AMG, amygdala, VTA, ventral tegmental area, HIPP, hippocampus, 
DR, dorsal raphe nucleus. 
 
Diagram from Crowley et al., 2015 
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1.2.3 Role of KOPrs in stress 
Activation of KOPrs causes aversive, anxiety-like and depressive-like behaviours in 
rodents and in humans (Pfeiffer et al., 1986, Carlezon et al., 2006). Accumulating 
evidence proposed that KOPr system induces these effects by regulating HPA axis 
(Van’t Veer et al., 2013). For example, a reduction in CRF mRNA expression in PVN of 
the hypothalamus and decreased corticosterone levels were detected in wildtype 
mice pre-treated with KOPr antagonist, norBNI, and acute swim stress-induced 
increases in corticosterone levels were reduced in prodynorphin knockout mice, 
which suggested that KOPr activation plays an important role in HPA axis regulation 
(Wittmann et al., 2009). Similar evidence was also revealed in rats i.e. lowered 
corticosterone levels were measured in rats following norBNI pre-treatment in 
response to food restriction stress (Allen et al., 2013). Importantly, it has been shown 
that KOPrs expression pattern overlaps with the regions that are involved in HPA 
activity, shown in figure 1.5, suggesting that KOPrs activation induces stress-like 



























At the molecular level, forced swim stress-induced CRF release or 
intracerebroventricular injection of CRF significantly increased activation and 
phosphorylation of KOPr in the VTA, amygdala, NAc and hippocampus regions, 
shown by Western blot analysis in mice, indicating that DYN/KOPr system plays a key 
mediating role in stress responses (Land et al., 2008). 
 
Stress induces the release of endogenous opioid peptide, DYN and activation of the 
KOPr system has also been reported to be strongly associated with behavioural 
responses in animal models of depression, anxiety and aversive effects. For example, 
footshock stress or forced swim stress produced aversive behaviours in conditioned 
aversion paradigm in male C57BL/6 mice, which could be reversed by selective KOPr 
antagonist, norBNI pre-treatment (Land et al., 2008). Also, administration of norBNI 
decreased immobility in the FST dose dependently in male Sprague-Dawley rats 
(Mague et al., 2003). Social defeat stress-induced analgesia responses and 
potentiation of cocaine-conditioned place preference (CPP) were also shown to be 
blocked by KOPr antagonism in wildtype C57BL/6 male mice and in mice with 
prodynorphin gene disruption (McLaughlin et al., 2003, McLaughlin et al., 2006a), 
suggesting that KOPr activation is important in mediating responses induced by acute 
stress. 
 
There is also accumulating evidence showing that the KOPr antagonist, norBNI, 
blocks stress-induced potentiation of drug-dependent CPP and drug self-
Figure 1.5 Schematic diagram of HPA axis and expressions of KOPrs, GRs and 
MRs. Glucocorticoid release regulated by negative feedback via MRs and GRs. 
KOPr expression overlaps with HPA axis. KOPrs, kappa opioid receptors, GRs, 
glucocorticoid receptors, MRs, mineralocorticoid receptors, ACTH, 
adrenocorticotropic hormone, CRF, corticotropin-releasing factor, HIP, 
hippocampus, BNST, bed nucleus of the stria terminalis, PFC, prefrontal cortex, 
PVN, paraventricular nucleus of hypothalamus, AMY, amygdala. Red arrows 
indicate positive feedback, blue arrows indicate negative feedback, green 
arrows indicate indirect connections from brain regions to the PVN in HPA axis. 
 
Diagram from Van’t Veer et al., 2013 
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administration. Consistent with these effects, prodynorphin knockout mice did not 
show the forced swim stress-induced cocaine CPP potentiation, which further 
confirms that KOPrs system plays an important role in inducing motivational effects 
of stress (McLaughlin et al., 2003, Sperling et al., 2010, Smith et al., 2012, Graziane 
et al., 2013). In addition, activation of KOPr by the agonist, U50,488, potentiated 
cocaine CPP in mice, which mimics the effects caused by stress, confirming that KOPr 
activation is important and strongly associated with stress-induced reinforcing 
properties of addictive drugs (McLaughlin et al., 2006b). 
 
In adult male rats study, bilateral microinfusion of norBNI directly into the ventricles 
or NAc induced antidepressant effects in the FST in a dose-dependent manner 
(Pliakas et al., 2001), similar to the antidepressant effects as seen in a learned 
helplessness (LH) paradigm following microinjection of norBNI directly into the NAc 
(core and shell) or hippocampal CA3 and dentate gyrus regions (Shirayama et al., 
2004), suggesting that norBNI-induced inhibition of KOPrs in the NAc or hippocampus 
could lead to enhanced dopamine transmission. Site specific administration of 
norBNI into the BLA blocked stress-induced anxiety-like behaviours in the elevated 
plus maze (EPM), highlighting the important role of KOPr system in the amygdala in 
mediating anxiety behaviours in response to stress (Bruchas et al., 2009). These 
studies indicate the expression of KOPr in the BLA, hippocampus and NAc and the 
potential role of dynorphin/KOPr in mesolimbic dopamine system, as well as 
potential therapeutic target for depression treatment (Shirayama et al., 2004). 
 
Overall, this evidence suggest that acute stress-induced physical and behavioural 
responses are mediated, at least in part, by dynorphin/KOPr activation and signalling, 
and the motivational and emotional role of KOPr in animal behavioural responses 
represent a potential drug target for psychiatric disorders. For example, KOPr 
antagonists have been proposed as potential novel drug treatments for depression 
and anxiety disorders. KOPr antagonists have also been suggested as potential 




1.2.4 Role of KOPrs in addiction 
As described above, KOPrs are important in regulating stress-induced motivational 
behaviours, increasing evidences has shown that KOPr signalling is not only involved 
in stress-induced neurological effects, but also strongly associated with craving and 
rewarding properties of addictive drugs, such as cocaine, heroin and alcohol (Nestler 
et al., 2005, Bruchas et al., 2010, Lalanne et al., 2014). Dysregulation of 
dynorphin/KOPr signalling is characterised in drug-seeking behaviours and drug 
dependence, and KOPr has been studied as a potential therapeutic target for the 
treatment of drug addiction (Nestler et al., 2005, Lalanne et al., 2014). 
 
In an early animal studies in Sprague-Dawley rats, microinjection of KOPr agonist 
U50,488 directly into VTA, NAc and mPFC produced conditioned place aversion (CPA) 
in a dose dependent manner (Bals-Kubik et al., 1993), similar effects were observed 
in C57BL/6 mice, which showed that pre-treatment of U50,488 effectively abolished 
morphine conditioned place preference (CPP) (Funada et al., 1993), suggesting that 
KOPr might play an important role in anti-rewarding effects in motivation of drugs of 
abuse. In addition to that, direct administration of norBNI into CA3 region of the 
hippocampus improved ethanol-induced spatial learning and memory impairments 
in rats in the water maze task (WMT), proving that KOPrs also play a key role in 
mediating the effects of alcohol on impaired learning and memory (Kuzmin et al., 
2013). Glick and colleagues reported that i.p. injection of U50,488 (10mg/kg) prior to 
drugs testing showed reduced cocaine and morphine self-administration, supporting 
the previous evidence for the inhibitory role of KOPr in rewarding properties of drug 
addiction (Glick et al., 1995), as well as suggesting that KOPr may act as a promising 
and novel pharmacological target for opioid addiction treatment.  
 
However, other studies demonstrated that the effects of KOPr on rewarding 
properties of drug addiction depended on timing, e.g., administration of the KOPr 
agonist, U50,488 15 minutes prior to cocaine significantly blocked cocaine-induced 
CPP, which was consistent with earlier evidence, whereas administration of U50,488 
60 minutes before cocaine significantly potentiated cocaine-induced CPP in C57Bl/6 
mice, which was inhibited by KOPr antagonist, norBNI pre-administration or KOPr 
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gene disruption (McLaughlin et al., 2006b). These results suggested that the timing 
between KOPr activation and cocaine treatment was crucial, resulting in both 
facilitatory or inhibitory effects of KOPr agonist on drug-induced CPP and highlighting 
the difficulties for KOPr clinical studies in the treatment of drugs of abuse 
(McLaughlin et al., 2006b). 
 
It is hypothesised that the mechanism underlying the KOPr-induced effects on 
addiction-related behaviours and drug-induced reward is by regulating the 
mesolimbic pathway. KOPrs are expressed on dopaminergic neurons in the 
mesolimbic pathway, and activation of KOPrs in these neurons results in decreased 
neurotransmission and inhibition of dopamine release in the NAc. This process is 
thought to be responsible for mediating the aversive effects of KOPr agonists 
(Trifilieff et al., 2013). Within the NAc, infusion of KOPr agonist, U69,593 into the NAc 
in rats demonstrated decreased dopamine release in the NAc using microdialysis 
(Spanagel et al., 1992), and systemic administration of U69,593 in rats also showed 
reduction in extracellular dopamine concentrations in the mPFC (Tejeda et al., 2013). 
The KOPr agonist, U69,593-induced CPA was abolished in knockout mice with 
deletion of KOPr on dopaminergic neurons, confirming that KOPr on dopaminergic 
neurons are necessary and sufficient to mediate aversive behaviours (Chefer et al., 
2013), the network of KOPr-regulated dopaminergic transmission in the mesolimbic 
pathway is shown in Figure 1.6. In vivo microdialysis studies in rats showed that 
systemic administration of KOPr agonist, salvinorin A, decreased extracellular 
dopamine concentrations in the NAc and regulating dopamine transmission in the 
NAc, which is a key component of mesolimbic rewarding system, supporting the idea 
that KOPrs activation modulates rewarding properties of addictive drugs (Carlezon et 
al., 2006). More importantly, as described above, KOPr antagonist, norBNI was 
reported to block stress-dependent reinstatement of cocaine-induced CPP in mice, 
highlighting the important role of KOPr in drug-seeking behaviours (McLaughlin et al., 
2003). Furthermore, another KOPr antagonist (non-selective, partial MOPr agonist), 
buprenorphine has also been shown to reduce cocaine self-administration and 
increase extracellular concentration of dopamine in the NAc, providing evidence that 
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KOPr activation is strongly associated with drug addiction behaviours and involved in 
regulating mesolimbic pathway (Brown et al., 1991, Robinson 2006). 
 
These neurochemical and behavioural evidence in animal studies proposed that KOPr 
antagonists could be developed for potential therapies for drug addiction treatment. 
However, there are still difficulties remain unsolved, addiction is a chronic process 
that involves time-dependent alterations and adaption of neuronal circuity in the 
brain, the better understanding of the effects of KOPr antagonists on different stages 
of the addiction development is required, which would facilitate an early 




Figure 1.6 Schematic diagram of mechanism underlies KOPrs-modulated 
dopamine transmission from VTA to NAc. Activation of KOPrs (coupled to 
Gi/o) on dopaminergic neurons leads to decreased release of dopamine in 
NAc. The dopaminergic transmission is reduced by activating K+ channels 
and inhibiting Ca2+ channels, resulting in hyperpolarisation of the neurons. 
The dopamine transporters are also stimulated to increase dopamine 
reuptake following KOPr activation. 
 
Diagram from Margolis et al., 2019 
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1.3 Sex differences 
Statistics indicate that women are more prevalent to develop certain psychiatric 
disorders such as depression and anxiety, compared to men (Mergl et al., 2015). 
Accumulating studies have reported that sex is a key factor that determines different 
effects of stress and opioids on behaviours and analgesic responses both in animal 
and human studies. These sex differences effects may result from different molecular 
mechanisms at the receptor level, neural mechanism in the brain networks and sex 
hormone levels (Bolea-Alamanac et al., 2018). This section focuses on the sex 
differences in stress, KOPr activation and depression, addiction responses, 
suggesting the evidence that may underlie these sex differences. 
 
1.3.1 Sex differences of opioid receptors in pain and analgesia 
In addition to dysphoria, depressive-like behaviours and increased immobility 
following KOPr activation, DYN/KOPr system has been also reported to be involved 
in nociception and to produce analgesic effects by inhibiting synaptic transmission in 
pain circuits (Meng et al., 2005). KOPrs are also found to be expressed in the dorsal 
horn of the spinal cord, dorsal root ganglia and rostral ventromedial medulla (RVM) 
and sensory thalamus, which are important regions involved in pain circuitry 
(Gutstein et al., 1998, Winkler et al., 2006). A number of studies showed that both 
physical and psychological stressors induce analgesia in animals via activating KOPr 
signalling (Takahashi et al., 1990, Menendez et al., 1993). However, it has been 
recently revealed that the effects of dynorphin-induced analgesia are influenced by 
sex. For example, Liu and colleagues showed that intrathecal administration of 
yohimbine, a selective 2 adrenoceptors antagonist, produced an anti-nociceptive 
effect by releasing dynorphin and activating the KOPr system, which in turn 
attenuated formalin-elicited nociception in male rats, but no effect was observed in 
females (Liu et al., 2013). Early studies on mice showed that administration of 
U50,488, a selective kappa opioid receptor agonist, produced more analgesia in male 
mice than female mice on the hot-plate (Kavaliers et al., 1987). One recent study in 
C57BL/6N mice demonstrated KOPr activation by selective KOPr agonist, U50,488 
produced a great anti-nociceptive effect in male mice, but not in female mice in the 
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tail flick assay. These sex-dependent analgesic effects induced by KOPr activation is 
regulated by estradiol levels and G protein-coupled receptor kinase 2 (GRK2) activity, 
which might underlie the sex differences in KOPr function in analgesic responses 
(Abraham et al., 2018). 
 
Whereas in human clinical studies reported the opposite effects, administration of 
mixed KOPr and MOPr agonists, pentazocine and nalbuphine produced significantly 
greater and prolonged analgesia in women subjects than in men after dental surgery, 
suggesting that kappa opioid receptor activation-induced analgesia is sex dependent 
and patient sex might have an impact on the efficacy of clinical opioid analgesics 
(Gear et al., 1996). The distinct sex difference effects observed between rodents and 
humans could due to different study designs and pain models were involved and 
different ligands were used. 
 
Altogether, this evidence indicates that KOPr-mediated analgesic effects depend on 
sex, strain, species and pain models. The mechanisms underlying the sex differences 
observed in KOPr-induced anti-nociception could result from sex chromosomes, 
gonadal hormones, distribution and expression levels of KOPrs in the brain, and the 




1.3.2 Sex differences in response to stress 
Epidemiological studies have shown that women have higher vulnerability to stress-
related psychiatric conditions than men, such as post-traumatic stress disorder (PTSD) 
and depression. The prevalence of depression in women is almost twice that in men 
in the global analysis (Kessler, 2003, Albert, 2015). Although, the mechanisms 
underlying these sex differences in chronic stress-related psychiatric disorders are 
not fully understood, studies have suggested that sex differences in stress sensitivity 
could result from different corticotropin-releasing factor (CRF) function, which is one 
of the key modulators in the HPA axis in response to stress, described in section 1.1.2.  
 
For example, in male and female Sprague-Dawley rats, Bangasser and colleagues 
showed that at receptor level, there is an enhanced CRF receptor signalling (greater 
CRF receptor coupling to Gs protein) in non-stressed female rats, which was not 
significantly affected by swim stress, but in male rats, CRF signalling is largely 
increased following swim stress (Bangasser et al., 2010), also, stress-induced CRF 
receptor internalisation was only observed in male rats, not in females, indicating 
that females have higher sensitivity to low levels of CRF and decreased ability to 
adapt to excessive levels of CRF, which might be an important molecular mechanisms 
that underlie higher vulnerability of females to develop psychiatric disorders and sex 
differences in response to stress (Bangasser et al., 2010). In addition, other evidence 
reported that there were higher basal ACTH and CRF expression in the PVN in female 
rats than males, especially in the presence of high levels of estrogen (Iwasaki-Sekino 
et al., 2009). In response to foot shock stress or restraint stress (RS), female rats 
showed higher levels of plasma ACTH and corticosterone than male rats (Viau et al., 
2005, Iwasaki-Sekino et al., 2009). These studies indicate different secretion of ACTH 
and corticosterone in response to stress between male and female rodents, 
suggesting that the function of stress-related PVN region and HPA axis-regulated 
hormone release are sex-dependent, which are implicated in sex differences in 
stress-induced psychiatric disorders. 
 
In contrast to rodent’s data, human studies reported that adult men showed 
significantly higher basal ACTH levels compared to age-matched women (Back et al., 
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2008). In response to an acute psychological stress e.g. public speaking, academic 
exam, male subjects also showed greater release of ACTH and cortisol than female 
subjects (Kudielka et al., 2005, Uhart et al., 2006). These opposite findings between 
rodents and human highlight sex differences in stress-activated HPA activation and 
the importance of future investigations of the mechanisms underlying stress-induced 
psychiatric disorders in human. 
 
Two important mediators of the antidepressant therapeutic targets, brain-derived 
neurotrophic factor (BDNF) and cyclic adenosine monophosphate response element-
binding protein (CREB) levels were investigated in response to foot shock stress in 
both male and female rats (Lin et al., 2009), which showed reduced CREB levels in 
the hippocampus and amygdala following this stress in male rats, but these effects 
were not observed in female rats. However, BDNF levels were not affected following 
chronic stress in male PFCx but were significantly decreased in female PFCx. Finally, 
during the stress response, stress-induced morphological changes were only found 
in male hippocampus, but not in female rats (Lin et al., 2009), these results further 
showed that sex is an important factor in mediating different effects in response to 
stress, suggest the further development of antidepressants could be sex dependent. 
Early studies have also shown that female rats had more rapid and significant 
increases in corticosterone levels than male rats during forced swimming stress (Kant 
et al., 1983), and female rats were more sensitive to HPA axis activation than male 
rats after prenatal stress (Weinstock et al., 1992). More recent studies on 
behavioural tests revealed that chronic stress significantly decreased sucrose 
preference and reduced time spent in the centre of open field tests in female rats, 
compared to the control groups, whereas male rats did not produce these effects in 
the behavioural test (Lu et al., 2015). 
Collectively, these findings in both human and animals proved the importance of sex 
differences in mediating stress-related behavioural responses and stress-induced 





1.3.3 Sex differences in KOPr and stress 
Stress-induced effects are strongly associated with KOPr activation, stress induces 
behavioural responses, at least in part, by activating dynorphin/KOPr system. As 
shown in the previous section, sex differences have been observed in animal 
behaviours in response to stress, and it is proposed that KOPr activation plays a role 
in mediating sex dependent behavioural response to stress. An increasing number of 
studies have been performed to investigate how sex influences the effects of KOPr 
activation. 
 
Activation of KOPrs produces depressive-like and anxiety-like states, blockade of 
KOPrs have been showed to improve stress-induced depressive-like behaviours and 
dysphoric states in animal studies. Consequently, the KOPr is proposed as a potential 
therapeutic target for the treatment of psychiatric disorders, such as depression and 
anxiety. However, several studies revealed the sex differences in the effects of KOPrs 
function on stress-induced behavioural responses. In recent animal studies on 
C57BL/6J and California mice, the KOPr selective antagonist, norBNI, blocked forced 
swim stress-induced immobility in a sex dependent manner, where male mice 
showed reduced immobility in the FST. This was not found in female mice, indicating 
that KOPr plays a greater role in mediating stress-induced effects in males, and forced 
swimming-induced immobility might be less dependent on KOPr signalling in female 
mice. This evidence confirms the importance of KOPr in mediating sex differences in 
stress-induced behavioural responses (Laman-Maharg et al., 2018). 
 
It also has been shown that the effect of KOPr activation by U50,488 treatment on 
motivational behavioural was not only sex dependent, but also dose dependent, 
female California mice demonstrated CPA with a low dose of U50,488 (2.5mg/kg), 
but CPP to a high dose of U50,488 (10mg/kg), whereas male mice only formed CPA 
to the high dose of U50,488 (10mg/kg) (Robles et al., 2014), which are supported by 
other studies on the sex differences in KOPr activation-induced behaviours, showing 
that low dose of U50,488 (2.5mg/kg) induced CPA in naïve female California mice, 
not in male mice, whereas naïve male mice only showed aversive effects following 
high dose of U50,488 (10mg/kg) treatment (Laman-Maharg et al., 2017), indicating 
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that females are more sensitive to KOPr agonist than male mice. More importantly, 
after long-term social defeat stress, female mice no longer demonstrated aversive 
properties with 2.5mg/kg of U50,488 treatment, no place aversion was observed 
with increased dose of U50,488 (10mg/kg), however, stressed male mice showed 
aversive effects in the presence of U50,488 (10mg/kg) treatment (Laman-Maharg et 
al., 2017). These findings suggest that long-term stress may attenuate KOPr-
mediated aversive properties in female mice, highlighting the importance of sex 
differences in the effects of chronic stress on KOPr function, and future study of how 
short or long-term stress could affect KOPr activation-mediated behaviours between 
males and females is needed. 
 
Although it has been shown that KOPr activation-mediated sex differences are 
dependent on estradiol levels and GRK2 activity (Abraham et al., 2018). The 
mechanisms that underlying different KOPr function between males and females are 
still not fully understood, further understanding of KOPrs distribution and expression 
levels, as well as the influences of sex chromosomes on KOPr function could facilitate 




1.3.4 Sex differences in KOPrs and addiction 
Similar to the sex differences in KOPr system-mediated stress responses, there are 
also evidence on sex differences in KOPr activation-induced addictive behaviours. It 
is known that dopamine release in the mesolimbic pathway is crucial in mediating 
motivated behaviours, however, recent study investigated the effect of KOPr 
activation on dopamine release in both male and female rats, which showed that 
administration of U50,488 suppressed dopamine release in the NAc more effectively 
in male mice, compared to the females (Conway et al., 2019). Also, KOPr activation 
by a selective KOPr agonist, U50,488 induced anhedonic effects and decrease in 
motivated behaviour in adult Sprague-Dawley male rats, but significantly less effects 
were observed in female rats, which is independent of gonadal hormones (Russell et 
al., 2014), these effects were measured with intracranial self-stimulation (ICSS), an 
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operant paradigm that is used for rodents to examine changes in rewarding function 
(Carlezon and Chartoff, 2007). 
 
In addition, administration of KOPr agonist prior to cocaine treatment potentiated 
cocaine-induced place preference in male mice (McLaughlin et al., 2006), it was 
proposed that cocaine-induced rewarding properties would produce different 
effects in female mice, which was showed by early studies from Sershen and 
colleagues, who reported that a KOPr agonist produced behavioural responses in a 
sex dependent manner, pre-treatment with KOPr agonist, spiradoline potentiates 
locomotor activity following cocaine treatment only in male mice, not in female mice 
(Sershen et al., 1998). Interestingly, opposite effects were observed in guinea pigs in 
the same study, where KOPr agonist, U50,488 significantly decreased cocaine-
induced locomotor activity in females, not males (Wang et al., 2011). 
 
All these inconsistent findings in sex differences in KOPr system-mediated stress 
responses and addictive behaviours emphasise the importance of sex-dependent 
therapeutics for addiction and affective disorders treatment.  
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1.4 Transgenic animal strains 
1.4.1 cFos 
Following exposure to a variety of stimuli, activated neurons alter gene expression 
by inducing a number of immediate early gene (IEGs), including cFos, c-Jun and zif268 
(Senba et al., 1997). cFos has low basal expression levels and is rapidly induced in 
response to different stimuli, it is widely used as a neuronal activity marker, i.e. 
upregulation of cFos gene expression indicates recent neuronal activities. Therefore, 
monitoring expression of cFos has been useful in identifying brain regions that are 
activated by a wide range of stimuli or regions involved in behavioural responses and 
pharmacological states (Gall et al., 1998). Since cFos is initially and transiently 
induced following a wide range of stimuli, it is an important neuronal marker not only 
for indicating recent neural activity, but also widely used to map neuronal changes 
and circuitry during development and identify the types of neurons activated by 
specific treatment in the brain networks (Hoffman et al., 1993, Rinaman et al., 1997). 
 
cFos is a proto-oncogene and belongs to a transcription FOS family with other 
members including FosB, FosB2, FosB, Fra-1 and Fra-2. It is activated rapidly and 
responsible for converting extracellular signals into changes of gene expression. cFos 
normally forms a heterodimer with another transcription factor c-Jun, a complex 
called activator protein-1 (AP-1), which has specific DNA binding sites that regulate 
target gene expression (Curran et al., 1988) (Figure 1.7). 
  Figure 1.7 Illustration of transcription factor cFos gene induction. 
Activation of cFos promoter initiates the production of cFos gene from 
5’ to 3’ following different stimuli. 
 30
1.4.2 cFos-GFP transgenic mice 
In order to understand the neuronal changes involved in stress and drug addiction-
related responses, the expression of the IEG cFos was used as a measure of recent 
neuronal activity. In this study, previously developed cFos-GFP transgenic mice were 
used (Barth et al., 2004). In these mice the cFos promoter is coupled to the coding 
region for enhanced green fluorescent protein (EGFP), illustrated in figure 1.8. Since 
the promoter and coding region from the cFos gene were fused in frame to EGFP, 
expression of GFP directly follows the cFos production in activated neurons.  
 
 
In addition, -aminobutyric acid (GABA) is the predominant inhibitory 
neurotransmitter in the central nervous system. In order to better understand the 
distribution and characterise GABAergic neurons, Tamamaki and colleagues 
developed glutamic acid decarboxylase - green fluorescence protein (GAD-GFP) 
knock-in mouse. As GAD is only expressed in GABAergic neurons, GFP expression in 
these mice is restricted to GABAergic neurons only (Tamamaki et al., 2003). These 
mice therefore enable us to visualise GABAergic neurons and identify whether the 
neurons are GABAergic neurons or non-GABAergic neurons in immunocytochemistry 
experiments (Chapter 6). 
  
Figure 1.8 Schematic diagram of cFos gene and cFos-GFP transgene structure 
in response to stressor stimuli. 
 
Diagram adapted from Barth et al., 2004 
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1.4.3 The advantages of using cFos-GFP mice 
The use of cFos-GFP transgenic mice facilitates identification of the brain regions and 
individual neurons activated by different stimuli; also cFos-GFP mice facilitate 
characterisation of activated neurons by performing electrophysiology or FACS 
sorting techniques. Upon neuronal activation, expression of both cFos protein and 
GFP in these transgenic mice would allow us to perform co-labelling of both proteins 
with immunofluorescent histochemistry (IHC) to quantify the number of GFP positive 
(GFP+) and GFP negative (GFP-) neurons. Considering the short half-life of cFos 
protein (Kovacs et al., 1998), GFP was previously determined to have a relatively 
longer half-life in cultured cells from mice (Corish et al., 1999). The more stable GFP 


































All studies used either male or female adult C57BL/6 cFos-GFP (Chapter 3, 4, 5 and 7) 
(Barth et al., 2004) or GAD-GFP transgenic mice (Chapter 3 and 6) (Tamamaki et al., 
2003). Original cFos-GFP mice were purchased from Jackson Laboratories (Bar 
Harbor, Maine, USA). Original GAD-GFP mice were a kind gift from Dimitri Kullman 
(UCL, UK) and were rederived by Charles River (Margate, UK). All animals used in this 
study were bred in-house from heterozygous males bred with wild type C57BL/6 
females (Charles River UK). 
 
All positive transgenic male or female mice used in the experiments were between 9 
weeks and 13 weeks old. Mice were housed in groups of 2 to 5 with water and food 
available ad libitum in a temperature and humidity-controlled environment under a 
12-hours light-dark cycle (lights on at 7 a.m.), all experiments were carried out during 
the light phase. All mice were handled and weighed one day before stress procedures 
(section 2.4 and 2.5) or drug treatment (section 2.6). All procedures were approved 




GAD-GFP mice were genotyped by using GFP goggles (BLS, Budapest, Hungary) when 
mice were <3 days post-partum. cFos-GFP mice were genotyped using polymerase 
chain reaction (PCR) amplification. Ear punch biopsy samples were collected from 3 
weeks old male and female mice. DNA was extracted by adding 75l of alkaline lysis 
reagent (25mM NaOH, 0.2mM disodium EDTA, pH 12), heat block at 95C for 20 
minutes. After heating, samples were cooled at 4C and followed by adding 75l of 
neutralising reagent (40mM Tris-HCl, pH 5) into each sample (Truett et al., 2000). The 
extracted DNA were used for PCR reaction, which was carried out by using Taq DNA 
polymerase with standard Taq (Mg-free) buffer kit (New England Biolabs, M0320S), 
dNTP mix (10mM) (Thermo Fisher Scientific, R0191) and previously designed gene 
specific primers (Sigma-Aldrich, UK; summarised in Table 2.1). For PCR reaction, 2.5 
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l 1x standard Taq (Mg-free) buffer (containing 10mM Tris-HCl, 50mM KCl, pH 8.3), 
2 l MgCl2 (1.5mM) solution, 0.5 l dNTPs (10mM), 2.5 l GFP forward primer (10M), 
2.5 l GFP reverse primer (10M), 1.25 l -actin forward primer (10M), 1.25 l -
actin reverse primer (10M), 0.25 l Taq polymerase, 8.25 l RNase-free water and 
4 l DNA sample were added in each PCR tube. The PCR tubes were placed in a PCR 
machine (MJ Research, PCT-200) with following reaction cycling conditions: 95C for 
30 seconds (denaturation), 40 cycles of 95C for 15 seconds (denaturation), 60C for 
30 seconds (annealing), 68C for 30 seconds (extension), followed by 68C for 5 
minutes for final elongation. The PCR products were separated on 1% agarose gel 
with ethidium bromide (0.2 g/ml, Sigma-Aldrich, UK) under 120V for 40 minutes. 
Finally, the DNA bands were visualised and imaged using GeneSnap (SynGene) 






Commercially available primary antibodies used were: rabbit anti-actin antibody 
(Abcam, ab1801), rabbit anti-cFos antibody (Santa Cruz Biotechnology Inc., SC-52), 
which was discontinued mid-way through the project and replaced with rabbit anti-
cFos antibody (Cell Signalling Technology, #2250), chicken anti-GFP (Green 
Fluorescent Protein) antibody (Abcam, ab13970). Secondary antibodies were: 
Primer Sequences 5’- 3’ Size References 
-Actin 
Forward: CTAGGCCACAGAATTGAAAGATCT 324 The Jackson 
Laboratory 
Reverse: GTAGGTGGAAATTCTAGCATCATCC 324 
GFP 
Forward: AAGTTCATCTGCACCACCG 173 The Jackson 
Laboratory 
Reverse: TCCTTGAAGAAGATGGTGCG 173 
Table 2.1 The genetic sequences of forward and reverse primer sequences 
for -actin (internal positive control) and GFP (transgene). 
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IRDye 800CW Donkey anti-Rabbit IgG (H+L) (LICOR, #926-32213) and IRDye 
680RD Donkey anti-Chicken IgG (H+L) (LICOR, #926-32218). Goat anti-Rabbit 
antibody Alexa Fluor 568 (ThermoFisher Scientific, A11011) and Goat anti-Chicken 
antibody Alexa Fluor 488 (Abcam, ab150169). 
 
2.4 Restraint stress 
Restraint stress was used as an acute stressor by placing the body into a modified 
50ml ventilated syringe for 2 hours (Kim and Han, 2006). The mouse body was 
stabilised by using the syringe plunger so that it can remain in the confined space. 
After 2 hours restraint stress, the mice were sacrificed by cervical dislocation, and 
the brains were dissected and removed for biochemical analysis, including protein 
extraction for western blotting (Section 2.7) and RNA extraction for RT-PCR (Section 
2.8 and 2.9). All non-stressed control mice were just handled and weighed. 
 
2.5 Forced Swim Stress (FSS) 
The forced swim test (FST) was used as an acute stressor (Contet et al., 2006). The 
FST was carried out in a glass beaker (height 34 cm, diameter 22 cm) with total 
volume 10 litres; the glass beaker was filled with water to approximately two thirds 
of the total beaker volume (height 23 cm), the water temperature was adjusted to 
25  1C. The mice were gently placed on the water in the beaker and allowed to 
swim for 15 minutes. After 15 minutes, the mice were removed from the water and 
dried before being placed into an empty holding cage with heated blanket 
underneath. The mice were further dried in the holding cage for at least 10 minutes 
before moving back to the home cage. The glass beaker was washed with 70% 
ethanol, rinsed with water at least 3 times and refilled with fresh water after each 
mouse. The mice were killed 2 hours after stressing and the brains were removed for 
biochemical analysis with Western blotting (section 2.7) and RNA isolation (section 
2.8) or proceeded to immunocytochemistry (section 2.10). All non-stressed control 
mice were just handled and weighed. 
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2.6 Kappa opioid receptor ligands 
U50,488 was used as a selective KOPr agonist (Vonvoigtlander et al., 1983) (Tocris, 
Avonmouth, UK), and was administered intraperitoneally (i.p.) at 20 mg/kg (Marrone 
et al., 2016). Norbinaltorphimine (norBNI) was used as a selective KOPr antagonist 
(Portoghese et al., 1987) (Tocris, Avonmouth, UK) and was administered i.p. at 10 
mg/kg (McLaughlin et al., 2003). All drugs were dissolved in 0.9% w/v saline (Hameln 
Pharmaceuticals, Gloucester, UK) and administered via i.p. route at a volume of 10 
ml/kg. NorBNI is characterised with a slow onset of activity (peaking at 24 hours) and 
long-lasting effects for 3-4 weeks (Endoh et al., 1992), therefore norBNI injections 
were administered 24 hours before stress or U50,488 treatment. 
 
2.7 Protein extraction and Western blotting 
In initial experiments (Chapter 3), brain GFP expression was quantified using Western 
blotting. Mice were killed by cervical dislocation and the brains were rapidly removed, 
the hippocampi and/or PFCx were dissected and immediately placed on dry ice. 
Samples were kept at -80C before processing. Protein was extracted from brain 
tissues by using 10 volumes of Radioimmunoprecipitation (RIPA) buffer (including 10 
mM Tris-HCl, pH 7.4, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% 
SDS, 140 mM NaCl, 1 mM PMSF). The protein concertation of the supernatant was 
determined using BCA protein assay (Pierce, Rockford, IL) (Bailey and Toth 2004). 
 
Proteins (20g) were separated by 10% SDS-PAGE (sodium dodecyl sulphate 
polyacrylamide gel electrophoresis), followed by transferring the separated protein 
onto PVDF (Polyvinylidene difluoride) membrane. The membranes were blocked by 
5% BSA (bovine serum albumin) at room temperature for 1 hour, then the blots were 
incubated with primary anti-GFP (diluted 1:5000) or anti-Actin antibody (diluted 
1:1000) in TBST (Tris Buffered Saline Tween 20) containing 2.5% BSA overnight at 4C. 
The next day, the membrane blots were rinsed with TBST 6 times (5 minutes each 
time) and incubated with fluorescence-conjugated secondary antibody (diluted 
1:5000) in TBST containing 2.5% BSA for 1 hour at room temperature. The proteins 
 37
of interest were then detected by LI-COR Bioscience Odyssey with 685nm and 785nm 
wavelength.  
 
2.8 RNA Isolation 
In initial experiments (Chapter 3), GFP was quantified using reverse transcription 
polymerase chain reaction (RT-PCR). Mice were killed by cervical dislocation and the 
brains were rapidly removed, the hippocampi were dissected and immediately 
placed on dry ice. Samples were kept at -80C before processing. Hippocampal RNA 
was isolated from brain tissues by adding 0.5 ml TRIzol (Invitrogen) and the mixtures 
were homogenised by a pellet pestle. Another 0.5 ml TRIzol was added and the 
mixtures were passed through a 23G needle (1 ml of TRIzol per 50-100 mg tissue). 20 
l glycogen (1 mg/ml) was added to the sample and mixed briefly. The homogenised 
sample was left for 5 minutes at room temperature. 200 l chloroform was then 
added to the sample in fume hood and vigorously shook by hand for 15 seconds and 
left at room temperature for 2-3 minutes. The mixture was centrifuged at 12,000  g 
for 15 minutes at 4C, which allows the mixture to separate into a lower red phenol-
chloroform phase and a colourless upper phase. The upper aqueous phase was 
collected into a new tube in fume hood and the lower phase was discarded. RNA was 
precipitated by adding 0.5 ml 100% propa-2-ol, the mixture was then incubated at 
room temperature for at least 30 minutes. After 30 minutes’ incubation, the mixture 
was centrifuged at 12,000  g for 15 minutes at 4C and the supernatant was 
removed. A further 1 ml of 75% ethanol per 1 ml TRIzol was added, followed by 
briefly vortexing. The mixture was centrifuged again at 7,500  g for 5 minutes at 4C. 
The liquid was removed, and the pellet was left to air dry for 5-10 minutes, the pellet 
was then re-suspended with 30l RNAse free water by passing solution through a 
pipette tip several times. Finally, the mixture was incubated at 55-60C for 10-15 
minutes and stored at -80C until use. 
 
DNA digestion was then carried out in order to remove DNA from extracted RNA 
solution. For each RNA sample, 4 l reaction buffer (New England Biolabs), 1 l 
RNAsin (40U/l, Fementas), 4 l DNAse (1U/l, Fementas) and 1 l RNAse free water 
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were added and incubated at 37C for 30 minutes. 10 l glycogen (1mg/ml) and 100 
l 100% ethanol were added to each sample to precipitate RNA, followed by at least 
30 minutes incubation at room temperature. The mixture was centrifuge at 12,000  
g for 15 minutes at 4C and the supernatant was removed. The pellet was washed 
with 250 l 75% ethanol, followed by briefly vortex and the sample was centrifuged 
at 12,000  g for 5 minutes at 4C. The supernatant was removed, and the pellet was 
left to air dry for at least 15 minutes at 37C. Finally, the RNA pellet was re-suspended 
in 20 l RNAse free water and the samples were stored at -80C until use. 
 
2.9 Reverse transcription PCR (RT-PCR) 
Reverse transcription PCR was carried out by using SuperScript One-step RT-PCR 
with Platinum Taq DNA polymerase kit (Invitrogen), which allows detection of the 
expression of a specific gene of interest by amplifying its sequence, using the 
previously designed gene specific primers (Sigma-Aldrich, UK; summarised in Table 
2.2). For PCR reaction, 12.5 l 2 x reaction buffer (including 0.4mM dNTP, 2.4mM 
MgSO4), 10.1 l RNase-free water, 0.4 l RT/Taq mix, 0.5 l forward primer (10M), 
0.5 l reverse primer (10M) and 1 l template RNA sample (0.2 g/l) were added 
in each PCR tube. The PCR tubes were placed in a PCR machine (MJ Research, PCT-
200) underwent the following reaction cycling conditions: 50C for 30 minutes 
(reverse transcription for cDNA synthesis), 94C for 2minutes (denaturation), 40 
cycles of 94C for 15 seconds (denaturation), 60C for 30 seconds (annealing), 72C 
for 30 seconds (extension), followed by final elongation at 72C for 5 minutes. The 
PCR products were separated on 1% agarose gel with ethidium bromide (0.2 g/ml, 
Sigma-Aldrich, UK) under 100V for 50 minutes - 1 hour, then the gene of interest 
(separated DNA bands) on the gel were visualised using GeneSnap (SynGene) 






Table 2.2 Gene specific forward and reverse primers designed for one step RT-    PCR.      
Primers were designed by using primer-designing tool (Primer-BLAST) or adopted 




Mice were treated with either a single i.p. injection of selective KOPr agonist 
(U50,488, 20mg/kg) or acute in vivo stressor (forced swim stress or restraint stress). 
Immediately after restraint stress, or, 2 hours after forced swim stress or KOPr 
agonist injection, mice were anesthetised with i.p. injection of pentobarbital 
(100mg/kg) and perfused intracardially with a solution of 0.1M of phosphate 
buffered saline (PBS), pH 7.4, followed by 4% paraformaldehyde (PFA), pH 7.4. The 
brain was removed and placed in a specimen bottle and post-fixed and stored in 4% 
PFA at 4C. The brain tissue was permeated with 30% sucrose in PBS solution at 4C 
overnight (16 hours) one day before immunohistochemistry. The brain tissues were 
cut into coronal sections (40m) on a vibratome, including PFC (Bregma +2.22 mm), 
NAc (Bregma +1.34 mm), dorsal hippocampus (Bregma -1.94 mm) and amygdala 
(Bregma -1.94 mm). For each mouse, one slice was taken for each brain region. The 
slices were rinsed in 0.01 M PBS, pH 7.4. Tissue sections were blocked in 0.01 M PBS 


















containing 0.1% Triton X-100 and 5% donkey serum for 2 hours at room temperature. 
After that, the tissue slices were incubated with affinity-purified primary antibodies 
(cFos, 1:500, GFP, 1:1000) in 0.01 M PBS containing 0.1% Triton X-100 and 2.5% 
donkey serum at 4C overnight (16 hours). 
 
The following day, tissue slices were washed with 0.01 M PBS at least four times for 
10 minutes. The slices were incubated with either IRDye 800CW Donkey anti-
Rabbit antibody (diluted 1:1000) and IRDye 680RD Donkey anti-Chicken antibody 
(diluted 1:1000) (Chapter 3 for LICOR images), or Alexa Fluor 568 Goat anti-Rabbit 
antibody (diluted 1:500) and Alexa Fluor 488 Goat anti-Chicken antibody (diluted 
1:500) (Chapter 4, 5 and 6 for fluorescent microscope images) in 0.01 M PBS 
containing 0.1% Triton X-100 and 2.5% donkey serum for 2 hours at room 
temperature. The tissue slices were washed four times over 2 hours and mounted 
with Vectshield (Vector Laboratories) on microscope slides. The infrared 
immunoreactivity was detected by scanning the whole brain slides at 700 nm or 800 
nm wavelength, infrared images were acquired with 21 m resolution and set with 
‘highest’ quality (Eaton et al., 2016). The fluorescence immunoreactivity was 
detected using a Leica DMI4000B inverted wide-field fluorescent microscope at 200x 
magnification. 
 
Fluorescent signals in regions of interest are directly proportional to the amount of 
protein on the brain slices; thus, the observed signal intensities were directly 
measured in ImageJ software. Two methods of quantification were trialled initially 
(see Chapter 3). In each experiment, shown in Chapters 4-6, background signals were 
measured and cFos or GFP signals data were normalised relative to corresponding 
background signals.  
 
2.11 Blood sampling 
The tail incision method was used for blood sampling in this study (Fluttert et al., 
2000; Sadler and Bailey 2016). All blood samples were collected between 9:00h and 
13:00h. Mice were carefully held and cupped by one person and the operator 
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stabilised the mouse by gently holding the tail on the bench. A small nick 
(approximately 2mm in width, 0.5mm in depth) was made on the lateral tail vein 
using a razor blade, perpendicular to the tail, approximately 2cm from the tip of the 
tail. Blood samples were then collected by using heparinised capillary tubes 
(Hawksley, Sussex, UK), approximately 40l of blood was collected from each mouse. 
All blood samples were then transferred to microcentrifuge tubes containing EDTA 
(3g/l) and stored on ice. Samples were then centrifuged at 2000 relative centrifuge 
force (rcf) for 20 minutes at 4C. After centrifugation, plasma was collected and 
stored at -20C until corticosterone analysis. 
 
2.12 Corticosterone analysis 
The corticosterone concentrations in each sample were determined by performing 
enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s 
instructions (IBL International, Hamburg, Germany) (Sadler et al., 2016). Plasma 
samples were diluted 10x and added to a 96 well plate (with standards of known 
corticosterone concentration), where wells were coated with an anti-corticosterone 
antibody. Enzyme conjugate (corticosterone conjugated to horseradish peroxidase) 
was added into each well and the well plate was mixed for 10 seconds, followed by 
1-hour incubation at room temperature and washed 3 times. Lastly, the enzyme 
substrate solution (tetramethylbenzidine) was added to each well and incubated for 
15 minutes at room temperature, the enzymatic reaction was terminated by adding 
a stop solution into each well. The final optical density was read at 450  10 nm using 
a microtiter plate reader (FLUOstar Optima, BMG Labtech). All samples were run in 
duplicate, with average values taken. The standard curve was calculated and 
constructed using MARS data analysis software (BMG Labtech) with a 4-parameter 
logistics curve fit, the average values from each sample duplicate were used to 






2.13 Data quantification and statistical analysis 
Normalised data were analysed with one-way (treatment) analysis of variance 
(ANOVA) followed by post-hoc Sidak’s test for each brain area in Chapter 4, 5 and 6. 
The effect of in vivo stressor and U50,488 on corticosterone levels were analysed 
using two-way (treatment x time) ANOVA followed by Sidak’s test in Chapter 7. All 
data are presented as mean  SEM and significance levels were P<0.05. 
 
2.14 Reagents and materials 
All reagents and materials were purchased from suppliers as mentioned above. All 
other reagents and materials were purchased from Signal-Aldrich (Poole, UK), except 
PVDF membrane, glycogen and paraformaldehyde (PFA) powder which were 
purchased from Thermo Fisher Scientific (Loughborough, UK), and agarose powder 






























Chapter 3 Optimisation of methods used to 






As described in Chapter 1, multiple brain regions are involved in the primary 
responses to stress, and there is considerable overlap between stress-related brain 
regions and those that express KOPrs and/or are activated by systemic 
administration of KOPr agonists or by dynorphin release. These brain regions include 
the PFCx, amygdala, NAc and hippocampus. 
 
cFos is an immediate early gene that is often seen as a marker of neuronal activation. 
Numerous studies have shown that acute stress can induce a significant increase in 
cFos expression. For examples, acute restraint stress induced significant induction of 
cFos mRNA in the hippocampus and PFCx (Melia et al., 1994, Ryabinin et al., 1995, 
Del Bel et al., 1998), and in immunohistochemistry studies, cFos protein expression 
was increased by acute restraint and forced swim stress in the hippocampus 
(Ryabinin et al., 1995, Pace et al., 2005).  
 
In this study we are using expression of cFos as a marker for neuronal activity, which 
will allow us to investigate the pattern of cFos activation / neuronal activation in 
response to stress and KOPr agonist administration. The initial aim of this study was 
to determine appropriate experimental procedures that robustly and reproducibly 
enable us to quantify cFos expression (mRNA or protein) following an acute stressor. 
After identifying an appropriate technique, this can then be used in subsequent 








In this chapter, male adult (9-13 weeks old, 25-30g) C57BL/6 cFos-GFP (Barth et al., 
2004) were used, which were originally purchased from Jackson Laboratories (Bar 
Harbor, Maine, USA). GAD-GFP (12 weeks old, 26g) (Tamamaki et al., 2003) 
transgenic mouse (Charles River, Margate, UK) were used for the anti-GFP antibody 
validation (Abcam, ab13970) experiment. 
 
3.2.2 In vivo stressor 
Restraint stress (section 2.4) and forced swim stress (section 2.5) were used as acute 
stressors to induce the cFos mRNA and cFos-driven GFP expression, which were 
detected by using RT-PCR (section 2.8, 2.9), Western blotting (section 2.7) and 
immunohistochemistry (section 2.10). 
 
3.2.3 Immunohistochemistry 
The immunohistochemistry details were descried in chapter 2, section 2.10. In this 
chapter, the mouse prefrontal cortex (Bregma +2.22 mm), dorsal (Bregma -1.94 mm) 
and ventral hippocampal (Bregma -2.80 mm) slices were cut using a vibratome. For 
each mouse, one slice was taken for each region, these slices were dual-labelled with 
anti-cFos and anti-GFP antibodies (section 2.3), followed by incubation with infrared-
labelled secondary antibodies: IRDye 800CW Donkey anti-Rabbit antibody (diluted 
1:1000) and IRDye 680RD Donkey anti-Chicken antibody (diluted 1:1000) for LICOR 
images (section 2.3) or goat anti-rabbit Alexa fluor 568 antibody (diluted 1:500) and 
goat anti-chicken Alexa fluor 488 antibody (diluted 1:500) (section 2.3). 
 
3.2.4 Quantification and statistical analysis 
Band intensities were measured in pixel/band and normalised to corresponding actin 
values by using ImageJ. In immunohistochemistry, two methods of quantifying the 
stress-induced cFos and cFos-induced GFP were shown in this chapter for 
comparison: the relative fluorescent signals (section 4.2.2) by using ImageJ and 
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manually counting the number of fluorescent-positive neurons. The data were 
analysed with unpaired Student’s t test. All data are presented as mean  SEM and 




3.3.1 Validation of anti-GFP antibody 
The long-term aim of this study was to use cFos-GFP transgenic mice, where GFP 
expression is under the control of the cFos promoter. In this way, quantifying GFP 
expression is an index of previous cFos expression. In initial experiments, the anti-
GFP antibody was validated. To do this, we used GAD67-GFP transgenic mice 
(Tamamaki et al., 2003), which constitutively express GFP in all GABAergic neurons 
in the brain. As GABAergic neurons are ubiquitously expressed in the brain and 
account for a relatively large portion of neurons, GFP expression in the brains of 
these animals is widespread and so GAD67-GFP transgenic mice are useful as a 
positive control for anti-GFP antibody validation. 
 
Subjects were one male adult wild type C57BL/6 mouse and one male adult GAD-GFP 
transgenic mouse; both PFCx and hippocampus were dissected from each mouse and 
immediately proceeded to protein extraction in solubilisation buffer, followed by 
separation and analysis by Western blotting using anti-GFP antibody, with actin 
controls. As shown in Figure 3.3.1, no GFP signal was observed in wild type PFCx and 
hippocampus samples, whereas robust GFP signals were shown in GAD67-GFP 
transgenic PFCx and hippocampus samples at 27kDa, which suggests that the specific 


















3.3.2 Expression of GFP following in vivo stress 
Once the anti-GFP antibody had been validated, it was then used to attempt to detect 
cFos-driven GFP induction following an acute in vivo restraint stressor, a well-
established model to induce depression and anxiety-like behaviours which has 
previously been shown to induce cFos expression in a variety of brain regions. In 
initial studies, the acute stressor used was restraint stress, previously shown to 
increase cFos expression in the hippocampus (Melia et al., 1994). 
 
Three cFos-GFP transgenic animals were exposed to restraint stress, then killed by 
cervical dislocation immediately after, 2 hours after or 4 hours after. The hippocampi 
were dissected and then processed for Western blotting using an anti-GFP antibody, 
with actin control. Control cFos-GFP animals were not exposed to restraint stress but 
were killed at the same time as restraint stress-treated animals. Two GAD-GFP 
transgenic animals were used as positive controls. 
 - Actin (42kDa) 
 - GFP (27kDa) 
Anti-GFP immunoblot 
Figure 3.3.1 Validation of anti-GFP antibody. Male adult (12 weeks) 
GAD-GFP transgenic mouse and wild type (WT) mouse were used. Both 
PFCx and hippocampus were obtained from each type of mouse. Tissues 
underwent Western blotting for GFP detection. 
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Figure 3.3.2A demonstrates that there was no robust increase in GFP expression after 
two hours restraint stress, compared to non-stressed mice (control A, B or C). Also 
the expression of GFP immediately after stress (RS 0) is similar to that of 2 hours (RS 
2) or 4 hours (RS 4) post stress (Figure 3.3.2A). In the same Western blot gel, 
hippocampal protein samples taken from two GAD-GFP transgenic mice were also 
analysed as a positive control and show strong GFP bands signals at 27kDa. Figure 
3.3.2B shows quantification of the Western blot shown in Figure 3.3.2A. Here there 
is a slight increase in the relative GFP/Actin signal immediately after stress (RS 0), 
which then declines after two- or four hours post-stress (RS 2, RS 4). One possible 
reason for this might be GFP is degrading over the time period, however, previous 
studies have shown that GFP protein is relatively stable, and so would be unlikely to 
degrade significantly over 2-4 hours (Barth et al., 2004). As in these preliminary 
validation experiments the sample size was effectively 1, we cannot say for sure 
whether GFP was increase at RS 0, but, the overall increase in GFP signal was minimal. 
 
Overall, these data fail to detect a robust increase in cFos-driven GFP expression in 
the hippocampus, following two hours restraint stress. This is in contrast to previous 
studies that have demonstrated cFos expression induced by restraint stress (Melia et 
al., 1994, Ryabinin et al., 1995). The reasons why this approach did not yield 
favourable results for us is unclear. 
  
The same experiment was repeated for cFos/GFP protein detection following forced 
swim as the stressor (rather than restraint stress) with both wild-type C57BL/6 mice 
and cFos-GFP transgenic mice, using both anti-cFos and anti-GFP antibodies. 
However, it showed a similar pattern to restraint stress, in that no consistent 
difference was seen between control and stress-treated animals (data not shown). 
We therefore used a different technique (RT-PCR) to attempt to quantify increases 
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Figure 3.3.2 GFP expression following two hours restraint stress. (A) Six male 
adult (12 weeks) C57BL/6 cFos-GFP transgenic mice; three were untreated, 
serving as controls (control A, B and C), three underwent two-hour restraint stress 
(RS) and were killed either immediately (RS 0) after stress, or two hours (RS 2) or 
four hours (RS 4) after stress. Hippocampi were dissected and cFos-driven GFP 
measured using Western blotting. Two untreated GAD-GFP transgenic mice 
duplication were used as positive controls for GFP detection. (B) Quantitation of 
expression of GFP represented by relative signal (GFP/Actin). 
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3.3.3 Expression of cFos mRNA following in vivo 
stress 
Since in vivo stressor stimulus did not profoundly affect the GFP expression examined 
using Western blots (Figure 3.3.2), it was then investigated whether an in vivo 
stressor (two hours restraint stress) could induce an observable increase in 
hippocampal cFos mRNA expression. This experiment used six cFos-GFP transgenic 
mice that were either untreated (3 controls) or exposed to two hours restraint stress 
as above (3 restraint stress treated). Immediately following in vivo restraint stress, 
mice were killed by cervical dislocation, the hippocampi were dissected and 
processed for mRNA analysis using RT-PCR. 
 
Figure 3.3.3A represents the cFos mRNA bands observed in all six samples (3 controls, 
3 restraint stress treated), with actin controls. However, as with previous Western 
blotting experiments, there was no significant difference between the control and 
stress-treated samples (Figure 3.3.3B). Notably, the RS 1 sample showed a slight 
increase in intensity, compared to the control 1 sample, whereas the opposite effect 
was observed between control 3 and RS 3 samples i.e. the intensity of control 3 is 
higher than that of RS 3 bands (Figure 3.3.3A), suggesting either that the two hours 
restraint stress did not produce robust increases in cFos mRNA levels, or that this 
method of detection is unsuitable. Furthermore, the same experiment was also 
carried out for cFos mRNA detection following forced swim wild-type C57BL/6 mice, 
but a similar pattern was observed (data not shown). Thus, further studies using a 
different technique, immunohistochemistry, were performed in order to derive a 













3.3.4 Immunohistochemical localisation of cFos 
and GFP expression 
As there were no detectable stress-induced increases in cFos or cFos-driven GFP 
effects observed in Western and mRNA analysis in the previous sections (Section 
3.3.2 & 3.3.3), immunohistochemical techniques were then used to attempt to 
β-actin (214 bp) 
cFos (129 bp) 
Figure 3.3.3 Expression of cFos mRNA after in vivo stressor. (A) Subjects 
were six male adults (10-12 weeks) C57BL/6 cFos-GFP transgenic mice. Three 
were untreated (control 1, 2 and 3) and three were underwent two-hour 
restraint stress (RS 1, 2 and 3). All mice were killed immediately after 
restraint stress. Hippocampi were dissected and processed to RNA 
extraction and RT-PCR. RNAse free water acted as negative control (-VE). (B) 
Quantification of cFos mRNA after restraint stress between control and RS 
groups, represented by relative signal (cFos/actin). All data are shown as 




































detect any cFos or cFos-driven GFP expression changes induced by stress, as previous 
immunohistochemistry studies have successfully demonstrated acute stress-induced 
increases in cFos expression in the hippocampus and PFCx in rats (Ryabinin et al., 
1995, Pace et al., 2005). 
 
Adult male (12 weeks) cFos-GFP C57BL/6 mice underwent two-hour restraint stress, 
with non-stressed controls. After two hours, the mice were anaesthetised with 
pentobarbital (100mg/kg), followed by cardiac perfusion fixation. Coronal brain 
sections (40m) were taken, containing either dorsal or ventral hippocampus and 
were co-stained with both rabbit anti-cFos and chicken anti-GFP antibodies, followed 
by incubation of fluorophore-labelled secondary antibodies, 800CW donkey anti-
rabbit and 680RD donkey anti-chicken antibodies. The slices were mounted on 
microscope slides and imaged using LI-COR Odyssey, shown in Figure 3.3.4. In the 
hippocampus, both dorsal and ventral hippocampus showed an increase in cFos and 
cFos-driven GFP immunoreactivity signals following acute two hours restraint stress, 
compared to the controls (Figure 3.3.4), indicating that two hours restraint stress 
induced an overall increase expression of cFos and cFos-driven GFP in the 
hippocampus in these mice. This immunohistochemical technique provides a 
promising methodology to detect the stress-induced effects in different brain regions 







































































Anti-cFos immunoreactivity Anti-GFP immunoreactivity 
Dorsal hippocampus sections 
Ventral hippocampus sections 
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3.3.5 Optimisation of immunohistochemical 
methodology  
The previous section (3.3.4) demonstrated that immunohistochemistry could be 
used to detect and measure the effects of stress on cFos and cFos-driven GFP 
expression in cFos-GFP transgenic mice. Although the LICOR detection method 
allowed us to visualise cFos and cFos-driven GFP expression in whole brain section, 
it lacks resolution on the single cell level. In order to detect cFos and cFos-driven GFP 
immunoreactivity with higher resolution at an individual neuronal level, regular 
immunofluorescence microscope was used. The same primary antibodies were used 
as in the previous section (rabbit anti-cFos and chicken anti-GFP antibodies) but with 
secondary antibodies conjugated to different fluophores to permit visualisation using 
a conventional immunofluorescence microscope, rather than in the infrared range 
(as with LICOR). Secondary antibodies used were goat anti-rabbit Alexa fluor 568 
antibody and goat anti-chicken Alexa fluor 488 antibody. 
 
cFos-GFP transgenic mice (n=6 animals per treatment group) underwent a single 
acute stress stressor (forced swim) with non-stressed controls. 2 hours later, animals 
were anaesthetised with pentobarbital (100mg/kg) followed by cardiac perfusion 
fixation. Brains were sectioned (40 m), immunolabelled, and imaged using a Leica 
DMI4000B inverted wide-filed fluorescent microscope. Sample images in the PFCx 
are shown in figure 3.3.5, which shows apparent increases in both cFos and cFos-
driven GFP following forced swim stress, compared to the non-stressed controls. The 
Figure 3.3.4 Coronal sections of the dorsal (Bregma -1.94 mm) and ventral 
(Bregma -2.80 mm) hippocampus in mouse brain immunostained for cFos 
and GFP. One adult male C57BL/6J cFos-GFP transgenic mouse underwent 2-
hour restraint stress, with one untreated mouse as control. 40 m tissue 
sections were stained with both anti-cFos and anti-GFP antibodies, followed 
by appropriate fluorescent secondary antibodies. cFos and GFP 
immunoreactivity on each slice was detected with the LI-COR Odyssey with 
21m resolution and 1mm offset. Adult male C57BL/6J cFos-GFP transgenic 
mice were treated with either two-hour restraint stress or no stress time-
matched controls. 
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fluorescence signals in these images were further quantified in two different ways: 
by measuring relative fluorescent signals in ImageJ software 
(https://imagej.net/Image_Intensity_Processing) and by counting the number of 
cFos or GFP-positive neurons manually, the quantified signals of both quantifying 









Figure 3.3.5 Example images of stress-induced cFos and cFos-driven GFP 
expression in the PFCx in male mice. 
Coronal sections of PFCx (40m) (Bregma +2.22 mm) were cut and 
immunolabelled with anti-cFos and anti-GFP antibodies.  cFos (red) and 
cFos-driven GFP (green) immunoreactivity was visualised under wide-field 
fluorescent microscopy, and cFos and GFP expression was increased in 
response to 15 minutes forced swim stress in the PFCx, compared to the 























Figures 3.3.5 & 3.3.6 show that stress-induced increases in cFos and cFos-driven GFP 
expression (in cFos-GFP transgenic mice) can be successfully detected using this 
technique. Sample images are shown from PFCx, but similar results were observed in 
hippocampal CA1 region taken from the same animals (Figure 3.3.7), and quantified 
by two different methods for comparison (Figure 3.3.8). Further, in similar 
preliminary experiments, in mice treated with a single injection of the KOPr agonist, 
Figure 3.3.6 Two different methods of quantifying the effects of stress on cFos 
and cFos-driven GFP expression in the PFCx in male mice. 
A, quantified fluorescent signals by measuring the relative signals. B, manually 
counting the number of positive neurons that express cFos or GFP 
immunoreactivity. All data are presented as mean  SEM. N = 6 animals per 








































































U50,488 (20mg/kg), there was also a detectable and significant increase in cFos and 
cFos-driven GFP using this immunohistochemical method (data not shown). This 
provide us with a protocol with which stress- and KOPr agonist-induced neuronal 
activity can be detected. The images could then be quantified by two different 
methods, shown in figure 3.3.6 and 3.3.8, demonstrating that both of the 
quantification methods yield similar results, suggesting either of the quantification 
method works for this analysis in further similar preliminary experiments. Therefore, 
this immunohistochemical methods with fluorescent-labelled secondary antibodies 









Figure 3.3.7 Example images of stress-induced cFos and cFos-driven GFP 
expression in the hippocampal CA1 region in male mice. 
Similar to the PFCx images shown above, coronal sections of CA1 region (40m) 
(Bregma -1.94 mm) were cut and co-stained with anti-cFos and anti-GFP 
antibodies. Comparing to the non-stressed samples, both cFos (red) and GFP 











































































Figure 3.3.8 Two different quantifying methods for analysing the FSS-
induced cFos and GFP expression in the CA1 region of the hippocampus 
in male mice. 
A, fluorescent signals were quantified by measuring the relative signal. 
B, the number of cFos- or GFP-positive neurons were counted manually. 
N = 6 per treatment group, unpaired Student’s t test, * = P<0.05. 
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3.4 Discussion 
Different techniques were used to attempt to detect cFos and cFos-driven GFP 
expression in cFos-GFP expression following in vivo stressors, that could be used 
throughout this study. Our results from Western blotting and mRNA (RT-PCR) 
analysis failed to show a robust increase in either cFos or cFos-driven GFP expression 
immediately following acute restraint and forced swim stressors, which did not 
further support the earlier evidence in adult male rats, showing that acute restraint 
stress caused high levels of cFos protein expression in the PFCx using Western 
blotting (Perrotti et al., 2004), or studies in adult male rats that showed increased 
expression of cFos mRNA in the hippocampus and PFCx immediately after acute two-
hour restraint stress (Melia et al., 1994, Ryabinin et al., 1995). In addition, previous 
evidence demonstrated cFos mRNA expression reached a peak level after 30 minutes 
to 60 minutes post-stress, and this stress-induced cFos mRNA expression remarkably 
decreased after 120 minutes (Cullinan et al., 1995), suggesting that stress intensity 
and duration or time course post-stress may directly affect the detection of cFos 
mRNA expression. 
 
The reason why we failed to replicate these findings is unclear, but, one possible 
reason is that cFos expression might not be increase across the hippocampus as a 
whole. Pace and colleagues showed that changes in cFos expression after novel 
experience was region-specific, with an increase in cFos-positive cells in the CA1, CA2, 
CA3 and inner layer dentate gyrus regions in the hippocampus, but a significant 
decrease in cFos-positive neurons in the outer layer of the dentate gyrus (Pace et al., 
2005). These findings might explain why there was no obvious difference in cFos 
mRNA and protein levels between control and stressed mice, as the whole 
hippocampus was taken in these experiments for RNA and protein extraction and 
analysis, the elevated cFos gene levels in one subregion might be balanced with 
decreases in other subregions of the hippocampus. Therefore, both Western blotting 
and RT-PCR techniques might not be sensitive enough to detect the changes in stress-
induced cFos expression within the hippocampus. In addition, as the whole 
 60
hippocampus was removed for RNA or protein extraction, it is unable to determine 
the stress-induced any effects in the subregions e.g. CA1 or dentate gyrus. 
 
However, as an alternative to Western blotting and RT-PCR, several studies have 
revealed the effects of acute stress on cFos protein expression in different brain 
regions using immunohistochemistry (e.g. Ryabinin et al., 1995, Pace et al., 2005, 
Perrotti et al., 2004, Briand et al., 2010). For example, the overall number of cFos-
positive neurons in the CA1 and CA2 regions of the hippocampus were increased 
after two-hour restraint stress in adult rats (Pace et al., 2005), while other evidence 
showed 15 minutes restraint stress or 6 minutes forced swim stress significantly 
increased the number of cFos-positive immunoreactive neurons in the hippocampus, 
PFCx, NAc and amygdala in adult rats (Ryabinin et al., 1995) and in adult mice (Briand 
et al., 2010). Our data using immunohistochemical techniques (Section 3.3.4 & 3.3.5) 
not only provided us with the best method to investigate the stress-induced cFos 
expression effects in different brain subregions, but also showed a significant 
increase in cFos and cFos-driven GFP expression in the PFCx (Figure 3.3.5 & 3.3.6) 
and hippocampal CA1 region (Figure 3.3.7 & 3.3.8)  in male cFos-GFP mice following 
an acute stress, which support the previous evidence on stress-induced effects in 
different brain areas in rodents. This method was then used to investigate cFos 
expression after an acute in vivo stressor and single administration of a KOPr agonist 
























Chapter 4 The effect of kappa opioid receptor 




The previous chapter demonstrates that immunocytochemistry allowed us to detect 
cFos expression in the prefrontal cortex and hippocampus in brain slices after acute 
restraint stress. In this chapter, investigations into neuronal activity induced by acute 
forced swim stress or KOPr agonist treatment were performed. Using fluorescence 
microscopy in different brain regions in male mice, cFos immunoreactivity at an 
individual neuron level was quantified, using the method shown in the previous 
chapter. 
 
As discussed in chapter 1, the PFCx, hippocampus (HPC) and amygdala are three 
primary regions that are important in mediating behavioural responses to stress 
(McEwen et al., 2010), while dopaminergic input from VTA to the NAc is the key 
component for rewarding properties of drugs of abuse (Adinoff 2004). It has been 
shown that NAc is not only the key region involved in drug addiction, but also 
implicated in depression and anxiety (Perrotti et al., 2004). Perrotti and colleagues 
showed increased cFos immunoactivity in the NAc in rats after acute restraint stress 
(Perrotti et al., 2004). Similarly, other studies also demonstrated that acute forced 
swimming stress significantly induced cFos expression in the NAc and PFCx in male 
mice (Briand et al., 2010). These data suggested the important role of NAc in the 
effects of acute in vivo stress, which may contribute to stress-induced enhancement 
of drug intake. In addition, both the hippocampus and the amygdala are also 
implicated in drug reward mechanisms and psychiatric diseases (Bolla et al., 2003), 
for example, studies in male rats showed exposure of foot shock stress and 30 
minutes of restraint stress significantly increased cFos expression in the NAc, 
hippocampus, central amygdala and basolateral amygdala (Funk et al., 2006), 
highlighting the crucial role of these brain regions implicated in mediating stress 




Stress exposure induces the release of an endogenous neuropeptide dynorphin 
(DYN), which primarily activates kappa opioid receptors (KOPrs) and produces 
dysphoria, anxiety and depressive-like behaviours (Bruchas et al., 2010). KOPr is a Gi 
protein-coupled receptor (GPCR) and belongs to the opioid receptor family. 
Increasing evidences suggests that KOPrs play a major role in both stress responses 
and addiction-related behaviours, and dysregulation of KOPrs is involved in 
psychiatric disorders, such as depression and addiction (Bruchas et al., 2010, Lalanne 
et al., 2014). KOPrs are highly expressed throughout the limbic brain areas implicated 
in the development of depression, anxiety and addiction such as the VTA, NAc, PFCx, 
hippocampus and amygdala (Knoll & Carlezon, 2010). 
 
A number of animal studies have shown that stress-induced dynorphin/KOPr system 
activation is a key component in the aversive stress behaviour and rewarding 
properties potentiation (McLaughlin et al., 2003, Carey et al., 2009, Shirayama et al., 
2004, Redila & Chavkin, 2008), thus, activation of KOPrs is used to mimic aversive 
effects of stress in animal models (Knoll & Carlezon, 2010). Importantly, antagonism 
of KOPr or disruption of prodynorphin gene significantly prevented stress-induced 
analgesia, reduced stress-induced immobility and blocked the stress-induced cocaine 
reinstatement (McLaughlin et al., 2003, Redila & Chavkin, 2008), suggesting that 
KOPr antagonists have anti-depressant-like effects, thus, KOPrs represent a potential 
therapeutic target for the depression treatment. Additionally, Russell and colleagues 
showed that administration of KOPr agonist, U50,488 (10mg/kg) significantly induced 
cFos expression in the NAc and amygdala in male rats (Russell et al., 2014). Other 
evidence in California male mice also reported U50,488-induced neuronal activation 
in the NAc by showing increased immunoactivity of p38 MAP kinase, an extracellular 
signal modulated MAP kinase that indicates the activation of KOPr (Robles et al., 
2014). 
 
The aim of this chapter is to investigate the effects of a single injection of KOPr 
agonist (U50,488), in mice, on neuronal activity in various brain regions (PFCx, NAc, 
hippocampus, amygdala) and compare the rain regions activated by KOPr agonist 
with those activated by in vivo FSS. Neuronal activity will be assessed by quantifying 
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cFos expression in each brain region using immunohistochemistry.  We hypothesise 
that, in mice, both a single injection of KOPr agonist and in vivo forced swim stress-
induced dynorphin release would activate KOPrs in vivo, and would induce neuronal 
activation in a similar fashion in PFCx, NAc, hippocampus and amygdala (as indicated 
by increased cFos expression). We further hypothesise that pretreatment of the 
animals with the KOPr antagonist nor-binaltorphimine (norBNI) would block the 
effects of KOPr agonist and may also inhibit (at least in part) forced swim stress-





Adult male (9-13 weeks old, 25-30g) C57BL/6 cFos-GFP transgenic mice (n = 6 animals 
per treatment group) were treated with either saline or KOPr antagonist, norBNI 
(10mg/kg; i.p.), after 24 hours, mice were treated with either a single injection of 
U50,488 (20mg/kg; i.p.) (Marrone et al., 2016) or 15-minute forced swim stress. Two 
hours later, mice were then anesthetised with intraperitoneal injection of 
pentobarbital (100mg/kg; i.p.) and perfused intracardially with a solution of 0.1M of 
phosphate buffered saline (PBS), pH 7.4, followed by 4% paraformaldehyde (PFA), pH 
7.4, illustrated in figure 4.1. 
 
The brain was removed and placed in a specimen bottle and post-fixed and stored in 
4% PFA at 4C for immunocytochemistry, which was described in chapter 2 section 
2.10. The coronal sections (40m) of PFCx (Bregma +2.22 mm), NAc (Bregma +1.34 
mm), amygdala (Bregma -1.94 mm) and hippocampal CA1 region and dentate gyrus 
(Bregma -1.94 mm) were cut on a vibratome. For each mouse, one slice was taken 
for each brain region. These slices were dual labelled with anti-cFos and anti-GFP 
antibodies (section 2.3), followed by fluophore-tagged secondary antibodies: goat 
anti-rabbit antibody Alexa Fluor 568 (diluted 1:500) and goat anti-chicken antibody 
Alexa Fluor 488 (diluted 1:500) (section 2.3). 
 
The fluorescence immunoactivity was detected using Leica DMI4000B inverted wide-
filed fluorescent microscope at 200X magnification and fluorescence intensity 
quantified in regions of interest (ImageJ). Fluorescent signals are directly 
proportional to the amount of protein on brain slices; thus, the observed signal 
intensities for each brain region on each slice were the average values of the left and 
right signals, measured in ImageJ software. In each experiment, cFos or GFP 
expression signals were corrected to the background signals. All data are presented 
as mean  SEM and significance levels were P < 0.05, all data were analysed with the 





24 hours later 
Pharmacological approach Physical in vivo approach 
2 hours later 
Cardiac perfusion fixation 
and immunocytochemistry, 
labelling for cFos and GFP 
Saline (10ml/kg) or the KOPr 
antagonist norBNI (10mg/kg) 
15-minute forced 
swim stress (FSS) 
or no stress 
A single injection with U50,488 
(selective kappa opioid receptor 
agonist, 20mg/kg) or saline 
Adult male C57BL/6 cFos-GFP 
transgenic mice 
Figure 4.1 Illustration of immunocytochemistry procedures for adult 
male (9-13 weeks old) C57BL/6 cFos-GFP mice following pharmacological 
(U50,488, 20mg/kg, i.p.) or physical in vivo stressors (FSS). 
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4.3 Results  
4.3.1 The effect of U50,488 in male PFCx 
To investigate how kappa opioid receptor activation affects different brain regions in 
male mice. Adult male C57BL/6J cFos-GFP transgenic mice were pre-administered 
with either saline or the KOPr antagonist norBNI (10mg/kg, i.p.). After 24 hours, the 
mice were treated with either saline or KOPr agonist, U50,488 (20mg/kg; i.p.) (n = 6 
animals per treatment group, i.e. 24 mice used in total). Two hours later, mice were 
killed and brains sectioned for immunocytochemistry. Typical expression patterns in 
the prelimbic area of the PFCx (layers 1-3, indicated in Figure 4.2A) are shown in 
Figure 4.2B. 
 
These fluorescent signals were quantified as shown in Figure 4.2B. In male mice, cFos 
expression was significantly increased in the prelimbic area (layers 1-3) of PFCx 
following U50,488 treatment (Figure 4.2C), compared to the saline-treated control 
group. A similar increase was also observed in cFos-driven GFP expression (Figure 
4.2C), demonstrating that the prelimbic area of PFCx was activated after a single 
injection of U50,488. In addition, administration of KOPr antagonist norBNI alone did 
not produce any significant effects on either cFos and GFP expression. More 
importantly, U50,488-induced effects were significantly blocked by 10mg/kg of 







Figure 4.2A Coronal section of mouse brain showing prefrontal cortex. The red square indicates 






























Figure 4.2B The Effect of U50,488 (20mg/kg) on cFos and GFP expression in PFCx 
(Bregma +2.22 mm) in the presence of norBNI (10mg/kg) in male cFos-GFP mice. 
Example images of coronal sections of PFCx (40m) in adult male C57BL/6J cFos-GFP 
transgenic mice, which were treated with either saline or norBNI (10mg/kg) 24 hours 
prior to the saline or U50,488 (20mg/kg) treatment. A single injection of U50,488 
increased cFos and GFP fluorescent signals, compare to the control saline-treated 










Figure 4.2C Quantified fluorescent signals of cFos and GFP expression 
following U50,488 (20mg/kg) in PFCx in male mice. 
Fluorescent signals were relative signals, which were corrected to the 
background. U50,488 treatment significantly increased both cFos (A) and GFP 
(B) signals, which were significantly abolished by pre-administration of norBNI. 
All data are presented as mean  SEM, * = P<0.05, ** = P<0.01. One-way 



























































































































4.3.2 The effect of FSS in male PFCx 
In order to compare the effects observed following KOPr activation (Figure 4.2) with 
an in vivo stressor, mice underwent 15 minutes FSS, instead of U50,488 injection, and 
proceed to immunocytochemistry. Both cFos and cFos-driven GFP expression were 
increased in the prelimbic area (layer 1-3) of PFCx following FSS, compared to the 
non-stressed control groups. Samples images are shown in Figure 4.3A, with 
quantified data shown in Figure 4.3B. The effect of FSS was similar to the effect of 
U50,488 shown in Section 4.3.1, however, unlike with U50,488, pre-administration 
of norBNI (10mg/kg) did not significantly attenuate the FSS-induced increases in cFos 
or GFP expression (Figure 4.3B). Overall, these data suggest that the in vivo stressor, 
FSS, initiates neuronal activation in the PFCx in a similar manner to U50,488, although 
FSS-induced effects were unlikely to be mediated by activating the KOPr system, 
since the acute stress-induced neuronal activity were not significantly blocked by 




































Figure 4.3A The Effect of 15-minute FSS on cFos and GFP expression in PFCx in 
the presence of norBNI (10mg/kg). 
Adult male C57BL/6J cFos-GFP transgenic mice were treated with either saline or 
norBNI (10mg/kg) 24 hours prior to 15 minutes FSS or no stress (NS). 2 hours later, 
animals were killed and brains sectioned. Both cFos and GFP fluorescent signals 
were imaged under fluorescent microscope, FSS induced cFos and GFP expression, 










Figure 4.3B Quantified fluorescent signals of cFos and GFP expression 
following FSS in PFCx. 
Fluorescent signals were relative signals, which were corrected to the 
background. 15-minute FSS significantly increased both cFos (A) and GFP (B) 
signals, which were not significantly decreased by pre-administration of 
norBNI. All data are presented as mean  SEM, * = P<0.05, ** = P<0.01. One-












































































































4.3.3 The effect of U50,488 in male NAc 
As we have seen significant effects of KOPr activation and in vivo stressor on neuronal 
activation in PFCx, we also investigated if these effects would produce a similar or 
different pattern in other brain regions i.e. nucleus accumbens core (Figure 4.4B). 
Comparing to the pattern we have seen in PFCx, similar patterns were observed in 
NAc: there was a significant effect of both cFos and GFP following a single injection 
of U50,488 (20mg/kg) (Figure 4.4C). These effects were also effectively abolished by 
pre-administration of norBNI (10mg/kg) and norBNI treatment alone did not produce 





Figure 4.4A Coronal section of mouse brain showing nucleus accumbens. The red square indicates 


































Figure 4.4B Illustration of cFos and GFP expression in NAc core (Bregma +1.34 
mm) after U50,488 (20mg/kg) treatment in the presence of norBNI (10mg/kg). 
There was an increase in expression of both cFos and GFP after a single injection 
of U50,488 compared to the control saline-treated groups, similar to that seen in 




  A 
B 
Figure 4.4C Quantification of fluorescent cFos and GFP signals following 
U50,488 (20mg/kg) in NAc core. 
Fluorescent signals were relative signals, which were corrected to the 
background. U50,488 treatment significantly increased both cFos (A) and GFP 
(B) signals, which were effectively blocked by pre-administration of norBNI. All 
data are presented as mean  SEM, * = P<0.05, ** = P<0.01. One-way ANOVA 




























































































































4.3.4 The effect of FSS in male NAc 
The effect of U50,488 on cFos and GFP expression in NAc was similar to that shown 
previously in PFCx (Section 4.3.3). The experiment was repeated after FSS, to 
compare cFos expression after pharmacological and physical stressors. Fluorescent 
images are shown in figure 4.5A. Again, there is a similar expression pattern on cFos 
and GFP expression following FSS stimulation in NAc as there was in PFCx i.e. both 
signals were effectively increased (Figure 4.5B). Interestingly, norBNI pre-
administration showed significant reduction in cFos expression in NAc, an effect that 
was not seen in PFCx, although the blocking effect of norBNI was not observed in GFP 
signals. Overall, cFos and cFos-driven GFP was expressed following an in vivo stressor 
in NAc, as shown previously in PFCx. In NAc, but not PFCx, this neuronal activation 
























Figure 4.5A Demonstration of cFos and GFP expression following 15-minute FSS in 
NAc core in the presence of norBNI (10mg/kg). 
C57BL/6J cFos-GFP transgenic mice were treated with either saline or norBNI 
(10mg/kg) 24 hours prior to 15 minutes FSS or no stress (NS). 2 hours later, animals 
were killed and brains sectioned. Both cFos and GFP fluorescent signals were 
imaged under fluorescent microscope, FSS induced cFos and GFP expression, 





Figure 4.5B Quantified fluorescent signals of cFos and GFP expression 
following FSS in NAc core. 
Relative fluorescent signals, which were corrected to the background. 15-
minute FSS significantly increased both cFos (A) and GFP (B) signals. Prior 
treatment with norBNI significantly inhibited cFos, but not GFP expression. All 
data are presented as mean  SEM, * = P<0.05, ** = P<0.01. One-way ANOVA 











































































































4.3.5 Overlapping expression of cFos and GFP in PFCx and 
NAc 
As we have used cFos-GFP transgenic mice, where expression of GFP directly follows 
the cFos production in activated neurons (Chapter 1), this facilitates identification 
and mapping of the brain regions and individual neurons induced by different stimuli 
(FSS and kappa opioid receptor agonists). Also, as the half-life of cFos is much shorter 
than that of GFP, it also gives the possibility of looking at temporal changes in cFos 
expression. For example, if single neurons express GFP, but not cFos, this may mean 
that cFos expression occurred at an early stage, but that the cFos protein has already 
degraded at the time-point used here, with GFP expression persisting. For this reason, 
fluorescent images labelled with cFos and GFP (as shown earlier) were merged 
together, shown in figure 4.6A, 4.6B. 
 
Figure 4.6A shows the cFos-expressing neurons (red), GFP-expressing neurons (green) 
and cFos/GFP overlapped images following a single U50,488 injection in PFCx and 
NAc. Yellow signals in the overlapping images show co-expression of both cFos and 
GFP in the same cell. The number of cells that were positive for cFos only, GFP only 
and both cFos and GFP (merged) were counted and presented as a percentage of 
total number of neurons (Figure 4.6C). In the PFCx, approximately 50% of neurons 
were positive for both cFos and GFP in control animals, with approximately 40% of 
neurons expressing GFP alone. Following U50,488 treatment, there was no 
significant change in the pattern of neurons that were positive for cFos alone, GFP 
alone or both cFos and GFP (Figure 4.6C). 
 
In the NAc, in slices from control animals, there was a similar pattern of cells positive 
for cFos alone (~10%), GFP alone (~40%) and cFos+GFP (~50%). However, after 
U50,488 treatment, there was a significant increase in the proportion of cells that 
were positive for cFos alone (Figure 4.6C). The proportion of cells that were positive 
for GFP alone or cFos+GFP both decreased, but not significantly.  
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A different pattern was seen in sections taken from animals that had undergone 15-
minute forced swim stressor (FSS) treatment; cFos alone (red), GFP alone (green) and 
both cFos + GFP (yellow) signals in PFCx and NAc (Figure 4.6B). In PFCx, after FSS, 
there was a significant increase in the proportion of cells positive for both cFos + GFP, 
and a significant decrease in cells positive for GFP alone (Figure 4.6C). 
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  cFos GFP cFos/GFP merged 
PFCx 
NAc 
Figure 4.6A Overlapping images of cFos-expressing neurons (red), GFP-expressing neurons (green) and cFos/GFP co-localised 
in the same neurons in PFCx and NAc core. 
Co-expression of cFos and GFP shown in yellow indicates recent neuronal activity induced by a single injection of U50,488 
(20mg/kg), scale bar = 100m. 
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 cFos GFP cFos/GFP merged 
PFCx 
NAc 
Figure 4.6B Overlapping images of cFos-expressing neurons (red), GFP-expressing neurons (green) and cFos/GFP co-localised 
in the same neurons in PFCx and NAc core. 
cFos and GFP co-expression is shown in yellow indicates recent neuronal activity induced by 15-minute FSS, scale bar = 100m. 
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Figure 4.6C Percentage of overlapping neurons in total neurons in PFCx (A) and NAc core (B). 
The cFos-positive, GFP-positive and cFos + GFP-positive neurons were counted separately and calculated as 
the percentage of total number of neurons for each treatment. The cFos + GFP-positive neurons indicated 
in grey bar represents cFos and GFP are co-expressed in the same cells. All data are presented as mean  
SEM, one-way ANOVA post-hoc Sidak’s test, ** = P<0.01, *** = P<0.001, **** = P<0.0001. 








































































4.3.6 The effect of U50,488 in male hippocampus 
As discussed in Chapter 1, the hippocampus is also an important region that is 
involved in stress responses and affective-related disorders. The experiment above 
was repeated, and fluorescent images taken in CA1 region and dentate gyrus of 
dorsal hippocampus, indicated in figure 4.7A. The typical expression patterns are 
shown in figure 4.7B and 4.7D. Similar to the effects seen in PFCx and NAc (Section 
4.3.1 – 4.3.4), in the CA1 region of hippocampus there was a significant increase in 
cFos and cFos-driven GFP expression following U50,488. Pre-administration of 
norBNI also inhibited these effects (Figure 4.7C). In contrast, in the dentate gyrus 
region of the hippocampus no changes in either cFos or GFP expression following 
U50,488 treatment were seen (Figure 4.7E). 
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Figure 4.7A Coronal section of mouse brain showing dorsal hippocampus. The red rectangle 
indicates the location of CA1 region of dorsal hippocampus, the blue rectangle shows dentate gyrus 

























Figure 4.7B Fluorescent images of cFos and GFP expression in CA1 region 
of dorsal hippocampus (Bregma -1.94 mm) after U50,488 (20mg/kg) 
treatment in the absence or presence of norBNI (10mg/kg).  
There was an increase in expression of both cFos and GFP after U50,488 
treatment, compared to the control saline-treated groups. The effect was 









Figure 4.7C Quantification of fluorescent cFos and GFP signals following 
U50,488 (20mg/kg) in hippocampal CA1 region. 
Fluorescent signals were relative signals, which were corrected to the 
background. U50,488 treatment significantly increased both cFos (A) and GFP 
(B) signals, which were effectively blocked by pre-administration of norBNI. All 
data are presented as mean  SEM, * = P<0.05, ** = P<0.01. One-way ANOVA 













































































































































Figure 4.7D Fluorescent images of cFos and GFP expression in dentate 
gyrus of dorsal hippocampus (Bregma -1.94 mm) after U50,488 (20mg/kg) 
treatment in the presence or absence of norBNI (10mg/kg). 
A single injection of U50,488 did not change expression of both cFos and 
GFP, compared to the control saline-treated groups, the presence of norBNI 








Figure 4.7E Quantification of fluorescent cFos and GFP signals following 
U50,488 (20mg/kg) in hippocampal dentate gyrus. 
U50,488 treatment did not change both cFos (A) and GFP (B) signals. NorBNI 
also had no effect. All data are presented as mean  SEM. One-way ANOVA 























































































































4.3.7 The effect of FSS in male hippocampus 
As shown in Section 4.3.6, the effect of U50,488 treatment on hippocampal CA1 
region was similar to that of in PFCx and NAc, but the hippocampal dentate gyrus did 
not respond to the U50,488 treatment. The experiment was then repeated in 
response to in vivo FSS. Sample images from the hippocampus are shown in figure 
4.8A and 4.8C.  
Surprisingly, in vivo FSS did not produce any effects on either cFos or GFP expression 
in hippocampal CA1 region and dentate gyrus (Figure 4.8B, 4.8D). Also, the presence 
of norBNI did not affect the cFos and GFP signals following FSS in the hippocampus. 
These effects were completely different from the effects observed in PFCx and NAc, 




























Figure 4.8A Fluorescent images of cFos and GFP expression in CA1 region 
of dorsal hippocampus (Bregma -1.94 mm) after 15-minute FSS. 
No significant changes in either cFos or GFP signals after FSS, compared to 
the control non-stressed groups. Pretreatment with norBNI had no effect. 





cFos expression A 
B 
Figure 4.8B Quantified fluorescent cFos and GFP signals following 15-
minute FSS in hippocampal CA1 region. 
FSS did not significantly alter cFos (A) and GFP (B) signals in the absence or 
presence of norBNI (10mg/kg). All data are presented as mean  SEM. One-

























































































































FSS   
cFos GFP 
Figure 4.8C Fluorescent images of cFos and GFP expression in dentate 
gyrus of dorsal hippocampus (Bregma -1.94 mm) after 15-minute FSS. 
No significant changes in either cFos or GFP signals were seen after FSS, 
compared to the control non-stressed groups. NorBNI was without effect. 




cFos expression A 
B 
Figure 4.8D Quantified fluorescent cFos and GFP signals following 15-minute 
FSS in dentate gyrus of hippocampus. 
FSS did not significantly alter either cFos (A) or GFP (B) signals in the absence 
or presence of norBNI (10mg/kg). All data are presented as mean  SEM. One-







































































































4.3.8 The effect of U50,488 in male amygdala 
It is known that the amygdala is an important region involved in anxiety and 
depression-related behaviours, as well as addiction-related behaviours, and high 
levels of KOPr mRNA have been detected in the amygdala (Chapter 1). We therefore 
investigated neuronal activity levels in both the central nucleus of the amygdala (CeA) 
and the basolateral nucleus of the amygdala (BLA) amygdala following a single 
injection of U50,488, indicated in figure 4.9A. Sample images in CeA are shown in 
figure 4.9B and BLA images are shown in figure 4.9D. 
 
Similar to the effects that were shown in other brains regions i.e. PFCx, NAc and 
hippocampal CA1 region, U50,488 treatment significantly induced expression of cFos 
and cFos-driven GFP in CeA, as well as in BLA. Similarly, the U50,488-induced cFos 
and GFP expression in CeA and BLA were effectively blocked by pre-administration 





Figure 4.9A Coronal section of mouse brain containing amygdala. The red square indicates the 
location of central amygdala (CeA), the blue square shows basolateral amygdala (BLA), where all 





















Figure 4.9B Fluorescent images of cFos and GFP expression in CeA 
(Bregma -1.94 mm) after a single U50,488 (20mg/kg) administration. 
A single injection of U50,488 induced both cFos and GFP, compared to the 
control saline-treated groups, an effect that was inhibited by norBNI. Scale 








Figure 4.9C Quantified fluorescent cFos and GFP signals following U50,488 
treatment in CeA. 
U50,488 induced both cFos (A) or GFP (B) signals, which were blocked by 
the presence of norBNI (10mg/kg). All data are presented as mean  SEM. 















































































































































Figure 4.9D Fluorescent images of cFos and GFP expression in BLA (Bregma 
-1.94 mm) after a single U50,488 (20mg/kg) administration. 
U50,488 significantly induced both cFos and GFP, compared to the control 
saline-treated groups, an effect that was inhibited by pretreatment with 






cFos expression A 
B 
Figure 4.9E Quantified fluorescent cFos and GFP signals following U50,488 
treatment in BLA. 
U50,488 induced both cFos (A) or GFP (B) signals, which were blocked by the 
presence of norBNI (10mg/kg). All data are presented as mean  SEM. One-



























































































































4.3.9 The effect of FSS in male amygdala 
As the previous section showed KOPr activation (U50,488 treatment) induced 
significant effects on cFos expression in both the central (CeA) and basolateral 
amygdala (BLA), the same experiment was repeated with an in vivo stressor (FSS). 
Sample fluorescent images were shown in figure 4.10A, 4.10C. 
 
Interestingly, FSS caused no increased expression in cFos or cFos-driven GFP in the 
CeA (Figure 4.10B), which is different to the increase in both cFos and GFP expression 
after U50,488 treatment (Section 4.3.8). In contrast, in the BLA, FSS induced both 
cFos and cFos-driven GFP signals (Figure 4.10D), but these effects were not 
significantly inhibited by pre-administration of norBNI. These findings in the BLA 
suggest that both KOPr activation and FSS induce cFos expression in that brain region, 

























Figure 4.10A Fluorescent images of cFos and GFP expression in CeA (Bregma 
-1.94 mm) following FSS. 
Both cFos and GFP expression were not affected by FSS or by pre-






cFos expression A 
B 
Figure 4.10B Quantified fluorescent cFos and GFP signals following 15-
minute FSS in CeA. 
FSS did not significantly alter either cFos (A) or GFP (B) signals in the absence 
or presence of norBNI (10mg/kg). All data are presented as mean  SEM. One-





























































































































Figure 4.10C Fluorescent images of cFos and GFP expression in BLA (Bregma 
-1.94 mm) following FSS. 
Both cFos and GFP expression were induced by FSS in BLA. No significant 






cFos expression A 
B 
Figure 4.10D Quantified fluorescent cFos and GFP signals following 15-minute 
FSS in BLA. 
FSS significantly induced both cFos (A) and GFP (B) signals in BLA. Pretreatment 
with norBNI did not significantly inhibit cFos or GFP expression. All data are 
presented as mean  SEM. One-way ANOVA post-hoc Sidak’s test, * = P<0.05, 









































































































4.3.10 Summary of different stimuli in male mice 
As discussed in Chapter 1, PFCx, NAc, hippocampus and amygdala are four important 
regions that are involved in stress responses, affective-related disorders and 
addiction-related behaviours. The effects of KOPr activation and in vivo stressor (FSS) 
on neuronal activity in these regions are summarised in Table 4.1. Apart from the 
dentate gyrus region in the hippocampus, all the regions showed similar effects in 
response to U50,488 treatment. In contrast, FSS only induced cFos expression in PFCx, 
NAc and BLA, not in hippocampus and CeA. In each case, if cFos expression was 
significantly increased, cFos-driven GFP expression was also significantly increased. 
 
The KOPr antagonist, norBNI, was effective in blocking all of the U50,488-induced 
increases in cFos and cFos-driven GFP effects. In general, norBNI did not significantly 
inhibit FSS-induced effects in these brain regions, with the exception of the NAc, 








Table 4.1. Summary of cFos and cFos-induced GFP expression in different brain regions following KOR 
activation, U50,488 and in vivo forced swim stress (FSS). Prefrontal cortex (PFCx), nucleus accumbens (NAc), 
CA1, dentate gyrus region of hippocampus (Hippocampal CA1, DG), basolateral amygdala (BLA), central 
amygdala (CeA),  < 0.05; * < 0.05;  < 0.01; ** < 0.01; ns = not significant. 
cFos norBNI GFP norBNI
PFCx ↑↑ ** ↑ *
NAc ↑↑ ** ↑ **
Hippocampal CA1 ↑ * ↑↑ **
Hippocampal DG ns ns ns ns
Central Amygdala (CeA) ↑ * ↑ *
Basolateral Amygdala (BLA) ↑↑ * ↑↑ **
cFos norBNI GFP norBNI
PFCx ↑↑ ns ↑↑ ns
NAc ↑↑ * ↑↑ ns
Hippocampal CA1 ns ns ns ns
Hippocampal DG ns ns ns ns
Central Amygdala (CeA) ns ns ns ns





All the images and figures 4.2-4.5 showed a common pattern, in that there was 
increased cFos and cFos-driven GFP expression, in both PFCx and NAc, following KOPr 
stimulation by a single injection of U50,488 or 15-minute in vivo FSS. These findings 
indicate that KOPr activation and FSS both enhance neuronal activity in these brain 
regions. 
 
U50,488 increased neuronal activity in male PFCx and NAc 
Our data (Section 4.3.1, 4.3.3) firstly showed increased neuronal activity in PFCx 
following KOPr agonist U50,488 administration, which was effectively blocked by the 
pre-treatment of norBNI (10mg/kg, i.p.), these novel findings confirm that the 
increased expression in cFos and GFP by U50,488 was caused by KOPr activation. 
Similar effects were observed in NAc following U50,488 treatment, which is 
consistent with previous evidence that U50,488-induced cFos expression in NAc in 
rats (Russell et al., 2014). KOPrs are widely distributed throughout the mouse brain 
and it has been shown that while the NAc has high density of KOPr expression, the 
PFCx only expresses KOPr with low density (Le Merrer et al., 2009). Therefore, 
although the U50,488-induced increase in cFos and GFP expression could result from 
activation of KOPrs within the PFCx or NAc, it may be as a result of KOPr activation in 
other brain regions that in turn project to the PFCx or NAc. 
 
FSS increased neuronal activity in male PFCx and NAc 
As shown in Section 4.3.2 and 4.3.4, FSS also significantly enhanced cFos and cFos-
driven GFP expression in PFCx and NAc. These findings support previous studies that 
acute social stress, restraint stress or forced swim increased cFos expression in 
various brain regions, including PFCx and NAc. For example, Funk and colleagues 
showed that exposure to environmental stressors, such as 10-minute foot shock, 30-
minute restraint stress or social defeat significantly increased cFos expression in 
medial prefrontal cortex and NAc in male rats (Funk et al., 2006). Other studies on 
male mice also demonstrated that acute (6 minutes) FSS significantly increased cFos 
expression in the prelimbic region of the PFCx and NAc (Briand et al., 2010). However, 
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Ons and colleagues reported that exposure of 30 minutes of FSS or immobilization 
stress in male rats did not increase cFos expression in the NAc shell, only in the 
prefrontal cortical areas (Ons et al., 2004), whereas our data showed a significant 
increase in cFos expression following 15 minutes of FSS in NAc core, suggesting that 
stress-induced neuronal activity within the NAc is region specific (core or shell), and 
NAc core may play a more important role in stress-induced neuronal activation. 
 
In contrast to U50,488, pre-administration of norBNI did not significantly reduce 
either stress-induced cFos or GFP expression in the PFCx (Figure 4.3B). This could be 
due to the complex and multifactored mechanism of stress responses. There are 
multiple signaling pathways activated and various signaling molecules secreted 
following stress exposure e.g. corticotropin-releasing factor (CRF), 
adrenocorticotropic hormone (ACTH), hypothalamic-pituitary-adrenal (HPA) axis and 
activation of the autonomic nervous system (McEwen et al., 2015). Although KOPrs 
have been implicated in mediating stress responses, it is unclear precisely what the 
mechanism of this interaction is. Therefore, pre-administration of norBNI may only 
partially block FSS-induced effects. However, MacLaughlin et al. showed that pre-
treatment of the KOPr antagonist norBNI (10mg/kg, i.p.) not only inhibited the forced 
swim stressed-induced analgesia and significantly reduced immobility in C57Bl/6 
mice, but also blocked FSS-induced potentiation of cocaine CPP (MacLaughlin et al., 
2003). In addition, other animal behavioural studies have shown that administration 
of norBNI (10mg/kg, i.p.) effectively prevent FSS-induced immobility and impaired 
learning and memory performance in adult male mice (Carey et al., 2009). These 
studies suggest that FSS-induced immobility, analgesia and impaired cognitive 
functions are mediated by KOPr system, and stress-induced KOPr activation may be 
sufficient to cause deficits in learning and memory.  
 
Notably, FSS-induced cFos expression in the NAc was effectively blocked by norBNI 
(10mg/kg, i.p.), indicating that the FSS-induced neuronal activation in NAc is largely 
mediated by KOPrs, or is downstream of KOPr activation (Figure 4.5B). 
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Overall, these results might suggest either that stress responses in the NAc, but not 
in the PFCx, are largely mediated by KOPrs or are downstream of KOPr activation. 
Alternatively, as only a single dose of norBNI was used in these experiments, it could 
mean that insufficient norBNI was administered to block any KOPr-mediated stress 
responses in the PFCx. It is possible that increasing doses of norBNI pretreatment 
could reveal inhibitory effects of norBNI in the PFCx following stress. 
 
Overlapping expression of cFos and GFP in PFCx and NAc 
If the relative proportion of GFP to cFos increases, this might mean that cells had 
been activated a long time prior to sectioning, allowing time for cFos to be activated 
first and degraded, with GFP expression persisting. Our immunocytochemistry 
images (Figure 4.6A, 4.6B) showed a different pattern of overlapping expression of 
cFos and cFos-driven GFP following different stimuli in PFCx and NAc. In particular, 
after FSS, there was a much higher proportion of cFos + GFP-positive neurons in the 
PFCx compared with in the NAc, even though both cFos and GFP expression overall 
was increased in both brain regions, which might suggest that FSS activates neurons 
in NAc first, and transiently, then activates PFCx later. After FSS, these was also a 
higher proportion of cFos + GFP-positive neurons in the PFCx than that of following 
U50,488 treatment, suggesting that FSS might activate the PFCx more slowly than 
U50,488 activates the PFCx. Whereas in NAc, the opposite effects were seen, i.e. the 
cFos + GFP-positive neurons after FSS is lower than that of U50,488 treatment, 
suggesting that FSS activates the NAc faster than U50,488 activates the NAc, or FSS 
activates neurons in the NAc only transiently. 
 
The reason for this is unclear at present but could reflect the different temporal 
expression of cFos and GFP. This might be as a result of the different temporal 
expression of cFos and GFP. cFos is a transient immediate early gene with a short 
half-life, whereas GFP is more stable with a longer half-life (Barth et al., 2004). 
Therefore, cFos-driven GFP expression would be expected to persist longer than cFos 
expression itself. In all of these studies, brains were taken at a single time-point after 
either U50,488 or FSS treatment. Therefore, as FSS increased cFos + GFP-positive 
neurons in the PFCx but increased GFP-only neurons to a greater extent in NAc, FSS 
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might activate NAc before it activates PFCx, or, FSS activates the NAc transiently, but 
activates the PFCx more persistently. There are no studies in the literature that have 
examined this, but, future experiments could be designed to take brain sections at 
different time-points after U50,488 or FSS treatments to further test this hypothesis. 
 
Conversely, U50,488 treatment increased the proportion of cFos-only neurons in the 
NAc, but not the PFCx. For the same reason as above, this could be due to U50,488 
treatment activating the PFCx prior to activation of the NAc.  
 
The effect of U50,488 and FSS in other brain regions 
Our data showed increased cFos expression in both central (CeA) and basolateral 
amygdala (BLA) following U50,488 (20mg/kg, i.p.), but FSS only induced cFos 
expression in BLA, not CeA, which conflicts with a previous study showing that a 
single injection of U50,488 (10mg/kg, i.p.) significantly increased cFos activation in 
CeA, but no effect was observed in BLA in male rats (Russell et al., 2014). However, 
other studies demonstrated the region-specific cFos expression pattern in the 
amygdala after a single social stress, where CeA exhibited the least change in cFos 
expression (Martinez et al., 1998). Also, the FSS-induced effect in BLA supports 
previous studies, which showed fear conditioning increased KOPr mRNA only in BLA, 
not in CeA in male rats, highlighting the important role of BLA involved in anxiety-
related behaviours (Knoll & Carlezon, 2010). As introduced in chapter 1, the 
amygdala is a brain region well-known for its regulatory role in response to stress 
and emotional perception (Bennur et al., 2007). Our results showed that the stress-
induced cFos expression was significantly increased only in BLA, where BLA is the 
major region in amygdala that has been shown an increase in spines density and 
expansion of dendrites following acute or chronic stress (McEwen et al., 2016). 
 
Our data showed that administration of KOPr agonist (U50,488, i.p.), but not FSS, 
significantly increased cFos expression in the CA1 region of hippocampus. The 
dentate gyrus region of the hippocampus was not activated following U50,488 or FSS 
treatment. The finding with KOPr agonist is a novel one, with no previous studies 
describing cFos expression following a single administration of KOPr agonist. 
 114
However, the finding that FSS does not induce cFos expression in the hippocampus 
conflicts with one of the early studies in male rats, indicating that restraint or 
immobilisation stress profoundly induced cFos expression in both the CA1 and 
dentate gyrus regions in the hippocampus in a time dependent manner (Titze-de-
Almeida et al., 1994). Other studies further support this by demonstrating that 60 
minutes of restraint stress in male rats produced high levels of cFos expression in the 
CA1-CA3 regions in the hippocampus (Fevurly et al., 2004). In addition, it has been 
shown that a combination of acute 30 minutes restraint stress and 5 minutes forced 
swim stress specifically increased cFos-positive neuronal density in the CA1 region of 
the dorsal hippocampus in male mice, leading to impaired long-term spatial memory 
(Yu et al., 2018). That our data conflicted with these studies could be due to various 
potential factors, such as the different animal species, different nature of stressors 
and durations. Previous studies successfully demonstrated stress-induced cFos 
expression in the hippocampus after at least 30 minutes of restraint stress or in 
combination with other stressor (e.g. FSS) time-dependently, which suggests that FSS 
(15 minutes) in this study might not be strong and persistent enough to induce cFos 
expression in the hippocampus. 
 
Overall, in most brain regions studied, there was a general overlap between the 
effects of a single administration of KOPr agonist, and an acute in vivo stressor. In 
general, although pretreatment of norBNI block U50,488-induced neuronal activity 
in different brain regions, it did not effectively block FSS-induced effects, except in 
NAc. This suggests either that stress responses are, in part, mediated by activation of 
KOPrs in NAc, or that activation of KOPr in NAc share similar neuronal network effects 
to an acute stressor. Other overlapped brain regions that are involved in both KOPr 
activation and in vivo stressor responses could be mediated by different mechanisms, 
i.e. FSS-induced effects in other brain regions are mediated by non-KOPr systems. 
Two brain regions that diverged in their responses were the hippocampal CA1 region 
and the central amygdala. This suggest that KOPr activation in these brain regions is 
not involved in the stress response. 
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As outlined in the introduction, there is growing evidence for sex differences in 
behavioural responses to both KOPr agonists and stress. In the following chapter, we 














Chapter 5 The effect of kappa opioid receptor 




Chapter 4 showed that, in male mice, KOPr activation (with a single injection of 
U50,488) increased neuronal activity in various brain regions, specifically in the PFCx, 
NAc, hippocampus and amygdala, as shown by increased cFos and cFos-driven GFP 
expression. These effects were blocked by pre-administration of the KOPr antagonist, 
norBNI. 
 
Following an acute in vivo stressor (FSS), cFos and cFos-driven GFP expression were 
also increased in the PFCx, NAc and BLA. In the CA1 region of the hippocampus and 
CeA, however, although U50,488 increased cFos and GFP expression, FSS had no 
effect. NorBNI was largely ineffective in inhibiting cFos and cFos-driven GFP 
expression after FSS, except in NAc. 
 
KOPrs have been implicated in the effects of stress, anxiety and depression, and 
addiction-related behaviours, and KOPr antagonists have been proposed as potential 
treatments for both anxiety/depression and addiction (Shirayama et al., 2004). In 
humans, women have higher prevalence of depression and anxiety than men, with 
statistics showing that women are more likely to be affected by affective disorders 
(Albert 2015). However, the majority of previous preclinical studies on the KOPr 
system and the effects of KOPr antagonists have been performed in male rodents. 
There is increasing evidence demonstrating sex differences in the analgesic effects 
of opioid receptor activation (Liu et al., 2013, Abraham et al., 2018). Further, recent 
studies have demonstrated that behavioural effects of stress and KOPr agonists are 
sex-dependent (See Chapter 1 & Russell et al., 2014), but sex differences in opioid 
receptor activation in response to stress at molecular level are less understood.  
 
The aim of this chapter is to compare the effects of different stimuli (FSS and U50,488 
administration) on cFos and cFos-driven GFP expression in different brain regions in 
female mice. We will investigate if there is a sex difference in the effects of KOPr 
activation and in vivo stressor at the molecular levels in different brain regions, and 
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whether the pre-administration of KOPr antagonist, norBNI would block the U50,488 
and FSS-induced effects in a similar way in male mice.  
It is hypothesised that the effects of KOPr activation and in vivo stressor are different 
between the sexes. We have repeated the experiment in chapter 4, using KOPr 
agonist, U50,488 (20mg/kg) and 15-minute FSS to investigate the neuronal activity in 





The immunohistochemistry (descried in chapter 2, section 2.10) was repeated in this 
chapter with adult female (9-13 weeks old, 20-25g) cFos-GFP transgenic mice (n = 6 
animals per treatment group). Before immunohistochemistry, the female mice were 
treated with the same procedures (KOPr agonist, U50,488 or in vivo 15-minute forced 
swim stress) as shown in chapter 4, illustrated in figure 4.1. 
 
The coronal sections (40m) of PFCx (Bregma +2.22 mm), NAc (Bregma +1.34 mm), 
amygdala (Bregma -1.94 mm) and CA1 region and dentate gyrus in dorsal 
hippocampal (Bregma -1.94 mm) slices were prepared on a vibratome. For each 
mouse, one slice was taken for each brain region. These slices were co-stained with 
anti-cFos and anti-GFP antibodies (section 2.3), followed by incubation of fluophore-
labelled secondary antibodies: goat anti-rabbit antibody Alexa Fluor 568 (diluted 
1:500) and goat anti-chicken antibody Alexa Fluor 488 (diluted 1:500) (section 2.3). 
 
The fluorescent immunoreactivity was detected by Leica DMI4000B inverted wide-
field fluorescent microscopy at 200X magnification. The relative fluorescent signals 
for each brain region on each slice were the average values of the left and right 
signals, which were quantified in ImageJ software (section 3.2.5). The data were 
analysed with one-way (treatment) ANOVA followed by Sidak’s test. All data are 




5.3.1 The effect of U50,488 and FSS in female PFCx 
Figures 5.1A & 5.1B show the effects of U50,488 in female mice. Sample fluorescent 
images are shown in figure 5.1A. Data are quantified in figure 5.1B. These data show 
that in female cFos-GFP transgenic mice, U50,488 had no effect on cFos or cFos-
driven GFP expression in the PFCx. This is indirect contrast to the effect seen in male 
mice (see Figures 4.2B & 4.2C). 
 
Figures 5.1C & 5.1D show the results from similar experiments where female mice 
were exposed to a single FSS session before brain sectioning. Sample fluorescent 
images are shown in figure 5.1C. Data are quantified in figure 5.1D. As with the 
effects of U50,488 (Figures 5.1A & 5.1B), FSS had no effect on cFos or cFos-driven 
GFP expression in PFCx in female mice. Again, this is in direct contrast to the robust 
increase in both cFos and cFos-driven GFP expression seen in male mice, using an 
identical experimental procedure (Figures 4.3A & 4.3B). 
 
NorBNI had no effect on cFos or GFP expression in PFCx in female mice. 
 
The effects of KOPr agonist, U50,488 and in vivo stress, FSS on the PFCx of both male 
and female cFos-GFP transgenic mice are summarised in table 5.1. Together, these 
data suggest that the PFCx is primary not involved in mediating stress responses and 
responses to KOPr agonists in female mice, as well as providing evidences for sex 
difference in the effects of stress and KOPr agonists in the PFCx. 
   Table 5.1. Comparison between male and female cFos-GFP mice on cFos 
and GFP expression in PFCx following U50,488 or FSS treatment. ; P < 
0.05, ; P < 0.01 vs saline/no stress, ns = not significant. 
cFos GFP cFos GFP




























Figure 5.1A Fluorescent images of cFos and GFP expression in female PFCx 
after U50,488 treatment. 
Neither cFos or cFos-driven GFP expression were affected by U50,488 






























Figure 5.1B Quantification of fluorescent cFos and GFP signals following 
U50,488 in female PFCx. 
cFos (A) and GFP (B) signals in female PFCx were unaffected by treatment in 
the absence and presence of norBNI. All data are shown as mean  SEM. N = 














































































































































Figure 5.1C Fluorescent images of cFos and GFP expression in female PFCx 
after 15-minute FSS. 
FSS did not affect either cFos or GFP expression in female PFCx, which were 




































Figure 5.1D Quantification of fluorescent cFos and GFP signals following 
FSS in female PFCx. 
FSS did not affect levels of cFos (A) or GFP (B) in female PFCx in the absence 
and presence of norBNI. All data are shown as mean  SEM. N = 6 animals 







































































































5.3.2 The effect of U50,488 and FSS in female NAc 
Section 5.3.1 suggests a sex difference in the effect of U50,488 injection and FSS in 
the PFCx, in that no cFos expression was seen in female mice, whereas robust cFos 
expression was seen in male mice (Chapter 4). We next investigated the effects of 
KOPr agonist- and FSS-induced activation of cFos in the NAc region of female mice. 
 
Sample fluorescent images following U50,488 injection and FSS are shown in figure 
5.2A and 5.2C respectively. In the NAc region from female mice, a single injection of 
U50,488 also did not induce either cFos or GFP expression, an effect that was similar 
to the effects observed in the PFCx from female mice (Figure 5.2B). This finding again 
suggests that neuronal activity induced by U50,488 is sex dependent as the same 
treatment resulted in a robust increase in cFos expression in the NAc region in male 
mice (see Figure 4.4). 
 
In contrast to the effect of U50,488, 15-minute FSS did induce both cFos and GFP 
expression in the NAc region of female mice (Figure 5.2D), similar to the effect 
previously shown in the same brain region in male mice (see Figure 4.5). The effects 
of KOPr agonist- and FSS-induced cFos activation in both male and female NAc are 
summarised in table 5.2. Furthermore, although there was a trend for decrease in 




Table 5.2. Comparison between male and female cFos-GFP mice on cFos and 
GFP expression in NAc core following U50,488 or FSS treatment. ; P < 0.05, 
; P < 0.01 vs saline/no stress, ns = not significant. 
cFos GFP cFos GFP
15-minute FSS ↑↑ ↑↑ ↑↑ ↑
Male Female
































Figure 5.2A Fluorescent images of cFos and GFP expression in female NAc   
core after U50,488 injection. 
cFos or GFP expression were not affected by U50,488 treatment in female 



































cFos expression A 
B 
Figure 5.2B Quantification of fluorescent cFos and GFP signals following 
U50,488 in female NAc core. 
cFos (A) and GFP (B) signals in female PFCx were unaffected by U50,488 
treatment in the absence and presence of norBNI. All data are presented as 


















































































































































Figure 5.2C Fluorescent images of cFos and GFP expression in female NAc 
core after FSS. 
cFos and GFP signals were increased following FSS. Pre-administration of 

















































Figure 5.2D Quantification of fluorescent cFos and GFP signals following 
FSS in female NAc core. 
cFos (A) and GFP (B) expression were increased by FSS in female NAc. Pre-
treatment with norBNI did not have a statistically significant effect. * = 
P<0.05, ** = P<0.01. All data are presented as mean  SEM. One-way 










































































































5.3.3 The effect of U50,488 and FSS in female hippocampus 
Chapter 4 showed different effects of U50,488 and FSS in the CA1 region of the 
hippocampus in male mice (Sections 4.3.6 & 4.3.7) in that U50,488 treatment, but 
not FSS, increased both cFos and cFos-driven GFP expression neuronal activity in that 
region. No effects were seen in the dentate gyrus following either U50,488 treatment 
or FSS. 
 
To investigate potential sex differences in the hippocampus, the same experiment 
was repeated in female mice. Sample images following U50,488 and FSS in the CA1 
region are shown in figure 5.3A and figure 5.3C. Figure 5.3E and 5.3G shows the 
fluorescent images in dentate gyrus following U50,488 and FSS respectively.  
 
Quantified signals demonstrated that KOPr activation stimulates neuronal activity in 
the CA1 region of hippocampus (Figure 5.3B), as seen by an increase in cFos 
expression, although no significant increase in cFos-driven GFP expression was seen. 
The increase in cFos expression by U50,488 was inhibited by pre-administration of 
the KOPr antagonist, norBNI. In contrast, in the FSS treatment group (Figure 5.3D), 
there was no increase in cFos expression or cFos-driven GFP expression in the CA1 
region of the female hippocampus. Both the effect of U50,488 and FSS treatment in 
the female hippocampus are similar to those previously observed in the male 
hippocampus. Furthermore, as previously seen in the dentate gyrus region from male 
mice, there was no increase in cFos expression in the dentate gyrus region from 
female mice, either following U50,488 injection or FSS treatment (Figure 5.3F, 5.3H).  
The effects of U50,488 or FSS on cFos expression in CA1 region of hippocampus 
between male and female mice are summarised in table 5.3, and dentate gyrus in 
table 5.4. 
 
Overall, similar cFos expression patterns were observed between male and female 
mice suggesting that the neuronal activity in the hippocampus in response to KOPr 
activation or stress is not sex-dependent.  
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cFos GFP cFos GFP
15-minute FSS ns ns ns ns
Male Female
U50,488 treatment ↑ ↑↑ ↑↑↑ ns
Table 5.3. Comparison between male and female cFos-GFP mice on cFos 
and GFP expression in CA1 region of hippocampus following U50,488 or FSS 
treatment. ; P < 0.05, ; P < 0.01, ; P < 0.001 vs saline/no stress, ns = 
not significant. 
cFos GFP cFos GFP
15-minute FSS ns ns ns ns
Male Female
U50,488 treatment ns ns ns ns
Table 5.4. Comparison between male and female cFos-GFP mice on cFos 
and GFP expression in dentate gyrus following U50,488 or FSS treatment, 


































Figure 5.3A Fluorescent images of cFos and GFP expression in female CA1 
region of hippocampus after U50,488 injection. 
U50,488 treatment increased cFos expression, but not in cFos-driven GFP 













































cFos expression A 
B 
Figure 5.3B Quantification of fluorescent cFos and GFP signals following 
U50,488 in female hippocampal CA1. 
U50,488 increased expression of cFos (A) but did not significantly increase 
cFos-driven GFP expression (B) in the hippocampal CA1 in female mice. ** = 
P<0.01, *** = P<0.001. All data are shown as mean  SEM. One-way ANOVA 


























































































































































Figure 5.3C Fluorescent images of cFos and GFP expression in female 
hippocampal CA1 region after FSS. 
FSS did not affect either cFos or GFP signals. NorBNI pretreatment also had 





































Figure 5.3D Quantification of fluorescent cFos and GFP signals following 
FSS in female hippocampal CA1 region. 
cFos (A) and GFP (B) signals in the hippocampal CA1 region of female mice 
were not affected by FSS. All data are shown as mean  SEM. N = 6 animals 








































































































































Figure 5.3E Fluorescent images of cFos and GFP expression in female 
dentate gyrus region of hippocampus after U50,488 injection. 
Neither cFos nor GFP expression was affected by U50,488 treatment in female 










































Figure 5.3F Quantification of fluorescent cFos and GFP signals following 
U50,488 in female hippocampal dentate gyrus. 
cFos (A) signals and GFP (B) signals were not affected by U50,488 in female 
hippocampal dentate gyrus. All data are presented as mean  SEM. N = 6 

























































































































































Figure 5.3G Fluorescent images of cFos and GFP expression in female 
dentate gyrus region of hippocampus FSS. 
Neither cFos nor GFP expression was affected by 15-minute FSS in female 



















































cFos expression A 
B 
Figure 5.3H Quantification of fluorescent cFos and GFP signals following 
FSS in female hippocampal dentate gyrus. 
cFos (A) signals and GFP (B) signals were not affected by FSS in female 
hippocampal dentate gyrus. All data are expressed as mean  SEM. N = 6 






































































































5.3.4 The effect of U50,488 and FSS in female amygdala 
It was previously demonstrated (Chapter 4) that both U50,488 and FSS induced cFos 
and cFos-driven GFP expression in the basolateral amygdala (BLA) in male mice, but 
different effects were observed following U50,488 and FSS treatment in the central 
amygdala (CeA) in that U50,488, but not FSS, induced cFos and GFP expression in 
male mice (Sections 4.3.8 & 4.3.9). 
 
In order to test if there are any sex differences in the amygdala, the experiment was 
repeated in female mice. Fluorescent images showing the effects of U50,488 and FSS 
on CeA are shown in figures 5.4A & 5.4C and sample images in BLA are shown in 
figures 5.4E & 5.4G. The fluorescent signals were quantified and illustrated in Figure 
5.4B, 5.4D, 5.4F & 5.4H. 
 
In the CeA, KOPr activation significantly induced both cFos and cFos-driven GFP 
expression, and the effects was significantly inhibited by norBNI pre-treatment 
(Figure 5.4B), whereas no increase in cFos and GFP expression were seen after FSS 
treatment (Figure 5.4D). These findings in the female CeA are similar to that of in the 
CeA in male mice (Table 5.5). In addition, similar to the effects observed in male mice, 
both U50,488 and FSS treatment significantly increased cFos and GFP expression in 
the BLA in female mice (Figure 5.4F, 5.4H), which were also significantly reduced by 
the pre-administration of norBNI. The U50,488- or FSS-induced effects on CeA in both 
male and female mice are summarised in table 5.5, while these effects in BLA 
between male and female mice are summarised in table 5.6. 
 
Overall, the effects of U50,488 and FSS on both CeA and BLA in female mice are 
similar to the effects observed in male amygdala, indicating that there is no sex 





cFos GFP cFos GFP
15-minute FSS ns ns ns ns
Male Female
U50,488 treatment ↑ ↑ ↑ ↑↑
Table 5.5. Summary of U50,488 or FSS-induced effects in CeA in both male 
and female cFos-GFP mice. ; P < 0.05, ; P < 0.01 vs saline/no stress, ns 
= not significant. 
cFos GFP cFos GFP
15-minute FSS ↑ ↑ ↑↑↑ ↑
Male Female
U50,488 treatment ↑↑ ↑↑ ↑↑↑ ↑↑
Table 5.6. Summary of U50,488 or FSS-induced effects in BLA in both male 




























Figure 5.4A Fluorescent images of cFos and GFP expression in CeA following a 
single U50,488 (20mg/kg) administration. 
Expression of both cFos and GFP was increased after U50,488 treatment, 
compared to the control saline-treated groups. The effects were inhibited by 





cFos expression A 
B 
Figure 5.4B Quantified fluorescent cFos and GFP signals following 
U50,488 treatment in CeA in female mice. 
U50,488 increased both cFos (A) and GFP (B) signals. The effect was 
blocked by norBNI (10mg/kg) pre-administration. Data are expressed as 
mean  SEM. One-way ANOVA post-hoc Sidak’s test, * = P<0.05, ** = 





















































































































































Figure 5.4C Typical expression pattern of cFos and GFP in CeA from female mice 
after FSS. 
No changes in the expression of cFos and GFP were seen following FSS in the 





















































Figure 5.4D Quantified fluorescent cFos and GFP signals following FSS in CeA 
in female mice. 
FSS did not change cFos (A) or GFP (B) signals in the absence and presence of 
norBNI (10mg/kg) pre-administration. Data are expressed as mean  SEM. N 



































































































































Figure 5.4E Fluorescent images of cFos and GFP expression in BLA of female mice 
following a single U50,488 (20mg/kg) treatment. 
U50,488 increased both cFos and GFP expression, compared to the control saline-
























































Figure 5.4F Quantified fluorescent cFos and GFP signals following U50,488 
injection in BLA of female mice. 
Both cFos (A) or GFP (B) signals were significantly increased by U50,488 
treatment. The effects was significantly inhibited by norBNI (10mg/kg) pre-
treatment. Data are expressed as mean  SEM. One-way ANOVA post-hoc 


























































































































































Figure 5.4G Fluorescent images of cFos and GFP expression pattern in BLA of 
female mice after FSS. 
FSS significantly increased both cFos and GFP expression following FSS, 






cFos expression A 
B 
Figure 5.4H Quantification of fluorescent signals following FSS in BLA in female 
mice. 
FSS increased both cFos (A) or GFP (B) signals. These stress-induced effects were 
not blocked by norBNI pre-treatment. Data are expressed as mean  SEM. One-











































































































The effects of KOPr activation and an in vivo stressor in different brain regions in 







A single administration of KOPr agonist U50,488 induced cFos expression in the CA1 
region of the hippocampus, central amygdala and basolateral amygdala, with no 
increase in cFos expression seen in the dentate gyrus region of the hippocampus. 
These effects were inhibited by pre-administration of the KOPr antagonist, norBNI. 
 
Surprisingly, in the CA1 region of the hippocampus, U50,488 induced a robust and 
highly significant increase in cFos expression, but no significant increase in cFos-
driven GFP expression. As outlined in Chapter 4, in these mice, we would expect cFos 
expression from a given stimulus to occur first, before cFos-driven GFP expression, 
and for cFos-driven GFP expression to persist longer than cFos expression. Therefore, 
cFos norBNI GFP norBNI
PFCx ns ns ns ns
NAcc ns ns ns ns
Hippocampal CA1 ↑↑↑ ** ns ns
Hippocampal DG ns ns ns ns
Central Amygdala (CeA) ↑ * ↑↑ *
Basolateral Amygdala (BlA) ↑↑↑ ** ↑↑ *
cFos norBNI GFP norBNI
PFCx ns ns ns ns
NAcc ↑↑ ns ↑ ns
Hippocampal CA1 ns ns ns ns
Hippocampal DG ns ns ns ns
Central Amygdala (CeA) ns ns ns ns
Basolateral Amygdala (BlA) ↑↑↑ ns ↑ ns
U50,488 (20mg/kg)
FSS (15 minutes)
Table 5.7. Summary of cFos and cFos-induced GFP expression in different 
brain regions in female mice following KOPr activation (U50,488) and in 
vivo stress (FSS). Prefrontal cortex (PFCx), nucleus accumbens (NAc), CA1, 
dentate gyrus region of hippocampus (Hippocampal CA1, DG), basolateral 
amygdala (BLA), central amygdala (CeA),  < 0.05; * < 0.05;  < 0.01; ** < 
0.01;  < 0.001; ns = not significant. 
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as there is cFos, but not GFP expression in the CA1 region of the hippocampus 
following U50,488 administration, however, both cFos and GFP expression is seen in 
the amygdala of the same animals. The different cFos and cFos-driven GFP expression 
pattern between hippocampus and amygdala might suggest that U50,488 induces 
neuronal activation in the amygdala before the hippocampus.  
 
Further, this pattern of cFos and GFP expression in the CA1 region of the female 
hippocampus is different to that seen in males, and, there are more profound 
differences between the patterns of cFos and GFP expression between male and 






In the hippocampal CA1 region, in male mice U50,488 administration increased both 
cFos and cFos-driven GFP expression. In contrast, in female mice, only an increase in 
cFos expression was observed. As mentioned before, GFP is only induced following 
cFos expression, meaning that cFos is induced first, GFP occurs later than cFos 
expression. For the reasons outlined above, a potential explanation for this is that 
KOPr activation activates CA1 neurons in male mice sooner than in female mice, i.e. 
there was no time for GFP to be expressed in female mice. There are no previous 
studies that have shown these effects, but this hypothesis could be supported by 
extending the time-points where c-Fos expression is investigated following U50,488 
treatment. 
cFos GFP cFos GFP
PFCx ♂ ♂ ♂ ♂ ♂ ♂ ♂
NAc ♂ ♂ ♂ ♂ ♂     ♂ ♂ ♂ ♂         ♂
Hippocampal CA1 ♂     ♂ ♂ ♂ ♂ ♂
Hippocampal DG
Central Amygdala (CeA) ♂             ♂ ♂         ♂ ♂
Basolateral Amygdala (BLA) ♂ ♂ ♂ ♂ ♂ ♂ ♂     ♂ ♂ ♂     ♂ ♂ ♂ ♂             ♂
U50,488 (20mg/kg) FSS (15 minutes)
Table 5.8. Summary of the sex differences in the expression of cFos and GFP 
following U50,488 and FSS treatment. Prefrontal cortex (PFCx), nucleus 
accumbens (NAc), CA1, dentate gyrus region of hippocampus (Hippocampal 
CA1, DG), basolateral amygdala (BLA), central amygdala (CeA). The number of 
sex symbols indicate the level of significance; ♂, ♀ < 0.05; ♂♂, ♀♀ < 0.01; 
♂♂♂, ♀♀♀ < 0.001. 
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Table 5.8 also shows more profound, and surprising, differences in neuronal 
activation between male and female mice. Although U50,488 induces neuronal 
activation in the PFCx and NAc in male mice (as seen by both increased expression of 
both cFos and cFos-driven GFP), the same treatment had no effect in the same brain 
regions in female mice. 
 
Following FSS, again sex-dependent patterns of neuronal activation were seen. In 
both male and female mice, FSS induced cFos and cFos-driven GFP in both the NAc 
and BLA. However, neuronal activation in the PFCx was only seen in male mice, not 
in female mice. 
 
These findings show sex differences in response to KOPr and stress in these brain 
regions, which may contribute to the sex differences in the behavioural responses to 
both KOPr activation and stress (discussed in Chapter 8). The majority of previous 
studies examining cFos activation following KOPr activation or stress have been 
performed in male animals (see Introduction & Chapter 4), however, two studies 
have investigated cFos expression in both male and female mice following KOPr 
activation. Russell and colleagues reported that KOPr activation, U50,488 (10mg/kg, 
i.p.) significantly induced cFos expression in the NAc core and shell of both male and 
female rats (Russell et al., 2013). However, sex-dependent increases in cFos 
expression were seen in the BNST where cFos expression was increased in female 
rats compared with in male rats, an effect that was dependent on the stage of the 
oestrus cycle.  
 
Another study showed that in the NAc shell, U50,488 increased phosphor-p38 cells 
immunoreactivity in both male and female California mice in a dose dependent 
manner, but no significant increases in phosphor-p38 immunoactivity in the NAc core 
in both sexes (Robles et al., 2014). Although there were no profound differences in 
phosphor-p38 expression between the sexes, U50,488 had effects in male rats at 
lower doses than in females, suggesting that the male rats were more sensitive to 
the KOPr effect, similar to the effect seen in the present study. Again, as in the 
previous paper mentioned, sex differences were seen in the BNST, but the effects 
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were opposite to that shown by Russell and colleagues, with phosphor-p38 
expression increased in males, but not in females. As it has been shown that 
activation of phosphorylated p38 MAP kinase is the key mechanism mediating 
dysphoric effect in response to stress-induced KOPr activation, which could be used 
as indirect marker for KOPr activation within neurons (Bruchas et al., 2007). These 
findings suggest that the effect of KOPr activation, U50,488 on neuronal activity in 
the NAc is not sex-dependent, which conflicted with our data showing an increase 
cFos expression in the NAc was only seen in male mice after U50,488 (20mg/kg, i.p.) 
treatment, but not in female cFos-GFP transgenic mice. There are possible reasons 
that may underly these conflicting data in KOPr activation-induced effects, our 
studies only used cFos-GFP mice, whereas previous studies used rats or California 
mice. As different animal species could exhibit different expression levels of KOPr 
throughout the brain, resulting in differences in broader network mechanisms. No 
previous studies have investigated the effects of KOPr agonist on cFos expression in 
either PFCx or hippocampus in both male and female mice. 
 
In terms of previous studies demonstrating sex differences in cFos activation 
following an acute in vivo stressor. Bland et al. (2005) examined the effects of acute 
restraint stress (100-minute duration) on cFos mRNA expression in both male and 
female rats. cFos mRNA was increased in the prelimbic and infralimbic regions of the 
PFCx in both male and female rats, compared to the non-stressed controls. However, 
the increase seen in male rats was significantly greater than that seen in female rats, 
similar to the data presented in this study. Interestingly, the sex-dependent effects 
were only seen immediately after the stressor (100 minutes after initiation of the 
stressor), but there was no difference in cFos mRNA levels between male and female 
animals at 60 minutes post-stress (i.e. 160 minutes after initiation of the stressor), 
indicating that the time point post-stress is an important factor to affect stress-
induced effects in PFCx. While our data only focused on one time-point (2 hours) 
post-stress or post- KOPr agonist treatment, which could be the potential reason that 
underlies the differences observed in this study. 
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In addition to acute stress, a more recent study in mice revealed that chronic mild 
stress (2 or 4 weeks in duration) induced changes in cFos expression that were sex-
dependent (Shepard et al., 2016). In NAc core, chronic mild stress induced a 
significant decrease in cFos expression in male mice, but not in female mice. In 
contrast, a decrease in cFos expression was observed in both the PFCx and the 
basomedial amygdala in female mice, but not in male mice. Interestingly, this study 
also demonstrated that the decrease in cFos expression in the PFCx of female mice 
was correlated with an increase in markers of GABAergic transmission (parvalbumin-
positive neurons and parvalbumin mRNA), suggesting that chronic stress-induced 
decrease in cFos expression in female PFCx could result from increased GABAergic 
signaling within the PFCx, which may underlie the sex differences in the effects of 
stress on neuronal activity, as well as high prevalence of stress-related affective 
disorders in females. However, care must be taken when interpreting data from 
chronic stress models with respect to acute stress models (as used here) because of 
adaptive responses taking place during chronic stress (Melia et al., 1994, Mohammad 
et al., 2000). 
 
A further study used two different models of stress in rats and observed sexually 
dimorphic effects on cFos expression (Sood et al., 2018). Acute immobilisation stress 
(2 hours) induced similar amounts of cFos expression between males and females in 
the prelimbic cortex, but less cFos expression in female infralimbic cortex compared 
with in males. In the dentate gyrus region of the hippocampus, acute immobilisation 
stress did not alter cFos expression but, surprisingly, and in contrast to the findings 
presented here, acute stress caused a decrease in cFos expression in female animals. 
Similarly, in the CA1 region of the hippocampus, sex differences were seen following 
acute stress with an increase in cFos expression in males, with no change in females. 
In the amygdala, no sex differences were seen, with acute stress inducing similar 
amounts of cFos expression in the basolateral, central and basomedial subregions of 
the amygdala. Furthermore, when the effects of a different stressor was examined, 
different patterns of cFos expression were seen. Using a subchronic forced swim 
stress paradigm (15 min on day 1, 5 min on day 2), increases in cFos expression were 
seen in the prelimbic cortex, infralimbic cortec and CA1 region of the hippocampus 
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in both male and female rats. In the dentate gyrus, cFos expression was increase in 
female rats, but not in male rats. This shows a different pattern of expression 
between the two types of stressor used in this study, as well as differences between 
the patterns of cFos expression we observed. As, in our data, a single acute FSS (15 
minutes) did not induce cFos expression in the PFCx, CA1 region, dentate gyrus of 
hippocampus and central amygdala in either males or females, which is in contrast 
to the findings shown previously (Sood et al., 2018), as Sood and colleagues showed 
that different in vivo stressors e.g. AIS and FSS affect neuronal activity differently, 
suggesting the effects of stress on various brain regions depend on sex and nature of 
stressors. The differences observed between our study and previous studies in 
different brain regions could result from different animal species, stressor natures, 
duration and intensity of the stressor.  
 
Our data showed sex differences in the effects of U50,488 treatment and FSS in the 
PFCx and NAc. There are a number of potential factors underlying the sex differences. 
First, the different circulating gonadal hormones between sexes could affect 
pharmacological effects of U50,488, although previous findings have stated that the 
effects of U50,488 in mice were independent of the phases of the estrous cycle (Craft 
and Bernal 2001, Russell et al., 2014). In future studies, the effect of gonadal 
hormones on sex differences in KOPr systems could be further investigated by vaginal 
lavage. Second, the sex chromosomes might also affect the KOPr activation, since 
early evidence has showed sex chromosome contributes to sex differences in 
nociception and analgesia in mice (Gioiosa et al., 2008). Third, different KOPr 
distribution in the brain or different KOPr coupling efficiencies could also underlie 
the sex differences. Wang et al., (2011) examined KOPr expression and KOPr agonist-
induced GTPS levels in male and female guinea pigs. Although some sex-dependent 
differences in KOPr expression were observed (e.g. in periaqueductal grey, 
substantia nigra), none were seen in the hippocampus, amygdala or NAc, and the 
prefrontal cortex was not studied. More profound changes were seen with KOPr 
agonist-induced GTPS expression, however, with less GTPS binding in females in 
the somatosensory and insular cortices (prefrontal cortex was not examined), and 
more KOPr agonist-induced GTPS expression in the dentate gyrus. Although there 
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was a trend for decreased KOPr agonist-induced GTPS expression in the amygdala 
and hippocampus, the effect was not statistically significant. No change was seen in 
the NAc. This study suggests complex sex-dependent differences in both KOPr 
expression and KOPr agonist-induced GTPS in guinea pigs. It is possible that similar 
differences may underlie the sex-dependent changes in cFos expression seen here in 
mice. 
 
Overall, this study showed novel findings that the effects of KOPr activation on 
neuronal activity in PFCx and hippocampus are sex-dependent in mice. NAc and PFCx 
are two important regions showed sex differences in response to KOPr activation and 
acute stress, particularly in female PFCx, which was insensitive to either KOPr 
activation nor acute stress. The conflicting data between this study and the previous 
evidence highlight the importance of potential factors, such as the nature of stressors, 
stress duration and intensity, different post-stress or post-KOPr activation time-













Chapter 6 Identification of activated neurons in 





Chapters 4 & 5 showed increased cFos expression in various brain regions following 
KOPr activation and in vivo stressor, indicating the recent neuronal activity in 
response to stress in different brain areas. To attempt to identify the type(s) of 
neurons where cFos expression is enhanced following stress or KOPr activation, we 
now use GAD-GFP transgenic mice, where the enhanced green fluorescent protein 
(eGFP) gene is controlled by Gad1 (GAD67) gene promoter, thus GFP is expressed 
only in GABAergic neurons (Tamamaki et al., 2003). GAD-GFP transgenic mice enable 
us to identify if the activated neurons are GABAergic or non-GABAergic neurons by 
overlaying cFos-positive and GFP-positive images together i.e. co-localisation of cFos 
and GFP-positive neurons indicate GABAergic neurons were being activated and 
different localisation of cFos and GFP-expressing neurons implies activated neurons 
were non-GABAergic neurons.  
 
In this chapter we focus on PFCx and NAc, regions of particular interest as previous 
chapters showed sex-specific effects of stress and KOPr agonist administration. In 
PFCx, the primary output neurons are glutamatergic pyramidal neurons, although 
there is also evidence, in mice, for GABAergic neurons that project to the NAc, as well 
as GABAergic interneurons (Lee et al., 2014). In NAc, the primary output neurons are 
GABAergic medium spiny neurons, as well as cholinergic interneurons (Meredith et 
al., 1993). Although there is evidence that KOPrs are expressed both in the PFCx and 
in the NAc (Fan et al., 2002), neuronal activation induced by an in vivo stressor or 
systemic administration of KOPr agonists could be due to network activity, and 
activation of KOPr elsewhere in the brain that in turn affects neuronal activation in 
the PFCx and NAc. The data presented here constitute a first attempt to identify the 
specific neurons where cFos is activated following KOPr agonist administration or in 






In this chapter, the immunohistochemistry (section 2.10) was repeated with adult (9-
13 weeks old) male (25-30g) and female GAD-GFP transgenic mice (20-25g). Before 
immunohistochemistry, the GAD-GFP mice were treated with the same procedures 
(KOPr agonist, U50,488 or in vivo forced swim stress) as shown in chapter 4, 
illustrated in figure 4.1. 
 
The coronal sections (40m) of PFCx (Bregma +2.22 mm) and NAc (Bregma +1.34 mm) 
of both male and female GAD-GFP mice were cut on a vibratome and proceed to 
immunohistochemistry. For each mouse, one slice was taken for PFCx and NAc. These 
slices were dual labelled with anti-cFos and anti-GFP antibodies (section 2.3) on the 
first day, followed by incubation of fluophore-labelled secondary antibodies on the 
second day, including: goat anti-rabbit antibody Alexa Fluor 568 (diluted 1:500) and 
goat anti-chicken antibody Alexa Fluor 488 (diluted 1:500) (section 2.3). The 
fluorescent immunoreactivity was detected and quantified exactly the same way as 
shown in chapter 4 and 5. 
 
All data were analysed with one-way (treatment) ANOVA followed by Sidak’s test and 




In vivo treatments and immunohistochemical imaging techniques were performed 
exactly as in Chapter 4 & 5 (although GAD-GFP mice were used instead of cFos-GFP 
mice); male and female mice were administered a single dose of KOPr agonist, 
U50,488, or a single in vivo stressor (FSS). Mice were then killed and sections of PFCx 
and NAc taken for immunohistochemical imaging. 
 
Figure 6.1 shows typical cFos expression patterns in PFCx from male mice following 
FSS and KOPr activation, alongside merged cFos/GABAergic images. Signal from the 
cFos antibody is shown in red. In these mice, GFP is only expressed in GAD67-positive 
neurons (GABAergic neurons), therefore green signal denotes GABAergic neurons. 
Figure 6.2 shows typical cFos expression patterns in NAc from male mice following 
U50,488 administration and FSS, alongside merged cFos/GABAergic images. 
Quantified data are shown in Figure 6.3. As in Chapter 4, both U50,488 and FSS 
significantly increased cFos expression in both the PFCx and NAc regions. An 
indication of whether cFos-positive neruons are GABAergic or not can be gained by 
examining neurons that exhibit cFos expression with those that are GFP-positive (and 
are therefore GABAergic neurons). As seen in the merged images (where red signal 
largely does not overlap with green signal), minimal overlap is shown between cFos- 
and GFP-positive neurons. Indeed, less than 5% of neurons express both cFos and 
GFP. Furthermore, the percentage of neurons that are positive for both cFos and GFP 
did not increase after KOPr activation or in vivo stress (see grey bars in Figure 6.3). 
Collectively, these data suggest that cFos expression, induced by either an in vivo 
stressor or KOPr agonist administration, does not take places in GABAergic neurons. 
 
Figure 6.4 & 6.5 show representative images from female mice showing cFos and GFP 
expression patterns in PFCx (Figure 6.4) and NAc (Figure 6.5) following KOPr 
activation and FSS. Quantified data are shown in Figure 6.6. As in Chapter 5, neither 
U50,488 or FSS caused an increase in cFos expression in PFCx, and FSS (but not 
U50,488) induced a significant increase in cFos expression in NAc. As in male mice 
(Figure 6.1 - 6.3) the green signal derived from cFos was largely separate from the 
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red signal derived from GFP (driven by GAD expression); less than 5% of neurons 
express both cFos and GFP. Further, the increase in cFos expression in female NAc 
following FSS did not cause an increase in neurons that were both cFos- and GFP-
positive. As in male mice, these data suggest that cFos expression in both the PFCx 


































Figure 6.1 Fluorescent images of cFos-expressing neurons (red), GABAergic neurons (green) and cFos/GABAergic 
neurons overlapping in male PFCx following U50,488 and FSS. Both U50,488 and FSS increased cFos expression, 
compared to saline-treated group, the majority of cFos-expressing neurons do not overlap with GABAergic neurons. 
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Figure 6.2 Fluorescent images of cFos-expressing neurons (red), GABAergic neurons (green) and cFos/GABAergic neurons 
overlapping in male NAc following U50,488 and FSS. In male NAc, both U50,488 and FSS increased cFos expression, 



















































Figure 6.3 Total number of cFos-expressing neurons that were induced by 
U50,488 or FSS in male PFCx and NAc. Comparison with GFP-positive 
neurons. In male PFCx (A) and NAc (B), cFos expression was significantly 
induced by both stimuli, compared to saline-treated group. Less than 5% of 
the neurons were both cFos and GFP-positive. Data are expressed as mean 
 SEM. N = 6 animals per treatment group. *P < 0.05, **P < 0.01. 
cFos only neurons






























































































Figure 6.4 Fluorescent images of cFos-expressing neurons (red), GABAergic neurons (green) and cFos/GABAergic 
neurons overlapping in female PFCx following U50,488 and FSS. Neither U50,488 nor FSS increased cFos expression, 




































Figure 6.5 Fluorescent images of cFos-expressing neurons (red), GABAergic neurons (green) and cFos/GABAergic 
neurons overlapping in female NAc following U50,488 and FSS. FSS, but not U50,488 increased cFos expression, 



































































Figure 6.6 Total number of cFos-expressing neurons that were induced by 
U50,488 or FSS in female PFCx and NAc. Comparison with GFP-positive 
neurons. In female PFCx (A), neither U50,488 or FSS increased cFos 
expression. In NAc FSS (B), but not U50,488, increased cFos expression when 
compared to the control group. Less than 5% of the neurons were both cFos 
and GFP-positive. Data are expressed as mean  SEM. N = 6 animals per 
treatment group. ****P < 0.0001. 
cFos only neurons

































This chapter shows the first attempt to further characterise the specific neurons that 
are activated in response to activation of KOPr or an in vivo stressor. 
 
In Chapter 4 & 5, cFos-GFP transgenic mice were used, to enable co-staining of cFos 
and cFos-driven GFP. Here, GAD-GFP mice were used, to enable co-staining of cFos 
and GFP selectively expressed in GABAergic neurons, to enable us to identify whether 
cFos is expressed in GABAergic neurons following administration of KOPr agonist or 
in vivo stressor. 
 
First, key findings from Chapter 4 & 5 are repeated here, in that both U50,488 and 
FSS increased the number of cFos-positive neurons in both NAc and PFCx in male 
mice. In female mice, neither FSS or U50,488 increased cFos expression in PFCx, and 
FSS increased cFos expression in NAc, but not in PFCx. Although the GAD-GFP and 
cFos-GFP mice are on the same background strain (C57/BL6) of mice, the data shown 
here indicate that the sex differences in cFos expression shown in the previous 
chapters are robust and repeatable, in a different substrain and cohort of mice. 
 
The overall aim of the experiments shown here were to identify the neurons where 
cFos is activated following U50,488 or FSS. If cFos was activated in GABAergic 
neurons, we would have expected the percentage of cFos AND GFP-positive neurons 
to increase in brain regions where cFos expression has increased. In each treatment 
group, however, this was not the case. Indeed, the overall percentage of neurons 
that were both cFos and GFP-positive under these conditions was less than 5%. 
Overall, this indicates that the primary neurons in which activated by U50,488 or FSS 
are not GABAergic neurons.  
 
In the PFCx, KOPrs are largely located pre-synaptically on nerve terminals, both 
dopaminergic inputs, as well as glutamatergic and GABAergic inputs. 
Electrophysiological studies in rats have shown that the KOPr agonist, U69,593 
significantly inhibited dopaminergic neurons projecting to the PFCx (Margolis et al., 
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2005). This finding was further supported by in vivo microdialysis in mice and rats, 
demonstrating that direct administration of the KOPr agonist, U69,593 into PFCx 
significantly reduced the local dopamine, glutamate and GABA levels, which could be 
reversed by KOPr antagonist, norBNI. Further, mice lacking KOPr in dopaminergic 
neurons showed that KOPr activation inhibits dopamine levels by directly acting on 
dopaminergic neuronal terminals in PFCx (Tejeda et al., 2013). These results are 
similar to previous evidence in rats, showing that the KOPr agonist, U50,488, largely 
inhibited electrically evoked dopamine release in the PFCx, which was effectively 
prevented by KOPr antagonist, norBNI (Heijna et al., 1990). All these results suggest 
that KOPrs are largely expressed on dopaminergic, glutamatergic and GABAergic 
neurons in PFCx, although our studies have shown the neurons activated by in vivo 
stress and KOPr activation are non-GABAergic neurons, further identification of the 
types of the neurons is required. 
 
In the NAc, a number of studies have shown that KOPrs are located pre-synaptically 
on both dopaminergic and glutamatergic inputs and KOPrs contribute to modulation 
of dopamine, glutamate and GABA release and neurotransmission. Similar to the 
findings in PFCx, the systemic administration of KOPr agonist, U50,488 significantly 
inhibited electrically induced release of dopamine in the rat NAc, which was fully 
blocked by norBNI (Heijna et al., 1990). This effect of KOPr activation on dopamine 
levels in rats NAc was further confirmed by another KOPr agonist, BRL52537, which 
demonstrated that single stimulus pulse-evoked overflow of dopamine was inhibited 
by application of BRL52537, an effect that was reversed by administration of norBNI. 
It was confirmed that this inhibitory effect of KOPr on dopamine release results from 
direct actions on presynaptic KOPrs located at dopaminergic nerve terminals in the 
NAc (Britt and McGehee, 2008). In vivo microdialysis studies showed that 
administration of KOPr agonist, U69,593 could reduce the release of dopamine and 
glutamate in rats NAc (Gray et al., 1999) and in vitro electrophysiology studies 
revealed that U69,593 reduced glutamatergic neurotransmission in the presynaptic 
terminals in the NAc of rats (Hjelmstad and Fields 2001). In addition to inhibiting 
glutamate release in the NAc, whole-cell voltage-clamp studies in rat brain slices 
showed that KOPr activation by the KOPr agonist U59,593 also showed reduced 
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GABA release in the NAc by directly acting on GABAergic neuronal terminals 
(Hjelmstad and Fields 2003). Overall, these studies provide evidence that activation 
of KOPr reduces dopamine, glutamate and GABA release by directly acting on the 
KOPrs on terminals of these dopaminergic, glutamatergic and GABAergic neurons in 
both PFCx and NAc regions, at least in male animals. 
 
Our data in both male and female mice showed that the majority of stress or KOPr 
activation-induced cFos expression was not merged with GFP-expressing neurons, 
which indicates that KOPr activation- or stress-activated neurons were mostly non-
GABAergic neurons. The use of GAD-GFP transgenic mice only allow us to identify the 
KOPr activation or stress-activated neurons are GABAergic or non-GABAergic 
neurons, and they are unable to identify the specific types of the neuron following 
stress or KOPr activation. In order to further characterise individual neurons that are 
activated by stress or KOPr activation, electrophysiology techniques can be used in 











Chapter 7 Effect of acute stress and kappa opioid 
receptor activation on plasma corticosterone in 





The data in previous chapters showed neurons in the PFCx, NAc, hippocampus and 
amygdala were activated in response to acute stress and KOR activation in a sex 
dependent manner. As describe in chapter 1, corticosterone is one of the 
glucocorticoids produced and secreted by the cortex of the adrenal glands in stress 
responses through activation of the hypothalamo-pituitary-adrenocortical (HPA) axis 
(Chapter 1). Previous evidence showed that forced swim stress significantly 
increased dynorphin immunoreactivity in the NAc and hippocampus (Shirayama et 
al., 2004), also elevated plasma corticosterone levels in wildtype male C57BL/6N 
mice (Wittmann et al., 2009). The stress-induced increased in corticosterone levels 
were significantly attenuated by pre-treatment of KOR antagonist, norBNI (10mg/kg) 
in wildtype mice and in male prodynorphin knockout mice (dyn -/-), suggesting the 
faciliatory role of endogenous dynorphin and KOR system in regulating 
corticosterone release in HPA axis in response to stress (Wittmann et al., 2009). The 
important role of dynorphin in stress-induced corticosterone responses was also 
supported by similar study in Sprague-Dawley male rats, which showed that stress-
induced high levels of plasma corticosterone were reduced by KOR antagonism, 
norBNI (20mg/kg) (Allen et al., 2013). The direct correlation between dynorphin/KOR 
system and glucocorticoid levels was reported by early studies, which showed that 
KOR agonist, U50,488 significantly increased rats plasma corticosterone in a dose 
dependent manner (Hayes and Stewam 1985, Iyengar et al., 1986). 
 
The exact mechanism of which dynorphin/KOR activation induces corticosterone 
levels in HPA axis still remains unclear, but it likely depends on the activation of 
corticotropin-releasing hormone (CRH) release in the hypothalamus. As in (dyn -/-) 
mice, CRH mRNA was reduced by almost 30% in the paraventricular nucleus of the 
hypothalamus (Wittmann et al., 2009). Further evidence showed that 
intracerebroventricular injection of CRH induces aversion, which was blocked by 
dynorphin gene disruption and KOR antagonism, norBNI treatment, suggesting the 
possible mechanism of dynorphin/KOR system in corticosterone responses is CRH 
dependent (Land et al., 2008). 
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To identify whether stress and KOR activation produce effects on plasma 
corticosterone levels. Blood samples were collected from male and female cFos-GFP 
transgenic mice following acute forced swim stress and U50,488 in the absence and 
presence of norBNI. To investigate the response to stress, it is involved that blood 
samples are collected carefully. The tail incision method, in which a small nick is made 
in the lateral tail vein, and it has been validated as a refined method for single or 
repeated blood sampling in adult mice (Sadler et al., 2013).  
 
It is hypothesised that plasma corticosterone levels would be significantly increased 
in response to forced swim stress and a single injection of U50,488 treatment, and 








In this chapter, both male (25-30g) and female (20-25g) adult (9-13 weeks old) cFos-
GFP transgenic mice were used, which were originally purchased from Jackson 
Laboratories (Bar Harbor, Maine, USA) (section 2.1). 
 
7.2.2 FSS and KOPr ligand treatment 
The blood samples were collected for baseline corticosterone levels measurements 
before norBNI (10mg/kg, i.p.) or saline (10ml/kg, i.p.) injections on the day 1. The 
following day, the mice were treated with either FSS (section 2.5) or KOPr agonist, 
U50,488 (20mg/kg, i.p.) (section 2.6) to investigate if stress or KOPr activation could 
affect the plasma corticosterone levels, after 30 minutes, the blood samples were 
collected for corticosterone measurements, the experiment timeline is illustrated in 
figure 7.1. 
 
7.2.3 Blood collection and corticosterone analysis 
The blood samples were collected using the tail incision method and corticosterone 
levels measurements were determined using ELISA kit (IBL International, Hamburg, 
Germany), details were descried in chapter 2, section 2.11 and 2.12.  
 
7.2.4 Statistical analysis 
All data are presented as mean  SEM for each treatment group. All corticosterone 
levels were analysed using a two-way ANOVA with factors ‘treatment’ and ‘time’ 
followed by post hoc Sidak’s test for each stress or KOPr activation experiment in 





The blood collection and corticosterone analysis methods are described in Chapter 
2, Section 2.11. In order to confirm HPA activation in response to acute FSS and a 
single injection of U50,488, and the effect of KOR antagonist on plasms 
corticosterone levels, the experimental design is illustrated in Figure 7.1. Blood 
samples were collected at baseline (24 hours pre-stress), and mice were then treated 
with either saline or KOR antagonist, norBNI (10mg/kg). After 24 hours, male or 
female mice were treated with either U50,488 (20mg/kg) administration or 15 
minutes FSS, blood samples were collected 30 minutes after U50,488 treatment, as 
previous evidence showed 30 minutes post KOR activation (U50,488) significantly 
induces corticosterone levels in rats (Hayes and Stewam 1985), blood samples were 
also collected 30 minutes after exposure to FSS, in order to allow the corticosterone 
levels reach its peak (Connor et al., 1997) (Figure 7.1). The collected plasma 





In adult male mice, there were no differences between non-stressed control groups 
and stressed groups at baseline corticosterone levels, the mean baseline values  
SEM, (n = 5/group) are 60  10 ng/ml, 76  18 ng/ml, 85  19 ng/ml. Forced swim 
stress produced a significant increase by almost 200%, compared to baseline 
measurements (F(1,24) = 30.87, P < 0.0001). These FSS-induced plasma levels of 
Figure 7.1 Experimental design for male and female mice treated with either 
stress (15 mins FSS) or KOR agonist (U50,488) in the presence or absence of 
norBNI pre-treatment. CORT, corticosterone, FSS, forced swim stress. 
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corticosterone were not affected by pretreatment of norBNI (10mg/kg) (Figure 7.2A). 
U50,488 administration also produced a significant increase in plasma corticosterone 
levels (F(1,24) = 18.69, P = 0.0002), compared to the baseline measurements (200% of 
baseline control) (Figure 7.2B). Surprisingly, pretreatment of norBNI also did not 
block elevated corticosterone levels in U50,488 treatment groups (Figure 7.2B).  
 
In adult female mice, similar to the measurements in male mice, there were no 
differences between control and treated groups at baseline corticosterone levels, the 
mean baseline values  SEM, (n = 5/group) are 75  12 ng/ml, 98  10 ng/ml, 97  17 
ng/ml. The plasma corticosterone levels were also significantly increased by FSS by 
160%, compared to baseline measurements (F(1,24) = 46.77, P < 0.0001) (Figure 7.3A). 
Similarly, U50,488 administration produced a significant increase in plasma 
corticosterone (F(1,24) = 37.83, P < 0.0001), 350% compared to the baseline levels, 
































Figure 7.2 Effect of forced swim stress (FSS) and U50,488 (20mg/kg) on 
corticosterone levels in male cFos-GFP transgenic mice. Blood samples were 
collected on day 0 as baseline levels. On day 1, blood samples were taken 30 
minutes after swimming and administration of U50,488. Blood samples were also 
collected for non-stressed and saline-treated mice as control groups. All data are 
presented as mean  SEM. N=5 per treatment group, Two-way ANOVA with Sidak’s 
test. ***P<0.001, ****P<0.0001. For FSS treatment (i.e. saline vs FSS: F(1,24) = 
46.77, P < 0.0001), and time (i.e. baseline vs test day: F(2,24) = 15.58, P < 0.0001). 
For U50,488 treatment (i.e. saline vs U50,488: F(1,24) = 37.83, P < 0.0001), and time 


























































































Figure 7.3 Effect of forced swim stress (FSS) and U50,488 (20mg/kg) on 
corticosterone levels in female cFos-GFP transgenic mice. Blood samples were 
collected on day 0 as baseline levels. On day 1, blood samples were taken 30 
minutes after swimming and administration of U50,488. Blood samples were 
also collected for non-stressed and saline-treated mice as control groups for 
comparison. All data are presented as mean  SEM. N=5 per treatment group, 
Two-way ANOVA with Sidak’s test. ****P<0.0001. For FSS treatment (i.e. saline 
vs FSS: F(1,24) = 30.87, P < 0.0001), and time (i.e. baseline vs test day: F(2,24) = 13.93, 
P < 0.0001). For U50,488 treatment (i.e. saline vs U50,488: F(1,24) = 18.69, P = 






































































Our studies have shown the baseline, swim stress-induced and U50,488-induced 
plasma corticosterone levels in both adult male and female C57Bl/6J mice. The mean 
basal corticosterone levels for male and female mice are 75 ng/ml and 90 ng/ml 
respectively, suggesting that female mice have higher baseline corticosterone levels 
than males. Direct comparison of baseline data with other studies is complicated by 
the method of blood collection which may influence the values obtained, however, 
similar findings are in the literature. For example, Malisch et al. (2007) showed mean 
baseline plasma corticosterone levels in females (115 ng/ml) were almost twice as 
high in males (59 ng/ml) in CD1 mice, with blood samples taken by retro-orbital sinus 
puncture. 
 
In response to acute FSS, our data showed a significant increase in corticosterone 
levels by almost 200% in male mice and 160% in females, compared to baseline 
corticosterone levels. These effects were similar to effects revealed in a previous 
study, demonstrating that two hours restraint stress significantly induced high levels 
of corticosterone concentrations by 220% over baselines in C57BL/6 male mice 
(Sadler & Bailey, 2016). Acute 30 minutes restraint stress produced a significant 
increase in both male and female C57BL/6 mice by over 500% and reached over 700 
ng/ml in males and over 800 ng/ml in females (Romeo et al., 2013). These restraint 
stress-induced corticosterone levels were much higher than the corticosterone levels 
we determined following 6 minutes FSS in our study, which could result from the 
nature and duration of the stressors. In addition, acute 40 minutes restraint stress 
produced a significant increase in corticosterone levels by almost 400% in male mice 
and 300% over baseline levels in female mice, resulting in elevated corticosterone 
levels approximately 300 ng/ml in males and 460 ng/ml in females (Malisch et al., 
2006). In that study, there was a higher percentage increase in stress-induced 
corticosterone levels in males, but because of the higher baseline levels in females, 
the final stress-induced corticosterone levels were higher in female mice than in male 
mice. The sex-dependent differences in corticosterone levels in response to stress 
was proposed to result from, at least in part, the involvement of gonadal steroids 
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such as estrogen in regulating corticosterone secretion and clearance rate in the HPA 
axis (Handa et al., 1994). 
 
Following U50,488 with a dose of 20 mg/kg treatment, our data showed a significant 
2-fold increase (200% of control) in plasma corticosterone levels in male mice and 
approximately 3-fold increase (350% of baseline control) in female C57BL/6 mice. 
Early studies showed that U50,488 at 5 mg/kg largely produced a 300% increase in 
plasma corticosterone in adult male rats (Hayes and Stewam 1985). Others reported 
that U50,488 at only 2 mg/kg induced elevated corticosterone levels (200% of control) 
in adult male rats (Iyengar et al., 1986). Dose-dependent increases in corticosterone 
in response to U50,488 induced KOPr activation have been shown in rats. U50,488 at 
8 mg/kg increased corticosterone levels to 550% and 16 mg/kg increased to 500% of 
controls, suggesting that 8 mg/kg is the dose to induce the maximum HPA activity 
and corticosterone responses, and corticosterone responses could be blunted with 
more than 8 mg/kg of U50,488 treatment (Iyengar et al., 1986). These changes seen 
in rats, albeit at lower doses, are similar to the corticosterone responses determined 
in mice in this study with 20 mg/kg of U50,488. In this study, the U50,488-induced 
percentage increase in corticosterone levels were greater in females than that of 
males, suggesting that female mice may be more sensitive to KOPr activation 
inducing increased in corticosterone response. 
 
As described above, both FSS and U50,488 treatment produced significant effects on 
plasma levels of corticosterone in both male and female C57BL/6 mice in this study. 
However, these stress-induced elevated plasma corticosterone levels were not 
blocked by pretreatment of KOR antagonist norBNI. These results were consistent 
with previous studies on the effects of restraint stress on corticosterone levels, which 
showed 10mg/kg of norBNI was unable to block restraint stress-induced increase in 
plasma corticosterone levels in male CD1 mice (Almatroudi et al., 2017). In addition, 
other studies also showed that neither the presence of norBNI in wildtype mice nor 
prodynorphin knockout mice affect FSS-induced elevated corticosterone in C57BL/6 
mice (McLaughlin et al., 2006). In rats, it has also been reported that norBNI pre-
administration (10mg/kg) did not block elevated corticosterone levels following FSS 
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in male Sprague-Dawley rats, suggesting that FSS-induced increase in corticosterone 
was independent of KOPr activation signaling (Polter et al., 2014). However, a 
number of studies demonstrated contradictory data, for example, Allen and 
colleagues reported that pre-administration of norBNI (20mg/kg) effectively reduced 
the elevated plasma corticosterone levels after food restriction in Sprague-Dawley 
rats (Allen et al., 2013). In addition, another group showed that the presence of 
norBNI (10mg/kg) reduced basal levels of plasma corticosterone in wild type C57/BL6 
mice, as well as in prodynorphin knockout mice, indicating the dynorphin/KOPr 
activity is involved, at least in part, in regulating corticosterone levels in the HPA axis 
activation (Wittmann et al., 2009). 
 
Overall, this study showed that the methodology used here to induce stress was 
stressful to the mice as the FSS procedure produced an increase in plasma 
corticosterone levels in both male and female mice. Similarly, this study confirmed 
that U50,488 (20 mg/kg) induced an increase in plasma corticosterone levels, as has 
been reported previously, in both male and female mice. However, norBNI did not 
reduce plasma corticosterone levels following FSS, which may suggest that FSS-
induced corticosterone levels were independent of KOPr system, although norBNI 
and other KOPr antagonists have been shown to effectively blocked stress-induced 
behaviours (Shirayama et al., 2004, Almatroudi et al., 2018). Moreover, norBNI did 
not effectively block U50,488-induced increase in plasma corticosterone in our study, 
which could perhaps result from an insufficient dose of norBNI or alternatively 

















The overall aims of this project were to determine which brain regions are activated 
by stress and KOPr activation, to help determine whether there is overlap between 
brain regions activated by both behavioural stimuli. As previous studies have shown 
sex differences in behavioural responses to physical stressors and KOPr activation, 
we also sought to determine whether there were sex differences in the brain regions 
activated by these in vivo stimuli. 
 
The key results in this thesis are that in male cFos-GFP transgenic mice there was 
considerable overlap in brain regions that were activated by both a physical stressor 
(FSS) and KOPr activation, with significant increases in cFos and cFos-driven GFP 
expression in the PFCx, NAc and basolateral amygdala. In the CA1 region of the 
hippocampus and central amygdala KOPr activation significantly increased cFos 
expression, whereas FSS was without effect.  
 
Surprisingly, there was a very different pattern of cFos expression seen in female 
mice undergoing the same experimental procedures. In the PFCx, neither KOPr 
activation nor FSS increased cFos expression. In the NAc, FSS but not KOPr activation 
increased cFos expression. In the CA1 region of the hippocampus, central amygdala 
and basolateral amygdala similar patterns of cFos expression were seen between 
male and female mice following both KOPr activation and FSS. 
 
Although in some brain regions there was cFos expression following both KOPr 
activation and FSS, pretreatment of animals with norBNI significantly inhibited cFos 
activation by KOPr, but generally had no effect against the FSS-induced increase in 
cFos expression.  
 
This chapter will discuss the potential factors that underlie these sex differences to 
the effects of KOPr activation and stress. Also, the limitations of these studies and 





8.1 Sex differences in KOPr expression 
Our data demonstrated sex-dependent cFos expression in PFCx and NAc following 
U50,488 treatment, but not in hippocampal CA1 and amygdala, i.e. male mice 
exhibited a significant increase in cFos expression in the PFCx and NAc after KOPr 
activation, an effect that was not seen in females. This could directly result from 
different expression levels of KOPrs in different brain regions between male and 
female mice. To our knowledge, there have been no previous studies examining sex 
differences in KOPr expression in male and female mice, but this hypothesis could be 
supported by previous evidence in guinea pigs (Wang et al., 2011). Using in vitro 
autoradiography with the KOPr agonist, U69,593, they showed that in some rain 
regions (somatosensory cortex, insular cortex, claustrum, endopiriform cortex, 
periaqueductal grey, substantia nigra), there was significantly less KOPr binding in 
female brains compared with male brains. Of the two brain regions that showed the 
most profound sex-dependent effect in our study (PFCx and NAc), there was no 
significant difference in KOPr expression seen in the NAc, and the PFCx was not 
studied.  
 
Moreover, recent studies reported the sex differences in KOPr distribution in healthy 
human subjects in vivo using PET imaging scanning (Vijay et al., 2016), which revealed 
that males had higher KOPr availability than that of females in multiple brain regions, 
including the frontal cortex and amygdala, with no sex-dependent differences seen 
in the hippocampus and amygdala (the NAc was not studies) (Vijay et al., 2016). 
These studies suggest that there are sex-dependent differences in KOPr expression. 
Similar future studies in mice are required before the sex-dependent differences in 
cFos expression shown in our study can be ascribed to differences in KOPr expression. 
There are also other potential explanations for our findings, and for the sex-






8.2 Sex differences in KOPr activation and signaling 
In addition to the differences in expression levels of KOPrs in different brain regions 
between males and females, it is also hypothesised that the sex differences observed 
in KOPr-induced cFos expression is caused, at least in part, by differences in KOPr-
mediated G protein activation in different brain regions. As well as investigating sex-
dependent differences in KOPr expression, Wang and colleagues also reported that 
G protein activation stimulated by the KOPr agonist, U69,593, was significantly 
greater in male guinea pigs than females in various brain regions, including 
somatosensory cortex and insular cortex, with no differences seen in the 
hippocampus or NAc (the PFCx was not investigated). In contrast, in the dentate 
gyrus in the hippocampus, there was significantly greater U69,593-stimulated G 
protein activity in females than in males (Wang et al., 2011). Moreover, by combining 
KOPr expression level data and KOPr-agonist stimulated G protein activation data an 
index of ‘Receptor-G protein coupling efficiency’ was derived, showing significantly 
lower coupling efficiency in female guinea pigs in several brain areas (cingulate 
cortex, somatosensory cortex, insular cortex, claustrum, medial geniculate nucleus 
and cerebellum), with significantly higher coupling efficiency in females in one brain 
area: the dentate gyrus. No difference was seen in NAc, hippocampus or amygdala, 
and the PFCx was not studies. Overall, although these studies do suggest that sex-
dependent differences in KOPr coupling efficiency may exist, they do not directly 
correlate with sex-differences in KOPr agonist-induced cFos expression presented 
here as no changes were seen in the NAc, and significant differences were seen in 
the dentate gyrus, where, in our study, KOPr activation did not increase cFos 
expression in either male or female animals. However, as these studies were 
performed in guinea pigs, further similar studies are required in mice to determine 
whether sex-dependent differences in receptor coupling efficiency underlie the sex-
dependent effects of KOPr activation presented in this thesis.  
 
Another recent study (Abraham et al., 2018) also demonstrated sex-dependent 
differences in KOPr signaling, comparing the effects of the KOPr agonist, U50,488, in 
male and female mice. As in previous studies, U50,488 was a less effective analgesic 
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in female mice compared with male mice, but, this was shown to be oestrogen-
dependent, as the sex-dependent effect was absent in ovarectomised animals, and 
there was a small, but significant, increase in KOPr agonist-induced analgesia in 
female animals in oestrus compared to those not in oestrus. Further investigations 
into the mechanisms underlying this effect showed that although KOPr agonist-
induced phosphorylation of p38 MAP kinase in males and females were equivalent, 
KOPr agonists induced phosphorylation of ERK1/2 only in males, with no effect seen 
in females. P38 MAP kinase phosphorylation is thought to be arrestin-mediated, 
following activation of KOPr, phosphorylation of the receptor by GRK2/3, and 
subsequent binding of arrestin to KOPr (Bruchas et al., 2006). In contrast, ERK1/2 
phosphorylation is thought to be mediated by activation of the  subunits of the G-
protein. One of the effects of GRK2 is to bind to  subunits of the G-protein and 
inhibit them (Daaka et al., 1997). Furthermore, oestrogen has been shown to 
enhance GRK2 levels, thereby decreasing KOPr signaling through G in females 
(Dominguez et al., 2009). A similar mechanism is one potential mechanism that may 
underlie the sex differences in cFos expression observed in our data, showing that 
female mice were less sensitive to U50,488 treatment in different brain regions, 
especially in PFCx and NAc. 
 
All of the evidence so far considered above is that the sex differences shown in this 
study might be because of altered KOPr expression or signaling in the brain regions 
involved (PFCx, NAc etc). However, the effects seen in this study were differences in 
cFos activation that are likely to be caused by activation of neurons. KOPrs are 
generally inhibitory, and so would be unlikely to cause direct activation of neurons 
on which they are expressed, but, KOPr activation could cause activation of neurons 
via changes in excitation within neuronal networks. For example, KOPrs are coupled 
to the Gi/o protein and activation of KOPr located at nerve terminals has been shown 
to inhibit neurotransmitter release, resulting in altered neuronal activity. Neurons 
are connected in complex neuronal networks, and so KOPr-induced inhibition of 
neurons in a brain region distinct from those investigated in this study could produce 
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disinhibition effects of these circuits, resulting in increased neuronal activity in the 
brain regions studies here (e.g. NAc, PFCx etc). 
 
For example, accumulating evidence has shown that there is a complex network 
effects in response to systemic KOPr agonist administration. In the PFCx, it has been 
shown that in male mice and rats, systemic administration of KOPr agonist, U50,488 
or intra-mPFCx administration U69,593 reduced extracellular dopamine, glutamate 
and GABA concentrations in the PFCx (Heijna et al., 1990, Tejeda et al., 2013), and it 
was confirmed that KOPr activation-induced decrease in dopamine overflow in the 
PFCx by directly activating KOPr on dopaminergic terminals (Tejeda et al., 2013). 
Additionally, local infusion of KOPr agonists into the VTA also reduced dopamine 
levels in the PFCx, showing that KOPr on dopaminergic afferents from the VTA could 
also regulate dopamine release in specific region e.g. PFCx. Thus, it is becoming clear 
that KOPrs are largely located presynaptically on nerve terminals of dopaminergic 
inputs, as well as at nerve terminals of glutamatergic and GABAergic inputs 
(Shippenberg et al., 2001, Tejeda et al., 2013). In the NAc, KOPrs are located 
presynaptically on dopaminergic inputs and glutamatergic inputs (Shippenberg et al., 
2001, Britt & McGehee, 2008). Activation of KOPr by systemic administration of 
U50,488 also reduced electrically-evoked dopamine release in the NAc in male adult 
rats (Heijna et al., 1990). In addition to decreasing dopamine release in the NAc, 
another study reported that KOPr agonist, U69,593 also inhibits glutamate and GABA 
releases in the NAc in male rats (Hjelmstad et al., 2003). 
 
Electron microscopy studies found KOPr-immunoreactivity on dopaminergic-positive 
neurons in the NAc (Svingos et al., 2001), and KOPrs are also expressed, at least in 
part, on serotonergic (5-HT) neurons and presynaptic glutamatergic cortical neurons 
in the NAc (Schindler et al., 2012, Hjelmstad et al., 2003). The effects of KOPr 
activation on different brain regions could be even more complicated, with a recent 
study showing that KOPr-induced inhibition on presynaptic terminal reduces the 
excitatory of dopamine D1 receptor activity, whereas presynaptic KOPr activation on 
inhibitory D2 receptor enhances excitatory activity (Tejeda et al., 2017), suggesting 
that KOPr activation effects not only depend on expression levels and localisation of 
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the KOPrs, but also on the types of neurons that KOPrs are expressed on. However, 
all the above studies were performed in male rodents, similar investigations on the 
effects of KOPr activation on neuronal transmission in female rodents have not been 
performed, nor have studies investigating the precise neuronal localization of KOPrs 
in female animals. 
 
Moreover, it is known that glial cells have an important role in regulating and 
supporting neurotransmitter metabolism and synaptic neurotransmission. Altered 
function of glial cells, particularly astrocytes, can be induced by both drugs of abuse 
and stress, leading to the suggestion that altered glial cell function may contribute to 
the development of drug addiction and psychological stress-related disorders 
(Miguel-Hidalgo, 2009). Furthermore, there are several studies demonstrating that 
KOPr activation is involved in regulating of Ca2+ channels and phospho-p38 
immunoactivity in astrocytes (Eriksson et al., 1993, Gurwell et al., 1996, Bruchas et 
al., 2006). This hypothesis was also supported by a study that reported the presence 
of KOPr mRNA in cortical, striatal and hippocampal glial cultures, confirming the 
expression of KOPrs in astrocytes in specific brain regions (Ruzicka et al., 1995). 
Therefore, a further possible mechanism that may underlie the sex-dependent 
patterns of cFos activation seen in this study may be because of sex-dependent 
differences in KOPr activation or signaling in astrocytes, rather than in neurons. 
 
 
8.3 Sex differences in stress-induced cFos expression 
Our study showed that an acute in vivo stressor, FSS, significantly induced cFos 
expression in a brain-region-dependent manner in both male and female mice. 
Similar to the effects of U50,488, FSS also significantly induced cFos expression levels 
in various brain regions, including PFCx, NAc and BLA in male mice. Whereas U50,488 
induced a significant increase in cFos expression in the CA1 region of the 
hippocampus and CeA, FSS had no effect in these brain regions. The pattern of cFos 
expression was similar in female mice, with the exception of PFCx where no FSS-
induced cFos activation was observed. As previously discussed in Chapter 1, stress 
 188
induces the release of the DYN, which is an endogenous ligand of KOPrs. Studies have 
shown that the prodynorphin gene is associated with drug addiction development in 
a sex-dependent manner. In mice, alcohol consumption in female mice was reduced 
in mice lacking the prodynorphin gene, with no effect in male mice (Blednov et al., 
2006). Similarly, a human study investigated single nucleotide polymorphisms (SNPs) 
in the prodynorphin gene and observed an interaction between distribution of 
prodynorphin SNPs and opioid dependence only in females, not in males (Clarke et 
al., 2009). These studies suggest sex differences in the roles of the prodynorphin 
gene (and thus the dynorphin/KOPr system), which in turn may underlie sex 
differences in stress-induced neuronal activity and behaviour. 
 
In our study, generally, the stress-induced cFos expression effects were not blocked 
by pretreatment with norBNI (KOPr antagonist), although a blocking effect trend 
towards significance was seen in some brain regions. In our data, norBNI significantly 
blocked stress-induced cFos only in the NAc in male mice, the blocking effect of 
norBNI was not observed in female mice and other brain regions in male mice. In 
behavioural studies, norBNI effectively blocked stress-induced analgesia, impaired 
learning and memory and reduced stress-induced immobility in male adult mice 
(McLaughlin et al., 2003, Carey et al., 2009). This could mean that these behaviours 
are largely mediated by KOPr activation in NAc, although this is unlikely, as NAc is 
thought to largely mediated euphoria/dysphoria, not analgesia. An alternative 
explanation is that the dose of norBNI used in this study is insufficient to fully block 
KOPrs. The main difference between KOPr activation following stress and KOPr 
activation following administration of U50,488 is the KOPr agonist used, with stress 
causing release of endogenous neurotransmitter dynorphin. Dynorphin is known to 
be highly efficacious, and previous studies have demonstrated spare KOPrs such that 
the effects of dynorphin can be seen at very low receptor occupancy (Chavkin and 
Goldstein, 1981). 
 
There have been few studies directly examining the effects of KOPr antagonists on 
stress-induced cFos expression in rodents, and the findings are somewhat conflicting. 
Carr and colleagues examined cFos expression after stress or norBNI in two rat strains: 
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Sprague Dawley and Wistar Kyoto. In Wistar Kyoto rats, norBNI induced an 
antidepressive-like phenotype (decreased immobility and increased swimming in the 
Forced Swim test), an effect that was absent in Sprague Dawley rats. In animals that 
had undergone the Forced Swim procedure, norBNI induced an increase in cFos 
expression in the NAc, with no effect in the CA1, CA3 or dentate gyrus regions of the 
hippocampus (PFCx was not studied). When comparing cFos activation between 
control animals and those that had undergone Forced Swim, cFos expression in the 
NAc was increased in the Forced Swim animals (Carr et al., 2010). Overall, this shows 
that Forced Swim can increase cFos expression (as shown in the present study), but 
that norBNI increases cFos expression even further. The mechanism underlying this 
is unknown, but it suggests that dynorphin release and KOPr activation is just one 
component of stress. Two caveats when comparing Carr et al with the present study 
are that this study was perpformed in rats, not mice, and the Forced Swim procedure 
was repeated in Carr et al (1x 15 min, 1x 5min) rather than a single 15 min stressor 
as performed here. 
 
A further study that investigated the effect of norBNI on stress-induced cFos 
activation is Nygard et al (2016) who examined yohimbine-induced reinstatement of 
nicotine conditioned place preference in male C57 mice (Nygard et al., 2016). NorBNI 
pretreatment effectively inhibited stress-induced reinstatement, and stress-induced 
reinstatement was similarly blocked in both KOPr and dynorphin knockout mice. 
Stress-induced reinstatement increased cFos expression in all brain regions 
investigated (BLA, CeA, Bed Nucleus Stria Terminalis, Dorsal Raphe nucleus), with 
norBNI inhibiting cFos activation only in the BLA and Dorsal Raphe nucleus (Nygard 
et al., 2016). This study unitizes a very different stressor from the one used in the 
present study but does show that although cFos expression is increased in multiple 
brain regions, norBNI is only effective in inhibiting this increase in some brain regions. 
Again, this suggests either that stress involves more components in addition to 
dynorphin release and KOPr activation (as discussed in Chapter 1), and/or the dose 
of norBNI used was insufficient to block all KOPrs in some brain regions. 
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Lastly, our data revealed that KOPr activation by U50,488 significantly induced cFos 
expression in the NAc only in male mice, not in female mice, indicating KOPr-
activated neuronal activity is greater in males than females in these brain regions. As 
previously mentioned in Chapter 1, U50,488 effectively produced decreases in 
motivational behaviours in intracranial self-stimulation paradigm in male rats, but 
significantly less effects were observed in female rats (Russell et al., 2014), and 
U50,488 was also shown to suppress dopamine release in the NAc more effectively 
in male mice, compared to females (Conway et al., 2019), which further suggests that 
female mice are less sensitive than males to KOPr activation. These neurochemical 
and behavioural responses correlate with our study, which showed a significant 
increase in cFos expression in the NAc in the male mice, not in females, suggesting 
that KOPr-mediated effects are less sensitive in females than males, and may explain 
the sex dependent motivational behaviours in response to KOPr activation. 
 
Similar KOPr-induced cFos expression pattern between sexes was observed in the 
PFCx, i.e. greater cFos induction in males than females PFCx. The PFCx plays an 
important role in decision making and memory (McEwen, 2010), which is more 
difficult to assess in a behavioural paradigm than in motivational behaviours for NAc. 
Future investigations in neurochemical changes in the PFCx or cognitive behaviours 
following KOPr activation could help to understand how these sex dependent cFos 




8.4 Future work 
Are there any sex differences in DYN release, KOPr expression levels and activation? 
As introduced in Chapter 1, KOPrs are widely expressed throughout the brain, in 
numerous brain region that play key roles in cognition, emotion, mood and 
motivational behaviours, including VTA, PFCx, hippocampus, NAc, substantia nigra, 
hypothalamus and amygdala. However, KOPr expression levels and distribution 
between male and female animals are not fully understood. Although previous 
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studies (Wang et al., 2011) showed differences in regional distribution of KOPrs in 
male and female guinea pig brains (Section 8.1.1), and PET imaging studies have 
taken place in humans, no studies have examined sex-dependent KOPr expression in 
rodents. Future experiments could investigate KOPr expression levels and 
distribution between male and female C57 mice by using quantitative in vitro 
autoradiography or immunohistochemistry (Shirayama et al., 2004, Wang et al., 
2011). Since DYN is one of the key neuropeptides released in response to stress and 
primarily activate on KOPrs, measuring DYN release following stress in both males 
and females using microdialysis could facilitate better understanding of mechanisms 
that underlying the sex differences in stress responses, and whether there are 
differences in DYN release between males and females that could explain the sex 
differences in cFos activation seen in the present study (Rocha et al., 1997). As 
Section 8.1.2 described, KOPr-mediated G protein activity may also underlie the sex 
differences in KOPr-induced neuronal activity, future studies including radioligand 
binding or GTPS binding assays could be used to determine the binding properties 
and activation levels of KOPrs following KOPr activation between male and female 
C57 mice. Immunolabelling of the KOPr activation-dependent phosphor-p38 activity 
following KOPr agonist treatment could be used to compare the KOPr-activated G 
protein activity in male and female rodents (Bruchas et al., 2006). 
 
What types of neurons that are activated following stress or KOPr agonist? 
As Section 8.1.2 discussed, KOPr activation produces different effects on neuronal 
transmission, depending on the types of neurons expressing KOPr, as well as the 
location of KOPr expression, e.g. pre or post-synaptically. Previous studies suggest 
that KOPrs are likely expressed presynaptically on nerve terminals of dopaminergic, 
glutamatergic and GABAergic inputs in many brain regions including NAc and PFCx 
(Section 8.2 & Chapter 6). Initial studies to investigate precisely which neurons have 
cFos activation following KOPr agonist administration or stress (Chapter 6) showed 
that U50,488 and forced swim stress-activated neurons induced cFos in non-
GABAergic-neurons. Future dual-labelling immunocytochemistry could be used to 
identify the types of neurons that were activated in response to KOR activation or 
stress. For example, glutamatergic neurons could be identified using an antibody 
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against Vesicular Glutamate Transporter 2 (VGLUT2) (Halasz et al., 2006), and 
dopaminergic neurons could be identified using an antibody against Tyrosine 
Hydroxylase (TH) (Procaccini et al., 2011). Therefore, using a similar approach to that 
used in Chapter 6, dual-labelling of brain sections with cFos and either anti-VGLUT2 
or anti-TH antibodies could help identify in which neurons cFos is activated. 
 
It is also possible that cFos is activated in glial cells following KOPr activation or stress. 
Glial cells are abundantly expressed in the central nervous system, and glial fibrillary 
acidic protein (GFAP) is found in astrocyte cells, anti-GFAP antibody is widely and 
specifically used as astrocyte marker, which could be used alongside anti-cFos 
antibody to test whether KOPr agonist-activated neurons are neuronal or non-
neuronal glial cells (Herrera et al., 1998). However, dual-labelling approaches have 
certain limitations, which would not allow us to determine the exact neuronal type 
in which cFos is located, therefore using the cFos-GFP transgenic mouse, 
electrophysiological recordings could be performed from GFP-positive neurons 
(hence, only from neurons where cFos has been activated by KOPr activation or 
stress). Electrophysiology could be used not only to determine the phenotype of 
neuron in which cFos is activated (glutamatergic, GABAergic etc), but also whether 
that neuron expressed KOPr itself, or if the cFos activation from systemic KOPr 
agonist administration was via neuronal network effects (Barth et al., 2004, Dai et al., 
2009). A final possible method that could be used to identify in which neurons cFos 
are activated following KOPr agonist activation or stress is FACS sorting of neurons 
from the cFos-GFP transgenic mouse, where neuronal phenotype could be 
determined, as well as potential molecular alterations in cFos-positive neurons (Liu 
et al., 2014). 
 
Are the KOPr activation-induced effects influenced by sex chromosomes and 
gonadal hormones? 
It is thought that sex differences in KOPr activation-mediated effects could result 
from, at least in part, chromosomal and hormonal factors (Gioiosa et al., 2008, 
Rasakham et al., 2011). Although how the gonadal hormones regulate stress 
responses and KOPr function is not fully understood, there are studies that have 
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reported the important role of gonadal hormones in regulating KOPr function in mice. 
For example, estradiol treatment significantly reduced DYN expression in adult 
female C57BL/6 mice, thus affected KOPr activation in response to stress (Gottsch et 
al., 2009). It also has been shown that DYN is co-expressed with estrogen receptor 
alpha (ER) in the spinal cord of adult female rats. Oestrogen or progesterone 
treatment increased this co-expression, resulting in elevated DYN release upon ER 
activation, which in turn affected KOPr function in response to stress in female 
animals (Gintzler et al., 2008). As mentioned previously, Abraham et al. (2018) 
showed altered KOPr signaling in females that was oestrogen-dependent, as the 
response in ovariectomised animals was the same as in male animals. Although this 
study shows an overall effect of oestrogen in KOPr activation, the effect of the 
oestrus cycle was much less than the effect of ovariectomy. Similarly, Russell & 
colleagues showed neuronal activation in the NAc (core and shell) and amygdala 
(central and basolateral) following U50,488 in female rats was independent of 
oestrous cycle stage (Russell et al., 2014). However, early animal studies in Swiss-
Webster male and female mice showed that swim stress-induced analgesia is 
dependent the effects of gonadectomy, showing that ovariectomised females 
demonstrated reduced stress-induced analgesia (Mogil et al., 1993). Other studies in 
CD1 mice using the open-field assay of anxiety-like bahaviours demonstrated that 
social stressed female mice spent significant less time in the open field only at 
oestrous and dioestrous stages, but not in proestrous stage, suggesting that stress-
induced anxiety-like behaviours is dependent on the oestrous cycle (Palanza et al., 
2001). 
 
In this study we did not determine what stage in the oestrus cycle the animals were 
in during experimentation, future work could incorporate vaginal lavage to assess 
the correlation between oestrus cycle and sex-dependent effects of KOPr activation 
and stress. 
 
Are there any sex differences after chronic stress or KOPr activation? 
In this study, acute forced swimming stress and a single injection of U50,488 were 
used, but the effect of acute stress and chronic stress differ significantly at both the 
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molecular level and behavioural level. For example, it has been shown that chronic 
stress induced dendritic shrinkage in the hippocampus and PFCx, resulting in 
impaired memory and cognition (Radley et al., 2004, McEwen et al., 2016), whereas 
acute restraint stress rapidly increases extracellular levels of glutamate in the 
hippocampus, enhanced excitability and improved memory (Lowy et al., 1993, 
McEwen et al., 2016). In addition, acute immobilisation stress largely increased cFos 
mRNA in the paraventricular nucleus (PVN) of rat hypothalamus, compared to the 
non-stressed control rats, but rats displayed significantly lower cFos mRNA signal 
after chronic stress (Bonaz & Rivest 1998). Similarly, chronic treatment of KOPr 
agonist, U50,488 not only induces prolonged KOPr phosphorylation and analgesic 
tolerance, but also modulates NMDA receptors in the hippocampus (McLaughlin et 
al., 2004, Dogra et al., 2016). All the studies suggest that the effects of stress on 
neuronal activity at molecular levels or behaviours are dependent on the stress 
duration. Therefore, future work could investigate whether chronic stress induces 
similar neuronal activity in various brain regions, whether this effect is sex-
dependent as we have shown with acute stress, and how KOPrs play different roles 
in chronic stress responses.  
 
In summary, our data demonstrate an apparent sex difference in brain regions that 
are activated by acute stressors and KOPr activation. In particular, only in male mice 
was their neuronal activation in the PFCx following either an acute stressor or KOPr 
activation. Further, although there were some common effects seen in both sexes 
(eg. hippocampal CA1 region and central and basolateral amygdala), in the NAc both 
KOPr activation and acute stress induced neuronal activation in male mice, only acute 
stress had that effect in female mice. As there is behavioural evidence that male and 
female rodents respond differently to acute stress and to KOPr activation, these data 
suggest that the PFCx and NAc may be key brain regions that mediate that sex 
difference. 
 
This work highlights the challenges for developing effective therapeutics for 
psychiatric disorders between men and women patients. Future work could focus on: 
identifying which specific neuronal types are activated in these brain regions 
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following acute stress and/or KOPr activation; whether the effect of chronic stress 
differs to that of acute stress; where KOPrs are expressed in these brain regions, and 
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